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I
n the 1970s, the introduction of computed tomography (CT) and magnetic resonance 
imaging (MRI) in medicine, made it possible to image the living brain. These images 
showed that cerebral white matter lesions and asymptomatic lacunar brain infarcts 
are extremely common in elderly people.1,2 Evidence is accumulating that these lesions 
are associated with an increased risk of late-life depression, gait disturbances, and 
cognitive decline.3-5 Eventually, they may either by themselves or in combination with 
Alzheimer’s pathology and other late life degenerative changes, lead to dementia.6-8 In 
addition to clinically manifest infarcts and hemorrhages, white matter lesions and lacu-
nar infarcts are frequently observed on brain images, suggesting a common etiology.9
Atherosclerosis-like changes and wall thickening of deep cerebral arterioles are 
observed on autopsy of elderly people in areas with white matter lesions and lacunar in-
farcts.10,11 Hence, these lesions are referred to as cerebral small vessel disease. The exact 
etiology of white matter lesions in elderly people is unknown and a wide variety of rare 
causes have been described.7,12-14 Nevertheless, almost all studies point to increasing 
age, arterial hypertension, and indicators of systemic atherosclerosis as the main risk 
factors.1,15,16 Post-mortem and blood-ﬂ ow studies show ischemia and hypoperfusion in 
brain areas with large white matter lesions.7,12 Reports on the evaluation of these brain 
lesions over time are scarce.17 A better understanding of the etiology of cerebral small 
vessel disease could contribute to the prevention of stroke, dementia and depression, as 
well as more subtle cognitive decline, depressive symptoms and gait disturbances in a 
rapidly increasing elderly population.14
The objective of this thesis was to gain more insight into the etiology of cerebral 
small vessel disease. To obtain this goal, we assessed the presence, severity and pro-
gression of cerebral white matter lesions and lacunar brain infarcts and studied the 
relationship with their potential causes. This was done within the Rotterdam Scan 
Study, a prospective population-based cohort study that included 1,077 non-demented 
people aged 60 to 90 years. All participants underwent brain MRI in 1995 to 1996, 668 
of whom underwent a second MRI more than three years later. In chapter 2, we review 
studies on the frequency of cerebral small vessel disease in the general population, and 
in patients with stroke and dementia. In chapter 3, we describe the relation between 
several risk factors and cerebral small vessel disease. First, in chapter 3.1, we focus on 
the risk of blood pressure, change in blood pressure, hypertension and treatment of hy-
pertension within a large European collaborative study. In chapter 3.2, we examine the 
relationship between homocysteine and cerebral small vessel disease. Chapter 3.3 deals 
with the relation between cerebral small vessel disease and low arterial oxygen satura-
tion and chronic obstructive pulmonary disease. Chapter 3.4 concentrates on the role of 
plasma amyloid ß and APOE ε4 in relation to lacunar infarcts and white matter lesions 
(3.4.1) and impaired cerebral autoregulation (3.4.2). In chapter 4.1, we describe the pro-
gression of white matter lesions and the risk factors associated with this progression. 
In chapter 4.2, the relation between the inﬂ ammation marker, C-reactive protein, and 
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progression of white matter lesions and incident lacunar infarcts is explored. Finally, 
we compare the risk of stroke between people with and without cerebral small vessel 
disease on MRI in chapter 5. In chapter 6, I reﬂ ect on the main ﬁ ndings in the context of 
current knowledge and give suggestions for future research.
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9Abstract
White matter lesions and silent lacunar infarcts are related to and may result from cerebral small 
vessel disease. Reported frequencies of these lesions vary largely among studies. Differences in 
imaging techniques, rating scales, cut-off points in lesion severity grading and study populations 
contribute to the variation, in addition to differences in risk factor proﬁ les across studies.
In this paper, we will ﬁ rstly discuss general methodological issues that may inﬂ uence  reported 
frequencies of white matter lesions and silent lacunar infarctions, and then review published data. 
We will focus on the results from population-based studies and only brieﬂ y comment on patient 
series of stroke and dementia. 
Frequency of white matter lesions and 
silent lacunar infarcts
2
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INTRODUCTION
White matter lesions and silent lacunar infarcts are frequently observed on CT and MRI 
scans of healthy elderly, as well as in patients with dementia and stroke. The pathogen-
esis of these lesions is not yet fully understood, although ﬁ ndings from epidemiological, 
clinical and neuropathological studies suggest that small vessel disease is a major cause. 
Arteriolosclerosis (micro-atheromatosis and hyalinosis) causes obstruction and endothe-
lial dysfunction of cerebral small vessels, resulting in ischemic damage.1-4
Although white matter lesions and silent lacunar infarcts do not result in acute 
symptoms, they are associated with dementia, stroke, depression and gait distur-
bances.5-8 Reported prevalences of white matter lesions and silent lacunar infarcts vary 
largely among studies, whereas data on incidence and consequences of these lesions 
are scarce. In this review, we will address the methodological issues that underlie the 
differences in reported frequencies of these small vessel disease related cerebral lesions, 
and provide an overview of the frequencies reported in population-based studies, and in 
series of dementia and stroke patients.
METHODOLOGICAL ISSUES IN COMPARING FREQUENCIES
Imaging
White matter lesions are visible on both MRI and CT images as patchy lesions in the 
white matter of the centrum semi-ovale or directly adjacent to the ventricles. On MRI, 
white matter lesions are seen as hyperintense lesions on Proton Density, T2-weighted 
or FLAIR images, without prominent hypodensity on T1-weighted images. On CT, white 
matter lesions are poorly delineated hypodense areas.9,10 Fisher deﬁ ned lacunar infarcts 
according to pathological observations as deep sharply margined focal lesions with a 
diameter ranging from 3 to 20 mm.11 Both on CT and MRI lacunar infarcts have ap-
proximately the same intensity as cerebrospinal ﬂ uid. However, small and incomplete 
infarctions located in the basal ganglia are often visible on T2-weighted MR images 
only. Differences in the deﬁ nition of these lesions can result in variation in the reported 
frequencies. Furthermore, misclassiﬁ cation of white matter lesions and lacunar infarcts 
may inﬂ uence frequencies in CT and MRI studies. Widened perivascular spaces can 
mimic lacunar infarctions.12,13 The sensitivity of MRI for white matter lesions is superior 
to CT, especially for small white matter lesions and white matter lesions in the parieto-
occipital region.9 The innovation in MR scanning techniques, i.e. higher ﬁ eld strength 
magnets, thinner slices and new pulse sequences, has resulted in even larger differences 
with CT studies and also in differences between MRI studies.10,14
EvD02.indd   10 23-03-2004, 13:42:27
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Rating scales
For the evaluation of the white matter lesions, numerous semi-quantitative rating 
scales are available. These rating scales differ in whether and to what extent they focus 
on size, number or conﬁ guration of the lesions, and whether they distinguish between 
lesions located in left or right hemisphere, in different lobes, and in periventricular or 
subcortical regions. The different rating scales are suitable for different study goals, 
albeit at the cost of their comparability.15,16 The moderate reproducibility of some scales 
is another source for variation. In addition to the semi-quantitative rating scales, white 
matter lesions can be assessed volumetrically. Semi- and full-automatic operating meth-
ods based on different principles are in use for this purpose.17,18 Further development of 
Figure 1a. Distribution of periventricular white matter lesions by 10 years age category.
Reprinted with permission.19
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Figure 1b. Distribution of subcortical white matter lesions by 10 years age category.
Reprinted with permission.19
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these methods will hopefully lead to more uniform and interpretable measures of white 
matter lesions.
Cut-offs of white matter lesions distribution
Most studies, even if they rate lesions (semi-) quantitatively, use a cut-off point when 
they report prevalences of white matter lesions. This implies that lesion severity is di-
chotomised somewhere along its spectrum. 
Figure 1 shows age-speciﬁ c distributions of periventricular and subcortical white 
matter lesion severity for the population based Rotterdam Scan Study and may illus-
trate the effect of dichotomisation at different cut-off points on the prevalence of white 
matter lesions.19 The most simple cut-off point for the dichotomisation is presence or 
absence of any white matter lesions. With this cut-off the prevalence of subcortical white 
matter lesions for people age 60 to 70 years is 87% (ﬁ gure 1b). If however a cut-off at 2 
ml was chosen, to indicate more severe white matter lesions, the reported prevalence 
would be less than 10%. 
Study population
The frequency of lesions will also depend on the deﬁ nition of the study population. Some 
studies are based on healthy volunteers, whereas others took representative samples 
from the general population, or only included dementia and stroke patients. Additional 
selection criteria that may have a major impact on frequency of lesions are a.o. exclusion 
of high-risk patients, co-morbidity, disease subgroups or exclusion based on age, sex or 
ethnicity.
Selective overrepresentation of subgroups with a different risk proﬁ le inﬂ uences the 
overall frequency. This effect can be extensive in hospital-based studies among patients 
with heterogeneous diseases like dementia and stroke. Furthermore, referral patterns, 
disease severity and disease subgroups will inﬂ uence the frequency in these hospital-
based populations as well.
Response rate and chance
Lower response rates in high-risk groups will decrease the overall frequency in popula-
tion-based studies.  In the Rotterdam Scan Study, response rate dropped from 74% in 
the 60- to 70-year-old age group to 41% in the 85-year-old and over age group.19 A Swe-
dish study (Lund Study) reported a drop from 77% in the 45- to 55-year-old age group to 
19% in the 85-year-old and over age group.20 In the Cardiovascular Health Study (CHS) 
respondents in the MRI subcohort were not only signiﬁ cantly younger and healthier, but 
also higher educated and more likely to have never smoked than the original cohort.21
Differences in frequencies can also be caused just by sample variation. In particular, 
in studies with a small sample size chance can result in extreme estimates.
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FREQUENCIES IN DIFFERENT STUDY POPULATIONS
Prevalence in population-based studies
We used Medline database to identify studies that were population-based, published 
in English, had substantial data available and used MRI to assess the prevalences 
of white matter lesions and silent lacunar infarcts. Table 1 shows the characteristics 
of the 7 studies included. The largest difference among studies is the age distribution 
in combination with sample size and response rate. Only the CHS and the Rotterdam 
Scan Study had a substantial amount of participants aged over 75 years. Furthermore, 
studies differed in respect that some excluded persons with neurodegenerative and cere-
brovascular diseases. 
Table 2 shows the overall prevalences of any white matter lesions, severe white 
Table 2. Prevalence of white matter lesions and silent lacunar infarcts in population-based 
studies with MR imaging
Study
White matter
lesions Silent 
Lacunes
(%)
Field 
strength 
MRI
Rating Scale white matter lesions 
and cut-off for severe lesionsAny
(%)
Severe
(%)
RS* n.s. 10 n.s. 1.5T Van Swieten scale (=Fazekas 
scale‡‡, without early conﬂ uent le-
sions rated as severe)
Lund† 62 23 8 0.2T Fazekas scale‡‡
HAS‡ 39/22†† 16/16†† 8 0.02T Fazekas scale‡‡ 
CHS§ 96 33 20 1.5T/0.35T Combined PVWML and SCWML 
score on a 10 point scale  (cut-off 
at 3)
ARIC|| 86 12 9 1.5T Combined PVWML and SCWML 
score  on a 10 point scale (cut-off 
at 3)
ASPS¶ 45 16 6 1.5T Fazekas scale‡‡
RSS** 95
80/92††
28
6/28†† 
19 1.5T PVWML on a 9 point scale (cut-off 
conform Fazekas scale‡‡) and SC 
WML approximated volumes based 
on the lesion diameter (cut-off at 
diameter >10mm)
n.s. = not speciﬁ ed; * Rotterdam Study52; † Lund Study20; ‡ Helsinki Ageing Study53; § Cardio-
vascular Health Study21,25; || Atherosclerosis Risk In Communities Study22,26; ¶ Austrian Stroke 
Prevention Study24,54; ** Rotterdam Scan study19,23; †† Prevalence of periventricular white matter 
lesions (PVWML) and subcortical white matter lesions (SCWML), respectively; ‡‡ PVWML and 
SCWML rated separately on a 3 point scale (cut-off for PVWML extending into the subcortical 
white matter, and for SCWML conﬂ uent and early conﬂ uent lesions)
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matter lesions and silent lacunar infarcts. A brief description of the used white matter 
lesions rating scale and MR scanner modalities is given. The prevalence of any white 
matter lesions ranges from 39 to 96%. The Helsinki Ageing Study and Austrian Stroke 
Prevention Study had relatively low prevalences. In the Helsinki Ageing Study, all cen-
tral nervous system and major psychiatric disease were excluded, a low ﬁ eld strength 
MR scanner was used, and periventricular and subcortical white matter lesions were 
only rated separately. In the Austrian Stroke Prevention Study, people with neurologi-
cal or psychiatric disease and those with an abnormal neurological examination were 
excluded. The prevalence of any white matter lesions in the CHS and Rotterdam Scan 
Study is almost 100%. In contrast with the other studies no participants below the age 
of 60 years were included. 
Most studies had data on severe white matter lesions deﬁ ned as early conﬂ uent or 
conﬂ uent subcortical white matter lesions or periventricular white matter lesions ex-
tending to the subcortical regions. This cut-off was based on a pathological study, which 
found that punctate subcortical white matter lesions and pencil-thin periventricular 
lining in contrary to the above mentioned lesions correlate badly with ischemic damage.1 
We used this cut-off to compare prevalences of more severe white matter lesions.
The highest prevalences of severe white matter lesions and silent lacunar infarcts 
were observed in the CHS and the Rotterdam Scan Study. The ARIC and the Rotterdam 
Scan Study did not exclude participants with a history of stroke or TIA. In the Rotter-
dam Scan Study, the prevalence of silent lacunar infarcts was similar in people with and 
without such a history.22,23 The combined prevalence of severe white matter lesions and 
silent lacunar infarcts in the Austrian Stroke Prevention Study was 20%.24 After exclu-
sion of participants with a history of stroke or TIA, the prevalence of this combination in 
the Rotterdam Scan Study was 33%.
Age – All studies consistently report that the prevalence and severity of both white mat-
ter lesions and silent lacunar infarcts increase with age. Age speciﬁ c data were given 
for three studies (ﬁ gure 2). Comparing data from Rotterdam Scan Study and ARIC 
suggest that the age distribution explains a major part of the differences in observed 
prevalences. The Lund Study shows the marked increase in prevalence from middle to 
older age. The lower prevalence in older age in this study may be explained by exclu-
sion of people with cardiovascular disease and the low response rate, especially in the 
highest age stratum. Prevalences of infarct like lesions (of which approximately 80% 
are lacunar infarcts) ranged from 8% in 55- to 59-year-old age group to 23% in 65- to 72 
year-old age group in the ARIC study, from 22% in 65- to 69-year-old age group to 43% 
in the age group over 85 years in the CHS, and from 8% in 60- to 64-year-old age group 
to 35% in 85- to 90-year-old age group in the Rotterdam Scan Study.22,23,25 This suggests 
that also differences in prevalence of lacunar infarcts across studies largely result from 
differences in age distribution.
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Sex – Sex differences in prevalence of white matter lesions were inconsistently found 
over studies, with higher frequencies and more severe lesions in women. However, much 
of the sex differences disappeared after adjusting for age. In the Rotterdam Scan Study 
women had signiﬁ cantly more frontal periventricular white matter lesions than men in 
all age strata.19 In the CHS the sex differences remained signiﬁ cant after adjusting for 
age. However, in the ARIC no signiﬁ cant sex difference was found. 
Silent lacunar infarcts were signiﬁ cantly more often seen in women in the CHS and 
Rotterdam Scan Study, adjusted for age. 
Ethnicity – Reports on ethnic differences in white matter lesions and silent lacunar 
infarcts prevalences are scarce and equivocal. Prevalence of any white matter lesions 
was signiﬁ cantly lower in Afro-Americans (81%) than in Caucasians (90%) in the ARIC 
study, adjusted for age and sex. However, the prevalence of severe white matter lesions 
was signiﬁ cantly higher in Afro-Americans (14 versus 11%). This difference was largely 
determined by a stronger effect of blood pressure in this group and not by differences in 
socio-economic status.26 
Prevalence of infarct like lesions was doubled in middle-aged African-Americans 
compared to Caucasians of the same age in the ARIC. No such difference was found in 
the older cohort of the CHS.25
There are no data on prevalence of white matter lesions in population-based studies 
in Asia. A Japanese study that included over 900 healthy volunteers without a history 
of cerebrovascular disease, found a prevalence of any subcortical white matter lesions 
of 6% and of moderate to severe periventricular white matter lesions of 20%.27 Possible 
0
20
40
60
80
100
35 45 55 65 75 85 95
%
ARIC
Rotterdam Scan Study
Lund Study
Age (y) 
Figure 2. Prevalence of any 
white matter lesion by age.
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explanations for these relatively low prevalences include the selection of healthy people 
and the large proportion participants younger than 60 years of age. The prevalence 
of silent lacunar infarcts in Japanese studies in healthy volunteers ranges from 11 to 
47%.27,28
Location – Subcortical white matter lesions are not equally distributed over the cerebral 
lobes. The highest prevalence is in the frontal lobe, followed by the parietal lobe.19 The 
larger volume of these lobes or overrepresentation of these regions on the scans can pos-
sible explain this ﬁ nding. Differences in vascular architecture or a different susceptibil-
ity for arteriolosclerosis of  medulary arteries in the frontal and parietal lobe probably 
play a role as well.29
The vast majority of silent lacunar infarcts are located in the lentiform nucleus, in-
ternal capsule (lenticulostriatal arteries) and thalamus (thalamoperforating arteries). 
Approximately two-third of the participants with silent lacunar infarcts has a single 
lesion.22,23,25
Prevalence in dementia patients
White matter lesions are associated with cognitive dysfunction in the general popula-
tion.30 A large number of studies reported the frequency, risk factors and clinical signiﬁ -
cance of these lesions in dementia. The reported prevalence of white matter lesions in 
dementia ranges from 44 to 100% for periventricular white matter lesions and from 60 
to 100% for subcortical white matter lesions.6 Heterogeneity in dementia populations 
plays an important additional role in the difference of reported frequencies of white 
matter lesions and silent lacunar infarctions. Different clinical criteria are used for both 
vascular dementia and Alzheimer dementia.31,32 This variation will inﬂ uence frequen-
cies in the dementia subgroups. The implementation of the NINDS-AIREN criteria will 
have contributed to differences between studies before and after 1993. According to 
these criteria, white matter lesions alone may be sufﬁ cient to diagnose vascular demen-
tia when 25% or more of the white matter is involved.33
Furthermore, selection on disease severity by referral patterns (patients from nurs-
ing homes, memory clinics, neurological outpatient’s clinics, tertiary centres, etc.) and 
history of the disease (early or late diagnosis in relation to disease onset) will cause in-
comparability. A case-control study by Barber et al. gives an overview of the prevalence 
of white matter lesions in the three main groups of dementia compared to age matched 
controls. The prevalence of any periventricular white matter lesions was 100% in vas-
cular dementia, Alzheimer dementia and Lewy body dementia compared to 92% in con-
trols. The prevalence of subcortical white matter lesions or hyperintensities in the basal 
ganglia was 89% in Alzheimer dementia, 96% in vascular dementia and 85% in Lewy 
body dementia, compared to 73% in controls. Both periventricular white matter lesions 
and subcortical white matter lesions were signiﬁ cantly more frequent and more severe 
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in demented of all three subtypes than in controls. Subcortical white matter lesions and 
hyperintensities in the basal ganglia were most frequent and most severe in vascular 
dementia compared to Alzheimer and Lewy body dementia.6
In other studies only periventricular white matter lesions were associated with 
Alzheimer dementia.7,34,35 However others conﬁ rm the association of Alzheimer demen-
tia with subcortical white matter lesions.36 Fazekas et al. proposed that the greater 
extent of periventricular white matter lesions in Alzheimer disease patients compared 
to controls is an epiphenominon of subcortical brain atrophy.34 Future longitudinal data 
should give clarity on this issue.
Prevalence in stroke
In 10 to 27% of stroke patients additional silent infarcts are observed on CT.37,38 About 
80% of these lesions are small lacunar infarcts, predominantly located in the basal gan-
glia or thalamus.37,39
Table 3 shows the prevalences of white matter lesions in stroke patients from studies 
that used CT imaging. The prevalence ranges from 3 to 44%. This variation in preva-
lence was largely based on differences in rating white matter lesions. One study rated 
white matter lesions only if the hypointensity involved both the periventricular white 
matter and the core of the centrum semi-ovale,40 where another already considered a 
hypointensity that only affected the ventricular margins as white matter lesions.5
Furthermore the prevalence of white matter lesions and silent lacunar infarcts with-
in stroke subtypes varies. Clinically manifest lacunar infarcts and deep intracerebral 
hemorrhage were associated with higher prevalence of silent lacunar infarcts and white 
matter lesions on CT within the studies. The highest prevalence of white matter lesions 
was found in the study that only included lacunar infarcts.41
MRI studies conﬁ rm the higher prevalence of severe subcortical white matter le-
sions (diameter lesions >10mm) in persons with lacunar infarcts compared to those with 
non-lacunar infarcts (53 versus 29%). They also show higher prevalences of moderate 
to severe periventricular white matter lesions (diameter lesions >5mm) in persons with 
border-zone infarcts compared to those with non border-zone infarcts.42 However others 
ﬁ nd no difference in prevalence or severity of white matter lesions on MRI in infarct 
subtypes.43
In patients with primary intracerebral hematoma the prevalence of early conﬂ uent 
and conﬂ uent white matter lesions on MRI is 45% and of silent lacunar infarcts is 51%.44 
Severe white matter lesions and silent lacunar infarcts were more frequent in patients 
with deep (basal ganglionic and thalamic) primary intracerebral hematoma compared to 
hemorrhages involving the lobar regions.44,45 In patients with clinical manifest lacunar 
infarction, the presence of multiple small lacunar infarcts was associated with white 
matter lesions.46 Progression of white matter lesions and small lacunar infarcts was asso-
ciated with symptomatic lacunar stroke compared to territorial stroke at study entry.47
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Incidence in population based studies
Very little data are available on incidence or progression of lesions over time. The Aus-
trian Stroke Prevention Study found progression within 3 years in 17.9% of the 273 
participants, of which 9.9% was minor (less than 4 new punctate lesions) and 8.1% was 
marked (more than 4 punctate lesions or a transition to early conﬂ uent or conﬂ uent 
lesions). Age was not associated with lesion progression.48 The main determinant of 
progression was the lesion load at baseline. A longitudinal study on gait disturbances 
and white matter lesions found a signiﬁ cant overall increase of white matter lesions 
volume from 3.1 to 4.2 ml in a mean follow-up of 4 years. The periventricular white mat-
ter lesions showed the most marked increase.8 Progression may be underestimated as 
a result of selective survival of the less severely affected.41,49-51 In the Austrian Stroke 
Prevention Study this selection effect will be even larger since people with an incident 
stroke, which was an end point in that study, were excluded.
SUMMARY AND CONCLUSIONS
Reported prevalence of white matter lesions and silent lacunar infarcts varies largely 
among studies. Differences in study design and assessment of lesions may account for 
the large variation in the frequencies reported.
Any white matter lesions are seen in almost all persons over the age of 70 years and 
studied with modern MRI techniques. Severe white matter lesions are seen in 10 to 33% 
and silent lacunar infarcts in 6 to 20%. Higher age is associated with higher prevalences 
of any white matter lesions, severe white matter lesions and silent lacunar infarcts. 
Women and Afro-Americans tend to have more severe white matter lesions and silent 
lacunar infarcts in some studies. 
Because of heterogeneity in dementia and stroke populations it is difﬁ cult to compare 
frequencies across populations. White matter lesions are more often seen in dementia, 
especially in vascular dementia but also in Alzheimer dementia and Lewy body demen-
tia. White matter lesions and silent lacunar infarcts are associated with clinical mani-
fest lacunar infarcts and deep hemorrhagic stroke. 
Harmonisation of methodological issues and assessment of lesions is needed for 
future studies on small vessel disease related cerebral lesions. Also there is a need for 
more data on incidence and progression of lesions in both population-based studies and 
patient series. 
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Abstract
Cerebral white matter lesions are frequently observed on magnetic resonance imaging (MRI) scans 
in elderly people and are associated with stroke and dementia. Elevated blood pressure is presumed 
one of the main risk factors, although data are almost exclusively derived from cross-sectional stud-
ies. We assessed in ten European cohorts the relation between concurrently and previously measured 
blood pressure levels, hypertension, its treatment and severe cerebral white matter lesions on MRI.
In total 1,805 non-demented subjects aged 65-75 years were sampled from on-going community-
based studies that were initiated 5-20 years prior to the MRI. White matter lesions in the periven-
tricular and subcortical region were rated separately using semi-quantitative measures. We did 
logistic regression analyses adjusted for potential confounders in 1,625 people with complete data.
Concurrently and formerly assessed diastolic and systolic blood pressure levels were positively 
associated with severe white matter lesions. Both, increase and decrease in diastolic blood pressure 
were associated with more severe periventricular white matter lesions. Increase in systolic blood 
pressure levels was associated with more severe periventricular and subcortical white matter le-
sions. People with poorly controlled hypertension had a higher risk of severe white matter lesions 
than those without hypertension, or those with controlled or untreated hypertension.
Higher blood pressure was associated with an increased risk of severe white matter lesions. 
Successful treatment of hypertension may reduce this risk. A potential negative effect of decreasing 
diastolic blood pressure level on the occurrence of severe periventricular white matter lesions should 
be taken into account.
The association between blood pressure, 
hypertension and cerebral white matter 
lesions
3.1
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INTRODUCTION
Cerebral white matter lesions are frequently observed on magnetic resonance imaging 
(MRI) scans in elderly people.1-3 These lesions are associated with an increased risk of 
stroke, cognitive decline and dementia.4-6 Although the exact pathogenesis of these le-
sions is not fully understood, they are considered to reﬂ ect ischemic small vessel disease. 
Elevated levels of blood pressure are thought to contribute to these lesions.7
Hypertension is extremely prevalent in elderly people.8 Cross-sectional population-
based MRI studies have shown a positive association between higher blood pressure and 
severity of white matter lesions.3 Longitudinal data are however scarce. Midlife blood 
pressure reportedly is associated with white matter lesions in the elderly.1,9-11 The Rot-
terdam Scan Study previously found that both an increase and a decrease in blood pres-
sure levels are related to white matter lesions.11 People with uncontrolled hypertension 
seem to have a higher prevalence of severe white matter lesions than people without 
hypertension or with controlled hypertension.1,10
We conducted a study in ten European cohorts to assess the relation between con-
current and earlier assessed blood pressure levels and cerebral white matter lesions in 
nondemented elderly. We also assessed the relation between change in blood pressure 
over time and white matter lesion severity. Finally, we assessed the relation between 
hypertension, its treatment, and severe white matter lesions.
METHODS
Study population
The Cardiovascular Determinants Of Dementia (CASCADE) Study is a multi-center col-
laborative study in Europe designed to study the etiology and natural history of brain 
abnormalities.12 The study is based on ten on-going community-based cohorts that had 
been established 5 to 20 years prior to the CASCADE measurement.2,13-20 Excluded for 
the CASCADE study were persons with a known clinical diagnosis of dementia or with 
Mini Mental State Examination scores <15 and those with contraindications for the 
MRI. In total 1,805 men and women aged 65-75 years, were randomly selected from the 
consecutive baseline cohorts. Since data on blood pressure-lowering medication were 
missing for the cohort from the United Kingdom (n=180), this study was excluded leav-
ing 1,625 participants.
Informed consent was obtained at each center in accordance with guidelines from 
local Institutional Review Boards. All the individuals who took part in the exam were 
mobile and competent to understand the nature of their participation.
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Measurement of risk factors
Data collection for CASCADE (i.e. concurrent) took place between 1996-1998 and in-
cluded blood pressure measurements, assessments of cognitive function and brain MRI. 
Also available to CASCADE were the risk factor data collected in previous surveys of 
the individual cohorts except for Austria and France. The average time between the 
CASCADE and the preceding assessment was 5.7 (SD 2.2) years and ranged from 2.5-10 
years, not taking into account the Zoetermeer Study in which it was 20 years.
Blood pressure was measured twice by a physician or trained research-nurse, on 
the right arm with the participant in sitting position and except for Italy with the use 
of a random-zero sphygmomanometer. The average of the two measurements was used. 
The methodology used to asses blood pressure levels followed MONICA protocol or a 
comparable protocol and was the same in all cohorts at all times the blood pressure was 
measured.21 Hypertension was deﬁ ned as a systolic blood pressure of ≥ 160mmHg, or a 
diastolic blood pressure of ≥ 95mmHg or the use of blood pressure lowering-medication, 
according to the WHO-guidelines for the treatment of hypertension at the time of the 
MRI assessment.22 Diuretics, calcium antagonists, beta-blockers and ACE-inhibitors or 
comparable preparations were considered as blood pressure-lowering medication. Sub-
jects were considered as successfully treated if they used blood pressure-lowering medi-
cation and their systolic and diastolic blood pressures were <160mmHg and <95mmHg, 
respectively. If their blood pressure still fulﬁ lled criteria of hypertension despite blood 
pressure-lowering medication, they were classiﬁ ed as poorly controlled.
Diabetes was deﬁ ned as a history of diabetes conﬁ rmed by the treating physician 
or as the use of oral anti-diabetics or insulin or as a fasting glucose level of 7mmol/l or 
greater, or a non-fasting glucose level of ≥11.1mmol/l. Smoking status was categorized 
as never, former and current cigarette smoking. Hypercholesterolemia was deﬁ ned as a 
total cholesterol level of ≥6.5mmol/l. Body mass index was calculated as weight divided 
by height squared.
White matter lesions
All MRI scans were made with a 1.0T or 1.5T machine. The core protocol included T1-, 
T2-, and proton density (PD)-weighted images with 20 axial slices, 5 or 6mm thick with 
an interslice gap of 20 percent. The same mobile MRI machine (1.0T, Siemens, Ger-
many) was sent to ﬁ ve study sites (Spain, Italy, Poland, Sweden, and UK). The German 
and Dutch cohorts acquired images on a 1.5T machine using the core MRI protocol. 
Subsequent to the start of CASCADE, two other centers with already collected scans 
were included (France and Austria); those scans had been obtained with comparable 
protocols.
White matter lesions were considered present if visible as hyperintense on PD and 
T2-weighted images, without prominent hypointensity on T1-weighted scans. Periven-
tricular white matter lesions grade (range 0-9) was assessed by summing three region 
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speciﬁ c semiquantitative grades (lesions adjacent to the frontal horns, the lateral walls, 
and the occipital horns of the lateral ventricle). We counted subcortical white matter 
lesions in three size categories based on their maximal diameter (<3mm, 3-10mm, 
>10mm). A total volume was approximated by assuming that these subcortical lesions 
were spherical with a ﬁ xed diameter (range 0-23ml).11
One neuro-radiologist trained three raters who scored hard copies of the images. One 
rater (Reading A) scored the scans from all the studies except from the Netherlands. The 
rater was blinded to center. The scans from the Netherlands were read by the two other 
raters (Reading B). There was no signiﬁ cant intra-reader difference in the measure-
ments between reading A and B. Both intrarater and interrater studies (n=100 from the 
Dutch cohorts) showed a good to excellent agreement (κ=0.79-0.90, r=0.88-0.95).11
Data analysis
White matter lesion distributions were dichotomized at the upper quintile to represent 
severe white matter lesions (for periventricular white matter lesions grade ≥4 and for 
subcortical white matter volume ≥1.5ml). We calculated relative risks as estimated by 
the odds ratio, by means of multivariate logistic regression to quantify the association 
between blood pressure measurements and severe white matter lesions.
Changes in blood pressure were calculated as change in mmHg per year to adjust 
for differences in length of follow-up. Subsequently it was grouped in ﬁ ve categories (for 
diastolic blood pressure: <-2.5; -2.5 to -0.5; -0.5 to 0.5; 0.5 to 2.5; >2.5 mmHg/year and 
for systolic blood pressure: <-2.5; -2.5 to 0; 0 to 2.5; 2.5 to 5; >5 mmHg/year). The mid-
dle category was used as the reference category after data inspection. Because of the J-
shaped association with change in diastolic blood pressure reported earlier in the Dutch 
cohorts, we repeated this analysis excluding the participants from these two cohorts to 
conﬁ rm this association in the other cohorts.11 Adjustment was made for age, sex, study 
site and potential confounding cardiovascular risk factors. Analyses with previous blood 
pressure data were additionally adjusted for follow-up time.
Prior to data pooling we visually inspected the cohort speciﬁ c estimates and assessed 
heterogeneity by formal testing of the study × blood pressure interaction. For the Ger-
man cohort the effect of blood pressure on severe white matter lesions was signiﬁ cantly 
different from the other cohorts. Therefore we assessed pooled estimates with and with-
out the German cohort.
We did logistic regression analysis with dummy variables for people with untreated 
hypertension, successfully treated hypertension and poorly controlled hypertension, to 
estimate the relative risks for severe white matter lesions compared to people with no 
hypertension.
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RESULTS
Table 1 presents characteristics of the study participants overall and stratiﬁ ed by study 
site. Blood pressure levels, the prevalence of hypertension and elevated blood pressure 
were highest in Poland and lowest in Spain and France.
Per 5 mmHg in diastolic blood pressure (concurrent)
Austria
France
Germany
Italy
Netherlands (RS)
Netherlands (ZS)
Poland
Spain
Sweden
All
All (without Germany)
Per 5 mmHg in diastolic blood pressure (previous)
Germany
Italy
Netherlands (RS)
Netherlands (ZS)
Poland
Spain
Sweden
All
All (without Germany)
Per 10 mmHg in systolic blood pressure (concurrent)
Austria
France
Germany
Italy
Netherlands (RS)
Netherlands (ZS)
Poland
Spain
Sweden
All
All (without Germany)
Per 10 mmHg in systolic blood pressure (previous)
Germany
Italy
Netherlands (RS)
Netherlands (ZS)
Poland
Spain
Sweden
All
All (without Germany)
0,25 0,5 0,75 1 1,25 1,5 1,75 2
Figure 1. Odds ratios with 
95% conﬁ dence intervals 
of concurrently and previ-
ously assessed diastolic (per 
5mmHg) and systolic blood 
pressure (per 10 mmHg) 
for severe periventricular 
white matter lesions overall 
and stratiﬁ ed on study 
site (adjusted for age, sex, 
diabetes, smoking, hyperc-
holesterolemia, use of blood 
pressure-lowering medica-
tion and study site).
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Higher concurrent and previous diastolic and systolic blood pressures were equally 
associated with an increased risk of severe white matter lesions (ﬁ gures 1 and 2). The 
estimates for the German cohort in relation to periventricular white mater lesions were 
signiﬁ cantly different from the others. The pooled fully adjusted relative risks (without 
Germany) of concurrently measured diastolic (per 5mmHg) and systolic (per 10mmHg) 
Per 5 mmHg in diastolic blood pressure (concurrent)
Austria
France
Germany
Italy
Netherlands (RS)
Netherlands (ZS)
Poland
Spain
Sweden
All
All (without Germany)
Per 5 mmHg in diastolic blood pressure (previous)
Germany
Italy
Netherlands (RS)
Netherlands (ZS)
Poland
Spain
Sweden
All
All (without Germany)
Per 10 mmHg in systolic blood pressure (concurrent)
Austria
France
Germany
Italy
Netherlands (RS)
Netherlands (ZS)
Poland
Spain
Sweden
All
All (without Germany)
Per 10 mmHg in systolic blood pressure (previous)
Germany
Italy
Netherlands (RS)
Netherlands (ZS)
Poland
Spain
Sweden
All
All (without Germany)
0,25 0,5 0,75 1 1,25 1,5 1,75 2
Figure 2. Odds ratios with 
95% conﬁ dence intervals 
of concurrently and previ-
ously assessed diastolic (per 
5mmHg) and systolic blood 
pressure (per 10mmHg) for 
severe subcortical white 
matter lesions overall and 
stratiﬁ ed on study site 
(adjusted for age, sex, 
diabetes, smoking, hyperc-
holesterolemia, use of blood 
pressure-lowering medica-
tion and study site).
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blood pressure were respectively 1.15 (95%CI 1.09;1.23) and 1.13 (95%CI 1.06;1.21) for 
severe periventricular white matter lesions and 1.14 (95%CI 1.07;1.21) and 1.12 (95%CI 
1.05;1.19) for severe subcortical white matter lesions. Additional adjustment for length 
of follow-up time or body mass index did not alter the association between previously 
assessed blood pressure and severe white matter lesions.
Both a decrease and an increase in diastolic blood pressure, were associated with 
a more than doubled risk of severe periventricular white matter lesions, compared to 
stable blood pressure levels over time (table 2). Additional adjustment for blood pres-
sure-lowering medication did not change these associations. The same pattern was 
observed in relation to severe subcortical white matter lesions, however these effects 
were not statistically signiﬁ cant. These J-shaped associations with changes in diastolic 
blood pressure became slightly stronger after exclusion of the two Dutch cohorts, in 
which this association was described before. A clear increase in systolic blood pressure 
was associated with a higher risk of severe periventricular and subcortical white matter 
lesions (table 3).
Hypertension is strongly related to severe subcortical and periventricular white 
matter lesions (table 4). People who were treated for high blood pressure and still had 
elevated levels had the highest risk of severe white matter lesions, compared to people 
without hypertension. They also had a signiﬁ cantly higher risk of severe white matter 
lesions than people with untreated or controlled hypertension. Exclusion of the German 
cohort did not alter these results.
Table 2. Odds ratios (95%CI) of change in diastolic blood pressure per year for severe white 
matter lesions (exclusive Germany).
Severe
white matter 
lesions
Change in diastolic blood pressure per year
<-2.5
mmHg/y
(n=105)
-2.5 to -0.5
mmHg/y
(n=255)
-0.5 to 0.5
mmHg/y
(n=268)
0.5 to 2.5
mmHg/y
(n=260)
>2.5
mmHg/y
(n=122)
Periventricular 
   Model 1 2.2 (1.1;4.3) 1.6 (1.0;2.5) 1.0 (ref) 1.7 (1.1;2.8) 2.8 (1.6;5.2)
   Model 2 1.9 (1.0;3.8) 1.4 (0.9;2.3) 1.0 (ref) 1.8 (1.1;2.8) 2.8 (1.5;5.1)
   Model 3 4.1 (1.6;10.8) 1.8 (0.8;4.1) 1.0 (ref) 1.8 (0.8;4.0) 4.4 (1.7;11.2)
Subcortical 
   Model 1 1.7 (0.9;3.2) 1.4 (0.9;2.3) 1.0 (ref) 1.6 (1.0;2.6) 1.3 (0.7;2.4)
   Model 2 1.5 (0.8;2.9) 1.4 (0.8;2.2) 1.0 (ref) 1.6 (1.0;2.7) 1.3 (0.7;2.4)
   Model 3 2.3 (1.0;5.3) 1.6 (0.8;3.3) 1.0 (ref) 1.5 (0.7;3.1) 1.9 (0.8;4.4)
Model 1 Adjusted for age, sex, diabetes, smoking, hypercholesterolemia and study site
Model 2 Additionally adjusted for blood pressure-lowering medication
Model 3 As model 2 and the 2 Dutch cohorts excluded
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DISCUSSION
This study demonstrates that concurrently and formerly assessed higher systolic and 
diastolic blood pressure levels are associated with a higher prevalence of severe peri-
ventricular and subcortical white matter lesions. These ﬁ ndings were observed in all 
individual cohorts from different European countries except for Germany. Both people 
with a clear increase and clear decrease in diastolic blood pressure had more periven-
tricular white matter lesions compared to people whose blood pressure remained stable. 
Increase in systolic blood pressure was associated with a higher prevalence of severe 
Table 3. Odds ratios (95%CI) of change in systolic blood pressure per year for severe white 
matter lesions (exclusive Germany).
Severe
white matter 
lesions
Change in systolic blood pressure per year
<-2.5
mmHg/y
(n=125)
-2.5 to 0
mmHg/y
(n=177)
0 to 2.5
mmHg/y
(n=400)
2.5 to 5
mmHg/y
(n=155)
>5
mmHg/y
(n=154)
Periventricular 
   Model 1 1.2 (0.7;2.2) 1.0 (0.6;1.6) 1.0 (ref) 1.2 (0.7;1.9) 1.8 (1.1;3.0)
   Model 2 1.1 (0.6;1.9) 0.9 (0.6;1.4) 1.0 (ref) 1.1 (0.7;1.9) 1.8 (1.1;3.0)
   Model 3 1.9 (0.9;4.0) 1.3 (0.7;2.7) 1.0 (ref) 1.4 (0.7;3.0) 2.4 (1.2;5.1)
Subcortical 
   Model 1 1.6 (0.9;2.8) 1.4 (0.9;2.2) 1.0 (ref) 1.4 (0.9;2.4) 1.6 (1.0;2.8)
   Model 2 1.5 (0.8;2.6) 1.3 (0.8;2.0) 1.0 (ref) 1.4 (0.9;2.3) 1.6 (1.0;2.7)
   Model 3 1.4 (0.7;2.7) 1.6 (0.9;3.0) 1.0 (ref) 1.2 (0.6;2.4) 1.2 (0.6;2.4)
Model 1 Adjusted for age, sex, diabetes, smoking, hypercholesterolemia and study site
Model 2 Additionally adjusted for blood pressure-lowering medication
Model 3 As model 2 and the 2 Dutch cohorts excluded
Table 4. Odds ratios (95% CI) of hypertension and its treatment status for severe white matter 
lesions compared to normotensives who did not use blood lowering medication.
Severe
white matter 
lesions
No
hypertension
Hypertension Hypertension treatment status
(n=814)
All
(n=811)
Untreated
(n=267)
Treated
successfully
(n=336)
Poorly
controlled
(n=208)
Periventricular 
Subcortical 
1.0 (ref)
1.0 (ref)
1.6 (1.3;2.2)
1.4 (1.1;1.8)
1.5 (1.0;2.2)
1.1 (0.8;1.7)
1.4 (1.0;2.0)
1.3 (0.9;1.8)
2.3 (1.6;3.4)
2.0 (1.4;2.9)
Adjusted for age, sex, diabetes, smoking, hypercholesterolemia, and study site 
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periventricular and subcortical white matter lesions. People with uncontrolled hyper-
tension had more often severe white matter lesions than those without hypertension or 
those with controlled or untreated hypertension.
The strengths of this study are its large number of participants originating from 
different countries reﬂ ecting the wide range of cardiovascular risk in Europe, and its 
longitudinal design in blood pressure measurements. Individual studies on risk factors 
of white matter lesions are often hard to compare due to methodological differences.23 
The standardized blood pressure and white matter lesions assessment and comparable 
study designs made it possible to pool the individual studies in CASCADE.
Some methodological limitations of this study need to be considered. First, par-
ticipants had to be survivors of the cohort they originated from. People with high blood 
pressure levels or extreme changes in blood pressure levels over time, may have prefer-
entially died and hence will be underrepresented.24 If this non-participation was prefer-
ential in people with severe white matter lesions, which could be due to possible shared 
vascular risk factors and susceptibility with myocardial infarction and stroke, selection 
bias would have led to underestimation of the real associations.
A second potential source of selection bias was the incomplete response.12 Non-re-
sponse was most likely in people with high blood pressure and more severe white mat-
ter lesions.10 Therefore, selection may have biased our results most likely towards an 
underestimation of the real associations.
Third, the association between blood pressure and white matter lesions might be 
confounded by other cardiovascular risk factors, study site, or length of follow-up time. 
However, adjustment for these factors did not signiﬁ cantly alter the association between 
blood pressure and white matter lesions, which suggests that white matter lesions are 
independently related to blood pressure levels and changes.
We did not observe differences between the cohorts from the different European 
countries with respect to the association between blood pressure and white matter le-
sions, except for Germany. There was no north-south gradient as seen in cardiovascular 
mortality.25 We do not have a biological explanation for the deviant results in the Ger-
man cohort. Selection, as mentioned above, may have preferentially effected the Ger-
man study. Additional analyses for the deviant ﬁ ndings in the German study conﬁ rm 
a clear selection effect (non-participants had a signiﬁ cant higher blood pressure, more 
vascular co-morbidities and a lower self perceived general health status than partici-
pants of the German cohort).
Concurrent and previous diastolic and systolic blood pressure levels had a similar 
magnitudes of association to more severe white matter lesions in this sample of non-de-
mented men and women. The main hypothesis regarding this association is that long-
standing hypertension causes structural changes of the cerebral small vessels, such as 
thickening of the vessel walls with narrowing of the lumen, hyalinosis of the media re-
sulting in stiffness, and tortuous elongation.7 Together these changes lead to increased 
EvD03-1.indd   36 23-03-2004, 13:44:00
Blood pressure, hypertension and cerebral WML
37
vascular resistance and hence hypoperfusion. Furthermore, longstanding hypertension 
may impair cerebral autoregulation. In healthy people the mean arterial pressure re-
mains within limits to assure perfusion during ﬂ uctuations in systemic blood pressure. 
These limits may shift upwards with chronic hypertension, resulting in transient falls 
in cerebral blood ﬂ ow during periods of lower blood pressure.26 Episodes of hypoten-
sion may then lead to hypoperfusion and ischemia of the white matter. Yet another 
pathogenetic mechanism may be involved. Hypertension may cause disturbances in the 
blood-brain barrier, which may cause lesions in the white matter by cerebral oedema, 
activation of astrocytes, destructive enzymes or other toxins which pass through the 
damaged vessel walls.27
This study conﬁ rms the association between decrease in diastolic blood pressure 
and periventricular white matter lesions, that was observed in the Rotterdam Scan 
Study.11 Most vulnerable for hypoperfusion are the areas that are already marginally 
perfused and lack a collateral circulation. The periventricular white matter represents 
such an arterial border zone, which in combination with insufﬁ cient autoregulation is 
highly sensitive for drops in blood pressure levels.28,29 Hypotension might be contributed 
to a too aggressive anti-hypertension treatment in elderly people with up-shifted au-
toregulation limits. People with the highest blood pressure levels in the past, who are 
therefore at a high risk, are most likely to drop substantially in blood pressure, due to 
treatment, change in life style, and aging. A drop in diastolic blood pressure may also be 
a consequences of arterial stiffening as part of progression of atherosclerosis, which is 
associated with white matter lesions.30,31
We found that people with poorly controlled hypertension have a higher risk of 
severe white matter lesions than people without hypertension. People with control-
led or non-treated hypertension had an intermediate risk. This observed association is 
compatible with reported data on Caucasians in a comparable age range.1 A possible 
explanation for our ﬁ nding is that adequate control of hypertension may lead to a lesser 
degree of cerebral small vessel disease. The observation that people with poorly control-
led hypertension have more severe white matter lesion than people without treatment 
may probably be explained by less severe and shorter duration of hypertension in the 
untreated group.
Perspectives
Our results may offer potential therapeutic possibilities in preventing and reducing the 
attendant cognitive decline and dementia. However, a randomized clinical trial would 
be needed to evaluate the effect of treatment of hypertension on the development of 
white matter lesions and its possible consequences.32 The potential adverse effect of 
lowering the diastolic blood pressure should be born in mind and data on white matter 
lesion progression should be noticed.33
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Abstract
Silent brain infarcts and white matter lesions are frequently seen on magnetic resonance imaging 
in healthy elderly people and both are associated with an increased risk of stroke and dementia. 
Plasma total homocysteine may be a potentially modiﬁ able risk factor for stroke and dementia. 
We examined whether elevated total homocysteine levels are associated with silent brain infarcts 
and white matter lesions. The Rotterdam Scan Study is a population-based study of 1077 people 
aged 60 to 90 years who had cerebral magnetic resonance imaging. The cross-sectional relation of 
total homocysteine with silent infarcts and white matter lesions was analyzed with adjustment for 
cardiovascular risk factors. The mean plasma total homocysteine level was 11.5 µmol/l (standard 
deviation 4.1). The risk of silent brain infarcts increased with increasing total homocysteine levels 
(odds ratio 1.24/standard deviation increase, 95% conﬁ dence interval 1.06- 1.45). The severity of 
periventricular white matter lesions and extent of subcortical white matter lesions were also sig-
niﬁ cantly associated with total homocysteine levels, even after excluding those with silent brain 
infarcts. The overall risk of having either a silent brain infarct or severe white matter lesions was 
strongly associated with total homocysteine levels (odds ratio 1.35/standard deviation increase, 
95% conﬁ dence interval 1.16- 1.58). We concluded that total homocysteine levels are associated with 
silent brain infarcts and white matter lesions independent of each other and of other cardiovascular 
risk factors. 
Homocysteine, silent brain infarcts
and white matter lesions
3.2
EvD03-2.indd   41 23-03-2004, 13:45:16
Chapter 3.2
42
INTRODUCTION
Silent brain infarcts and white matter lesions are frequently seen on brain magnetic 
resonance imaging (MRI) in healthy elderly and either is associated with an increased 
risk of stroke1 and dementia.2,3 The presence of these lesions has been associated with 
several cardiovascular risk factors.4,5 Both prospective and retrospective studies report-
ed that an elevated total homocysteine (tHcy) concentration is a potentially modiﬁ able 
risk factor for stroke.6-9 More recently, several retrospective studies have shown that el-
evated levels of tHcy may also be a risk factor for dementia.10,11 A recent study suggested 
that elderly patients with elevated tHcy levels had an increased risk of silent brain 
infarcts, but that study did not examine any associations with white matter lesions.12 
We examined whether elevated plasma tHcy, as a potentially modiﬁ able risk factor,13 
is associated with an increased risk of silent brain infarcts and white matter lesions in 
elderly people and assessed the extent to which any such associations are independent 
of other cardiovascular risk factors and of each other.
PATIENTS AND METHODS
The Rotterdam Scan Study was designed to study the etiology and natural history of age-
related brain changes in the elderly. In 1995 to 1996, we randomly selected participants 
aged 60 to 90 years by sex and by age in 5-year age strata from the population-based 
Zoetermeer14 and Rotterdam15 studies. A total of 1077 non-demented elderly persons 
participated in our study (overall response 63%).16 Each person gave informed consent to 
participate in our study, which had been approved by the medical ethics committee. 
Total plasma homocysteine level
We collected nonfasting blood samples into vacutainers containing sodium citrate in 
1995 to 1996. Samples were put on ice immediately, centrifuged within 60 minutes, and 
aliquots of plasma were stored at -800C. In 1999 to 2000, plasma levels of tHcy were 
determined by ﬂ uorescence polarisation immunoassay on an IMx analyser (Abbott 
Laboratories, Chicago, IL). This method has an intralaboratory imprecision of less than 
5% and showed linearity throughout the 5 to 45 µmol/l range.17 Blood samples were not 
available for 39 participants because of failure to obtain a sample. Seven participants 
were excluded because their tHcy level fell outside this range.
Cardiovascular risk factors
We obtained information on the following variables by interview and physical examina-
tion in 1995 to 1996: systolic blood pressure, antihypertensive drugs, diabetes mellitus, 
pack years of smoking, and vitamin use.18 The presence of carotid artery plaques, the 
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intima-media thickness of the common carotid artery, and the presence of peripheral 
arterial disease were assessed as noninvasive markers of atherosclerotic disease.19
Cerebral infarcts and white matter lesions
We obtained axial T1, T2 weighted and proton density MRI scans of the brain on 1.5 
Tesla MRI scanners (MR Gyroscan, Philips, Best, the Netherlands, and MR VISION, 
Siemens, Erlangen, Germany) in 1995 and 1996. The slice thickness was 5 or 6 mm 
(scanner dependent) with a 20% interslice gap.
Infarcts were rated by a single rater and were deﬁ ned as focal hyperintensities on T2 
weighted images, 3 mm in size or larger. Proton density scans were used to distinguish 
infarcts from dilated perivascular spaces. Lesions in the white matter also had to have 
corresponding prominent hypointensities on T1 weighted images in order to distinguish 
them from cerebral white matter lesions.18 We obtained a history of stroke and tran-
sient ischaemic attack (TIA) by self-report and by checking medical records in all 1,077 
participants. A neurologist subsequently reviewed the medical history and scans and 
categorized the infarcts as silent or symptomatic. We deﬁ ned silent brain infarcts as 
evidence of one or more infarcts on MRI, without a history of a (corresponding) stroke 
or TIA. Participants with both symptomatic and silent infarcts were categorized in the 
symptomatic infarct group. Twenty participants with a conﬁ rmed history of stroke had 
no infarcts on MRI. Three of them experienced a hemorrhagic stroke; the 17 others with 
ischaemic (n = 12) or unspeciﬁ ed (n = 5) stroke had minor symptoms.
White matter lesions were considered present if visible as hyperintense on proton 
density and T2 weighted images, without prominent hypointensity on T1 weighted 
scans. We scored periventricular and subcortical white matter lesions separately. Peri-
ventricular white matter lesions were rated semiquantitatively (grade range 0-9). A to-
tal volume of subcortical white matter lesions was approximated based on number and 
size of lesions (volume range 0-29.5 ml).20
Statistical analysis
Participants with symptomatic infarcts were excluded from all analyses. We analyzed 
the association between quintiles of tHcy and presence of silent brain infarcts us-
ing multiple logistic regression. Using a dichotomous approach, the reference group 
comprised all participants without infarcts visible on MRI. No distinction was made 
between participants with one or more infarcts on their scan. We evaluated the associa-
tion of quintiles of tHcy and white matter lesions using analysis of covariance. The re-
lationship of tHcy levels and white matter lesions was also analyzed continuously using 
multiple linear regression models. We performed separate analyses for periventricular 
and subcortical lesions. All analyses were adjusted for age, sex, systolic blood pressure, 
antihypertensive drugs, diabetes mellitus, and pack years of smoking. Additionally, we 
adjusted for markers of atherosclerotic disease to examine whether such associations 
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with tHcy were mediated by atherosclerosis.
Since the presence of silent brain infarcts and white matter lesions on MRI are 
highly correlated, we tested whether the association of tHcy with white matter lesions 
was explained by the relation between tHcy and silent brain infarcts. We therefore 
repeated the above analyses with white matter lesions after exclusion of participants 
with silent infarcts on MRI, and vice versa for the association with silent brain infarcts. 
Finally, we analyzed the association of tHcy with the presence of either silent infarcts 
or severe white matter lesions, deﬁ ned as white matter lesions in the upper quintile of 
their distribution.
RESULTS
Selected characteristics of the study population are shown in Table 1. Twenty percent 
had one or more silent brain infarcts on MRI, 80% of the 1077 participants had any 
periventricular, and 92% any subcortical white matter lesions. The mean plasma tHcy 
was 11.5 µmol/l (SD 4.1). Plasma tHcy concentrations signiﬁ cantly increased with age 
(1.5 µmol/l increase/10 yrs) and were about 1.1 µmol/l higher in men than in women, 1.2 
Table 1. Characteristics of the study population in 1995-1996.
All participants
n = 1077
Age (yr) 72.2 (SD 7.4)
Women 51.5%
Plasma total homocysteine (µmol/l) 11.5 (SD 4.1)
Systolic blood pressure (mm Hg) 147 (SD 22)
Use of antihypertensive drugs 34.7%
Diabetes mellitus   5.8%
Smoking: never (0 pack yr)
 > 0 and < 20 pack yr
 ≥ 20 pack yr
34.6%
29.6%
35.8%
Use of vitamins   5.8%
Participants with infarcts on MRI: silent
 symptomatic
 both
20.1%
  2.4%
  1.5%
White matter lesions: periventricular (grade)
 subcortical (ml)
2.4 (SD 2.2)
1.4 (SD 2.9)
Values are unadjusted means (standard deviation) or percentages.
SD = standard deviation.
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Table 2. Association of quintiles of plasma total homocysteine (tHcy) level with silent brain 
infarcts, severe white matter lesions, and both on magnetic resonance imaging.
tHcy in quintiles (µmol/l)
SBI
OR (95% CI)c
Severe WMLa
OR (95% CI)c
SBI and/or
severe WMLb
OR (95% CI)c
I 5.0-  8.5 1 (ref) 1 (ref) 1 (ref)
II 8.6-  9.8 1.4 (0.8-2.5) 1.9 (1.0-3.4) 1.7 (1.0-2.9)
III 9.9-11.3 1.7 (1.0-3.1) 2.1 (1.1-3.7) 2.0 (1.2-3.3)
IV 11.4-13.7 1.6 (0.9-2.9) 2.0 (1.1-3.7) 2.3 (1.4-3.8)
V 13.8-45.0 2.5 (1.4-4.5) 2.3 (1.3-4.2) 3.0 (1.8-5.2)
aPresence of severe periventricular and/or severe subcortical white matter lesions, deﬁ ned by the 
upper quintile of their distribution.
bPresence of silent brain infarcts and/or severe periventricular and/or severe subcortical white mat-
ter lesions.
cAdjusted for age, sex, systolic blood pressure, antihypertensive drugs, diabetes mellitus, and 
smoking.
SBI = silent brain infarcts; OR = odds ratio; CI = conﬁ dence interval; WML = white matter le-
sions.
µmol/l higher in participants who took antihypertensive drugs, and 1.4 µmol/l lower in 
participants who used vitamins than those who did not. Plasma tHcy levels were 0.6 
µmol/l higher for every increase in plaque category. However, this association disap-
peared after adjustment for age, sex and other confounders (0.1 µmol/l per increase in 
plaque category (95% conﬁ dence interval –0.2-0.4)). Plasma tHcy was also not associ-
ated with intima-media thickness nor with peripheral artery disease (data not shown).
Silent brain infarcts were 2.5 times as common in the top quintile compared with 
the bottom quintile of plasma tHcy levels (Table 2). Because the crude and adjusted 
risk estimates and 95% conﬁ dence intervals were almost identical, only the adjusted 
risk estimates are presented. The results were unaltered by further adjustment for 
markers of atherosclerosis (data not shown). Participants were 24% more likely to have 
silent infarcts per standard deviation increase in tHcy (95% conﬁ dence interval 6-45%). 
The association of silent brain infarcts with tHcy was also signiﬁ cant in participants 
after exclusion of those with periventricular white matter lesions (odds ratio 1.79/SD 
increase, 95% conﬁ dence interval 1.08-2.98).
White matter lesions were also associated with plasma tHcy levels (Figure). Partici-
pants in the top quintile of tHcy had more than double the prevalence of severe white 
matter lesions on MRI compared with those in the bottom quintile (see Table 2). Severity 
of both periventricular and subcortical white matter lesions increased with higher tHcy 
levels (Table 3). These associations were unaltered by further adjustment for atheroscle-
rotic disease. After exclusion of those with silent infarcts on MRI, the association of tHcy 
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Table 3. Association of plasma total homocysteine (tHcy) levels with periventricular and sub-
cortical white matter lesions
Periventricular white matter lesions
(Mean increase in grade, 95% CI)a
Subcortical white matter lesions
(Mean increase in volume [ml], 95% CI)a
All participants Participants
without infarcts
All participants Participants
without infarcts
Model 1b 0.19 (0.06-0.31) 0.21 (0.08-0.33) 0.24 (0.07-0.42) 0.14 (0.003-0.28)
Model 2c 0.18 (0.05-0.30) 0.19 (0.06-0.32) 0.25 (0.08-0.42) 0.14 (0.001-0.28)
Model 3d 0.17 (0.05-0.30) 0.16 (0.03-0.29) 0.25 (0.08-0.43) 0.11 (–0.03-0.25)
a Mean increase in grade or volume (ml) per standard deviation increase in tHcy level.
b Adjusted for age and sex.
c Additionally adjusted for systolic blood pressure, antihypertensive drugs, diabetes mellitus, and 
smoking.
d Adjustments as in Model 2, with atherosclerotic markers included in the model.
CI = conﬁ dence interval.
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Figure. Association between quintiles of plasma total homocysteine (tHcy) level and periven-
tricular (A) and subcortical (B) white matter lesions (mean grade or volume (ml) and 95% conﬁ -
dence intervals, adjusted for age, sex, systolic blood pressure, antihypertensive drugs, diabetes 
mellitus, and smoking).
A B
with periventricular white matter lesions was unaltered; the association of tHcy with 
subcortical white matter lesions was attenuated but remained signiﬁ cant.
A total of 378 (36%) of the 1,077 participants had either infarcts on MRI, severe 
white matter lesions or both. Plasma total tHcy levels were increased in these partici-
pants (see Table 2). The risk of having either a silent brain infarct or severe white mat-
ter lesions was strongly associated with tHcy levels (odds ratio 1.35/SD increase, 95% 
conﬁ dence interval 1.16- 1.58), and further adjustment for atherosclerotic markers did 
EvD03-2.indd   46 23-03-2004, 13:45:23
Homocysteine, silent brain infarcts and WML
47
not alter these associations. Exclusion of participants who used vitamins or who had a 
history of stroke but no infarct on MRI did not change any of the results above.
DISCUSSION
The present study demonstrated a strong and signiﬁ cant association between plasma 
tHcy levels and silent brain infarcts and white matter lesions on MRI. We showed that 
plasma total tHcy is an independent risk factor for the presence of silent brain infarcts, 
white matter lesions, and both. The relationships of these MRI lesions with tHcy levels 
were continuous and graded, with no obvious threshold below which lower tHcy levels 
were not associated with lower risks of disease.
The strengths of this study are the population-based design and the large number of 
elderly participants. However, because the response rate in our study was about 63%, it 
is possible that selection bias may have inﬂ uenced the results. Those people who agreed 
to participate were signiﬁ cantly younger and had a lower prevalence of hypertension 
compared with nonresponders.20 Old age and hypertension are known risk factors for 
the presence of both silent brain infarcts and white matter lesions. Hence, people with 
infarcts and severe white matter lesions on MRI may be somewhat underrepresented in 
our study. This bias might be expected to result in an attenuation of any association of 
tHcy with MRI lesions. 
The plasma tHcy level was measured without knowledge of other risk factors or pres-
ence of lesions on MRI. Silent brain infarcts and white matter lesions were scored also 
blind to all other data. Therefore, any misclassiﬁ cation will be random and result in an 
underestimation of the strength of any risk associations. The use of a single tHcy meas-
urement to classify persons may have underestimated the strength of any associations 
because of regression dilution by 10% to 15%.21 
Elevated tHcy levels reﬂ ect nutritional deﬁ ciencies, genetic defects, or renal impair-
ment. We do not have data on any of these determinants of tHcy concentrations and 
hence the present study is unable to address these issues. Further studies are required 
to address the extent to which the differences caused by tHcy levels reﬂ ect vitamin B12 
or folate deﬁ ciency or renal impairment.
Recently, a study involving 153 participants reported a fourfold increased risk of si-
lent brain infarcts in elderly with a tHcy greater than 15 µmol/l, but it did not present an 
odds ratio of silent brain infarcts after adjustment for all other confounders.12 This study 
showed no attenuation of the association between tHcy and silent brain infarcts after 
adjustment for renal function. The strong association between tHcy and silent brain 
infarcts is consistent with results from previous studies that showed that tHcy is a risk 
factor for symptomatic infarcts.6,7,22 There have been no previous published studies that 
have examined the relationship between tHcy and white matter lesions. Plasma tHcy 
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levels showed a signiﬁ cant relationship with both periventricular and subcortical white 
matter lesions, although the latter association was attenuated after exclusion of those 
without infarcts on MRI. We previously suggested periventricular and subcortical white 
matter lesions might have a different pathophysiology.23 The vascular supply to the sub-
cortical white matter is believed to be superior to the periventricular region, which as an 
arterial border zone may be more vulnerable to hypoperfusion.24,25 We hypothesize that 
this may render the periventricular white matter more susceptible to damage caused by 
elevated tHcy levels. This might explain our ﬁ nding of a stronger relationship of tHcy 
levels with periventricular than with subcortical white matter lesions.
The mechanisms through which elevated tHcy levels might cause vascular damage 
to the brain are unclear. Elevated tHcy levels may promote atherosclerosis by damaging 
the vascular wall26 or by its direct toxic effect on nerve cells.27 We tested whether the 
action of tHcy may be mediated via peripheral atherothrombosis by adjusting for the 
additional effects of markers of atherosclerosis. This did not modify the effect of tHcy on 
risk of silent brain infarcts or white matter lesions in any of the analyses. This is con-
sistent with Fassbender’s ﬁ nding that tHcy was associated with small vessel disease but 
not with large vessel disease.28 However, Clarke and colleagues reported in a study of 
patients with histologically conﬁ rmed Alzheimer’s disease that both patients with and 
without macroscopic cerebral infarcts had higher tHcy concentrations than age-matched 
controls.10 Further histopathological studies in patients with suspected dementia are 
needed to examine the associations of tHcy (and other risk factors) with microvascular 
disease. Whether plasma tHcy causes direct neurotoxicity cannot be tested in vivo, so 
the underlying mechanism remains unclear.
In conclusion, we found a strong relation between plasma tHcy levels with silent 
brain infarcts and with white matter lesions. However, this is a cross-sectional study 
and the results should be conﬁ rmed by prospective longitudinal studies. Whereas ran-
domised controlled trials have shown that vitamin supplements can effectively reduce 
plasma tHcy levels,29 the results of ongoing large-scale trials are needed to determine 
whether lowering tHcy levels reduces the risk of stroke and other cardiovascular disease. 
Several such trials designed to assess the effects of folic acid-based vitamin supplements 
on cardiovascular risk include an assessment of cognitive function. However, further 
trials in high-risk elderly populations are needed to assess whether such therapy may 
reduce the risk of dementia.
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Abstract
Objective — To study whether lower arterial oxygen saturation (SaO
2
) and chronic obstructive pul-
monary disease (COPD) are associated with cerebral white matter lesions and lacunar infarcts.
Methods — We measured SaO
2
 twice with a pulse oximeter, assessed the presence of COPD, and 
performed MRI in 1077 non-demented people from a general population (age 60 to 90 years). We 
rated periventricular white matter lesions (on a scale of 0 to 9) and approximated a total subcorti-
cal white matter lesion volume (range 0 to 29.5 ml). All analyses were adjusted for age and sex and 
additionally for hypertension, diabetes, body mass index, pack years smoked, cholesterol, haemo-
globin, myocardial infarction, and left ventricular hypertrophy.
Results — Lower SaO
2
 was independent of potential confounders associated with more severe pe-
riventricular white matter lesions (score increased by 0.12 per 1% decrease in SaO
2
 (95% conﬁ dence 
interval 0.01 to 0.23)). Participants with COPD had more severe periventricular white matter le-
sions than those without (adjusted mean difference in score 0.70 (95% conﬁ dence interval 0.23 to 
1.16)). Lower SaO
2
 and COPD were not associated with subcortical white matter lesions or lacunar 
infarcts.
Conclusion — Lower SaO
2
 and COPD are associated with more severe periventricular white mat-
ter lesions.
 
Arterial oxygen saturation, COPD
and cerebral small vessel disease
3.3
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INTRODUCTION
Cerebral white matter lesions and lacunar brain infarcts are frequently observed on 
magnetic resonance imaging scans of elderly people.1-4 Evidence is accumulating that 
these lesions play an important role in the development of cognitive decline and demen-
tia.5-7 Although the exact pathogenesis of these lesion is not fully understood, they are 
considered to be caused by ischaemic small vessel disease, with hypertension and in-
creased age as the most important risk factors. Degenerative changes of cerebral small 
vessels result in narrowing and obstruction of the arteriolar lumen and alteration of the 
cerebral autoregulation, both resulting in hypoperfusion of the cerebral white matter 
and basal ganglia.8 
In addition to cerebral perfusion, the arterial oxygen content determines the total 
amount of oxygen available in the brain. Low arterial oxygen pressure strongly ag-
gravates brain damage caused by cerebral hypoperfusion. Pure hypoxaemic insults, 
however, fail to cause brain damage.9 Whether lower arterial oxygen pressure in elderly 
people plays a role in the pathophysiology of white matter lesions is unknown. 
The assessment of the arterial oxygen pressure is a relatively invasive procedure 
and therefore not applicable in a large population based study. The oxygen saturation of 
haemoglobin, as assessed by pulse oximetry, is a non-invasive measurement that gives 
an indication of the arterial oxygen pressure. We studied the association between arte-
rial oxygen saturation (SaO
2
) and white matter lesions and lacunar infarcts. Chronic 
obstructive pulmonary disease (COPD) is a common disease among elderly people.10-13 
Patients with COPD suffer from oxygen deprivation for prolonged periods, especially 
during physical exercise, exacerbation of disease and sleep.14,15 We therefore also exam-
ined the association between COPD and white matter lesions and lacunar infarcts.
METHODS
Study sample
The Rotterdam Scan Study was designed to study the aetiology and natural history of 
age related brain changes in the elderly. In 1995 to 1996, we randomly selected par-
ticipants aged 60 to 90 years by sex and 5 year age strata from the population based 
Zoetermeer16 and Rotterdam17 studies. These populations were almost entirely white. A 
total of 1077 non-demented elderly persons participated in our study (overall response 
63%).3 Each person gave informed consent to participate in our study, which had been 
approved by the local medical ethics committee.
Arterial oxygen saturation and COPD 
All participants underwent an interview and a physical examination at the time of MRI 
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scanning. SaO
2
 was measured twice, 5 minutes apart, with a pulse oximeter (Oxycount, 
Andos, Hamburg, Germany) on the right index ﬁ nger. The two measurements were av-
eraged (correlation coefﬁ cient was 0.73 and the range was 88 to 99%).
Participants were asked to bring all their prescription drugs with them to the re-
search centre. The research physicians recorded these and checked their indication.
COPD was considered present if a person was taking inhalation medication from at 
least one of the following groups: sympaticomimetics, parasympaticolytics, or glucocor-
ticosteroids. 
Measurements of other covariates
Blood pressure was measured twice on the right arm with a random zero sphygmoma-
nometer, and the average of these two measurements was used. Hypertension was de-
ﬁ ned as a systolic blood pressure of ≥140 mm Hg, a diastolic blood pressure of ≥90 mm 
Hg, and/or the use of blood pressure lowering medication.
We collected non-fasting blood samples from all participants. We considered diabe-
tes mellitus to be present if a person used oral anti-diabetics or insulin and/or had a 
glucose level ≥11.1 mmol/l. The body mass index was calculated as weight (kg) divided 
by height squared (m2). A research physician obtained information on smoking habits 
using a structured questionnaire. Patients were categorised as having smoked or never 
smoked. Furthermore, we calculated for every participant the number of pack years 
smoked (number of cigarettes per day × years of smoking/20). Serum total cholesterol 
levels were measured from non-fasting blood samples using an automated enzymatic 
method. The presence of left ventricular hypertrophy and myocardial infarction was 
assessed by MEANS interpretation of a 12 lead electrocardiogram (Acta electrocardio-
graph; Esaote, Florence, Italy).18 Haemoglobin levels were assessed using a standard 
and validated method.19
Cerebral white matter lesions and lacunar infarcts
All participants underwent MRI scanning of the brain. We made axial T1, T2 and proton 
density weighted scans on 1.5 T MRI scanners (MR Gyroscan; Philips, Best, the Nether-
lands, and MR Vision; Siemens, Erlangen, Germany). The slice thickness was 5 or 6 mm 
(scanner dependent) with an interslice distance of 1 mm.
White matter lesions were considered present if visible as hyperintense signals 
on proton density and T2 weighted images, without prominent hypointensity on T1 
weighted scans. When the largest diameter of the white matter lesion was directly ad-
jacent to the ventricle, it was deﬁ ned as periventricular, otherwise as subcortical. The 
scoring method has been described in detail previously.20 Brieﬂ y, periventricular white 
matter lesions were rated semiquantitatively from 0 (no lesion) to 3 (large conﬂ uent le-
sion) at three regions (adjacent to the frontal horns, the lateral walls, and the occipital 
horns of the lateral ventricle). We added the sum of the region speciﬁ c scores to acquire 
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a total periventricular white matter lesion score (range 0 to 9). We counted subcortical 
white matter lesions in three size categories based on their maximal diameter: small 
(<3 mm), medium (3 to 10 mm), and large (>10 mm). A total volume was approximated 
by assuming these subcortical lesions to be spherical with a ﬁ xed maximal diameter 
(volume range 0 to 29.5 ml). Both inter- and intra-reader studies (n=100) showed good 
to excellent agreement (for periventricular white matter lesion grade the kappa values 
were 0.79 and 0.90, respectively, and for subcortical white matter lesion volume the 
intra-class correlation coefﬁ cients were 0.88 and 0.95, respectively). We deﬁ ned lacunar 
infarcts as focal hyperintensities on T2 weighted images 3 to 20 mm in size and located 
in the subcortical white matter or basal ganglia. Proton density scans were used to 
distinguish infarcts from dilated perivascular spaces. Lesions in the white matter also 
had to have corresponding prominent hypointensities on T1 weighted images for us to 
distinguish them from cerebral white matter lesions.
Data analysis
The relationship of SaO
2
 and periventricular and subcortical white matter lesions was 
analysed using multiple linear regression models with SaO
2
 categorised in tertiles and 
subsequently with SaO
2
 as a continuous variable. We used linear regression analysis to 
calculate adjusted mean differ-
ences of periventricular white 
matter lesion score and subcor-
tical white matter lesion volume 
between participants with and 
without COPD. We analysed 
the association between SaO
2
 
and COPD and the presence 
of lacunar infarcts by multiple 
logistic regression analysis; 
from these analyses all people 
with cortical infarcts were 
excluded (n=33). All analyses 
were adjusted for age and sex 
and additionally for hyperten-
sion, diabetes, body mass index, 
pack years smoked, cholesterol 
level, haemoglobin concentra-
tion, myocardial infarction, and 
left ventricular hypertrophy. 
We performed supplementary 
analysis separately for those 
Table 1. Characteristics of the study population in 
1995-1996
All participants
(n=1077)
Age, years 
Women, %
Hypertension, %
Diabetes Mellitus, %
Body mass index, kg/m2
Ever smoked cigarettes, %
Smoking, pack years
Total cholesterol, mmol/l
Haemoglobin, mmol/l
Left ventricular hypertrophy, %
Myocardial infarction, %
Oxygen saturation, %SaO
2
Lacunar infarcts, %*
White matter lesion severity
    Periventricular, score 0-9 
    Subcortical, ml
72.2 (7.4)
51.5
73.0
7.0
26.7 (3.6)
66.4
19.1 (24.0)
5.9 (1.0)
8.7 (0.7)
2.9
10.3
96.5 (88-99)
21.6
2.4 (2.2)
1.4 (2.9)
Values are percentages or unadjusted means (SD), or for 
oxygen saturation the median (range).
* People with cortical infarcts were excluded (n=33)
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patients who had ever smoked and those who had never smoked. All regression analyses 
were followed by residual analysis to conﬁ rm assumptions of the model.
RESULTS
Table 1 gives selected characteristics of the study population. We measured SaO
2
 for all 
participants, except for 11 subjects for whom we could not get a signal from the oxime-
ter. These 11 people did not differ in the presented characteristics from the participants 
that had complete data. Seventy three participants had COPD, 31 (43%) of whom had 
chronic bronchitis, 9 (12%) had lung emphysema, and 33 (45%) had a combination of 
both or was not further speciﬁ ed.
SaO
2
 was on average lower in men, those who were ever cigarette smokers, and high-
er age. Participants with COPD were on average older, more often men, and were more 
often ever cigarette smokers. The unadjusted mean SaO
2
 was 0.84% (95% conﬁ dence 
interval (CI) 0.55 to 1.13%) lower in participants with COPD than in those without. 
Among the smokers, those with COPD smoked on average more pack years than those 
without COPD.
Figure 1 shows the association between SaO
2
 in tertiles (means 95.3%, 96.7%, and 
97.8%) and white matter lesions. People in the lowest tertile of SaO
2
 had more severe pe-
riventricular white matter lesions than those in the upper tertile, but did not have more 
severe subcortical white matter lesions. The age and sex adjusted mean periventricular 
white matter lesion score increased by 0.12 per 1% decrease in SaO
2
 (95% CI 0.02 to 
0.21). After additional adjustment for hypertension, diabetes mellitus, body mass index, 
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Figure 1. Association between tertiles of arterial oxygen saturation and severity of periventricu-
lar (A) and subcortical (B) white matter lesions (mean score or volume adjusted for age, sex, 
hypertension, diabetes mellitus, body mass index, pack years smoked, cholesterol level, haemo-
globin concentration, prevalent myocardial infarction, and left ventricular hypertrophy with 95% 
conﬁ dence intervals). *p=0.01 for difference between ﬁ rst and third tertile.
A B
*
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smoked pack years, cholesterol level, haemoglobin concentration, myocardial infarction, 
and left ventricular hypertrophy, this association remained unaltered (periventricular 
white matter lesions score increased by 0.12 per 1% decrease in SaO
2
 (95% CI 0.01 to 
0.23)). Arterial oxygen saturation was not associated with volume of subcortical white 
matter lesions (0.06 ml increase per 1% increase in SaO
2
 (95% CI -0.07 to 0.20)) or the 
risk of lacunar infarcts (odds ratio 1.01 per 1% increase in SaO
2
 (95% CI 0.89 to 1.15)), 
adjusted for age and sex. The association between SaO
2
 and periventricular white mat-
ter lesion severity was not different for those who had ever and those who had never 
smoked (increment of 0.12 (95%CI -0.02 to 0.25) versus 0.11 (95%CI -0.08 to 0.30) per 
1% decrease in SaO
2
 in the fully adjusted model).
Participants with COPD had more severe periventricular white matter lesions than 
those without (table 2). This difference was independent of vascular risk factors, and 
observed in both ever and never cigarette smokers (age and sex adjusted difference for 
those who had ever (0.59 (95% CI 0.08 to 1.11)) and never (1.11 (95% CI 0.08 to 2.14)) 
smoked). Participants with and without COPD did not differ in subcortical white matter 
lesion volume (table 2) or the risk of lacunar infarcts (age and sex adjusted odds ratio 
1.00 (95% CI 0.54 to 1.87)).
DISCUSSION
In this population based study, we found that lower SaO
2
 was associated with more 
severe periventricular white matter lesions, but not with subcortical white matter le-
sions or lacunar infarcts. This association was independent of vascular risk factors, 
haemoglobin concentration, and measurements of cardiac function. Furthermore, we 
found that participants with COPD had more severe periventricular white matter le-
sions, but did not differ in subcortical white matter lesion volume or in prevalence of 
lacunar infarcts.
Table 2. Mean differences (95% conﬁ dence interval (95% CI)) of periventricular white matter 
lesion score and subcortical white matter lesion volume (ml) between participants with and 
without COPD
Excess white matter lesions in participants with COPD
Periventricular score (95% CI) p Subcortical volume (95% CI) p
Model 1*
Model 2†
0.70 (0.23 to 1.16)
0.69 (0.23 to 1.14)
<0.01
<0.01
0.43 (-0.21 to 1.08)
0.43 (-0.22 to 1.08)
0.19
0.20
*Adjusted for age and sex
†Adjusted for age, sex, hypertension, diabetes mellitus, body mass index, cholesterol level, pack 
years smoked
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The strengths of this study are the population based design and the large number 
of elderly participants for whom MRI scans were performed. Before interpreting the 
results, we must address some methodological issues. The pulse oximeter accurately 
and precisely measures SaO
2
 within the range of 70 to 100%.21,22 All SaO
2
 measurements 
presented in this paper were in this range. In 11 participants, the pulse oximeter failed 
to give a signal, probably caused by cold ﬁ ngers or low peripheral perfusion. We do not 
think that the exclusion of this small group, which did not differ from the study popula-
tion with respect to the measured covariates or outcome variables (data not shown), has 
markedly inﬂ uenced our results.
SaO
2
 is an indirect measure of arterial oxygen pressure in the cerebral arteries. The 
SaO
2
 is linked to the arterial oxygen pressure by the oxygen-haemoglobin dissociation 
curve. Changes in blood CO
2
 concentration, temperature and 2,3-diphosphoglycerate 
concentration shift the dissociation curve.23 We did not measure these variables, but we 
performed the oximetry for each patient under comparable circumstances. Furthermore, 
pulse oximetry assesses SaO
2
 in arterial blood, whereas these factors mainly affect the 
relation between oxygen saturation and oxygen pressure in capillary blood.23 We there-
fore think that SaO
2
 gives a good indication of the arterial oxygen pressure. 
Deﬁ ning COPD as the use of medication for this indication may have introduced 
misclassiﬁ cation. COPD cases that were not being treated will have been missed, and 
this may explain why the prevalence of COPD in our study is somewhat lower than in 
some other population based studies.10,11,13 However, the age and sex speciﬁ c prevalence 
of COPD in our study was comparable with a large Canadian study using health ques-
tionnaires.12 Both SaO
2
 and the presence of COPD were assessed without knowledge 
of other risk factors or presence of white matter lesions. The MRI scans were rated by 
researchers blinded to all other data. Therefore, any misclassiﬁ cation in the assessment 
of SaO
2
 or COPD will be random and result in an underestimation of the strength of any 
association.
People with lower SaO
2
 had signiﬁ cantly more severe periventricular white matter 
lesions. However, the differences were not very large and probably do not represent clin-
ically signiﬁ cant disturbances on an individual level. It should be noted that we studied 
a large cohort of non-demented elderly people representative of the general population 
and not a selected group of patients. Consequently, the majority of the participants had 
SaO
2
 values within the normal range. Within this population based range we found that 
a decrease in SaO
2
 was associated with an increase in periventricular white matter le-
sion severity. This observation was supported by the consistent result with COPD.
In the Cardiovascular Health Study, an association between lower forced expiratory 
volume in 1 second (a measure of lung function) and white matter lesion severity was 
observed.1 In that study, the association disappeared after adjusting for sex and history 
of smoking. Smoking is the most important determinant of COPD.11,13 However, we also 
observed an association between COPD and white matter lesions in subjects who had 
EvD03-3.indd   57 23-03-2004, 13:46:18
Chapter 3.3
58
never smoked, indicating that this relation was not based on the potential confounding 
effect of smoking.
Chronic hypoperfusion is thought to play an important role in the development of 
white matter lesions. Experimental studies show that hypoxaemia in the absence of a 
reduced cerebral blood ﬂ ow does not result in neuronal damage.24-26 Hypoxaemia addi-
tional to hypoperfusion, however, strongly exacerbates ischaemic brain damage.9 This 
difference in effect between pure hypoxaemia and the combination of hypoxaemia and 
ischaemia may be explained by the physiological increase in cerebral blood ﬂ ow under 
conditions of reduced blood oxygen content.27 In our study, we did not assess the cerebral 
blood ﬂ ow of the cerebral white matter. Therefore we can only speculate on the interac-
tion between ischaemia and hypoxaemia in the development of white matter lesions. 
The periventricular white matter is an arterial border zone and therefore relatively 
hypoperfused, in particular when total cerebral blood ﬂ ow decreases and autoregulation 
is impaired.28 Areas with severe white matter lesions show hypoperfusion on perfusion 
weighted MRI and PET scan studies.29-31 Furthermore vasomotor reactivity is dimin-
ished in people with severe white matter lesions.32,33 As a consequence, the physiological 
compensation of hypoxaemia might be insufﬁ cient in people with cerebral small vessel 
disease, especially in border zone areas. Altered cerebral autoregulation may be the 
main cause of periventricular white matter lesions, whereas concentric narrowing of 
the arteriolar lumen may be the main cause of subcortical white matter lesions and la-
cunar infarcts. Lower SaO
2
 is possibly more detrimental in combination with chronic or 
intermittent hypoperfusion, as in disturbed autoregulation, than in instances of acute 
hypoperfusion, as in arteriolar obstruction.25
In conclusion, our study shows that COPD and lower SaO
2
 are associated with more 
severe periventricular white matter lesions. This ﬁ nding suggests that not only cerebral 
hypoperfusion, but also hypoxaemia may contribute to the aetiology of periventricular 
white matter lesions.
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Amyloid ß, APOE and cerebral small
vessel disease
3.4
3.4.1
Plasma amyloid ß, APOE, lacunar infarcts 
and white matter lesions 
Abstract
Lacunar brain infarcts and cerebral white matter lesions are frequently observed on magnetic reso-
nance imaging scans in elderly subjects. These lesions are also frequent in patient with cerebral 
amyloid angiopathy. We examined whether plasma amyloid ß peptide (Aß) levels are associated 
with lacunar infarcts and white matter lesions in the general population, and whether the apolipo-
protein E (APOE) genotype modiﬁ es these associations.
We studied 1,077 participants within the population-based Rotterdam Scan Study, who were 
60 to 90 years of age and free of dementia. Cross-sectional associations were analyzed by regression 
models with adjustments for age, sex, creatinine levels, and hypertension.
In APOE ε4 carriers, plasma Aß levels were positively associated with lacunar infarcts and 
white matter lesions, whereas in noncarriers no associations were observed. Per standard deviation 
increase in Aß
1-40
 and Aß
1-42
 levels the odds ratios for lacunar infarcts were 1.72 (95% conﬁ dence 
interval [CI] 1.22-2.43) and 1.93 (95% CI 1.31-2.85), the periventricular white matter lesion grade 
increased by 0.32 (95% CI 0.08-0.57) and 0.29 (95% CI 0.00-0.57), and the subcortical white matter 
lesion volume increased by 0.48ml (95% CI 0.04-0.91) and 0.24ml (95% CI -0.27-0.75).
Higher Aß levels are associated with more lacunar infarcts and white matter lesions in elderly 
subjects who carry an APOE ε4 allele.
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INTRODUCTION
Lacunar brain infarcts and cerebral white matter lesions frequently are observed on 
magnetic resonance imaging (MRI) scans in elderly subjects.1,2 These lesions are associ-
ated with an increased risk of stroke and dementia.3-5 They are considered to be caused 
by ischemic small vessel disease, with hypertension and increased age as the most im-
portant risk factors. The exact pathogenesis is however not fully understood.6-8
Lacunar infarcts and white matter lesions also are observed frequently in patients 
with cerebral amyloid angiopathy (CAA).9-12 CAA is characterized by deposits of amyloid 
ß peptide (Aß) in small and medium sized cerebral arteries.13 This deposited Aß is a pep-
tide consisting of either 42 (Aß
1-42
) or 40 (Aß
1-40
) amino acids, derived from the proteolytic 
processing of the amyloid precursor protein (APP).14
We investigated whether higher plasma Aß levels are associated with the presence 
of lacunar infarcts and severity of white matter lesions in nondemented elderly subjects. 
Because aggregation and clearance of Aß may be inﬂ uenced by the apolipoprotein E 
(APOE) polymorphism, we also investigated whether any relationship was modiﬁ ed by 
the presence of an APOE ε4 allele.15-17
SUBJECTS AND METHODS
The Rotterdam Scan Study is a population-based study designed to study the etiology 
and natural history of age-related brain changes in the elderly. In 1995-1996, we ran-
domly selected participants, aged 60 to 90 years, stratiﬁ ed by sex and 5-year age strata 
from the population-based Zoetermeer18 and Rotterdam19 studies. Subjects who were 
demented at baseline were excluded.4 A total of 1,077 elderly participated (overall re-
sponse 63%). Each person gave written informed consent to participate. The study was 
approved by the medical ethics committee of Erasmus Medical Center, Rotterdam.
Plasma amyloid ß levels
We collected nonfasting blood samples into vacutainers containing sodium citrate in 
1995 to 1996. These samples were put on ice immediately and centrifuged within 60 
minutes, and aliquots of plasma were stored at –80 0C. In 2001 to 2002, plasma levels 
of amyloid ß were determined by a double-antibody sandwich enzyme-linked immuno-
sorbent assay method (Pﬁ zer, Ann Arbor, MI).20 The mean coefﬁ cients of within and 
between assays variation were 4.4% and 10.1% for Aß
1-40
, and 4.9% and 14.8 % for Aß
1-42
. 
The detection limits were 10 to 1,000 pg/ml for Aß
1-40
 and 5 to 100 pg/ml for Aß
1-42
. Seven 
participants were excluded, because their Aß levels fell outside these ranges. In 44 par-
ticipants we failed to obtain blood samples.
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Apolipoprotein E genotyping
Apolipoprotein E (APOE) genotyping was done on coded genomic DNA samples in 929 
participants.21 The distribution of APOE genotype and allele frequencies in this popula-
tion were in Hardy-Weinberg equilibrium.
Other measurements
Hypertension was deﬁ ned as a systolic blood pressure of 140 mm Hg or higher and/or a 
diastolic blood pressure of 90 mm Hg or over and/or the use of blood pressure-lowering 
medication. Diabetes mellitus was deﬁ ned as the use of oral antidiabetics or insulin or a 
random or postload glucose level of 11.1 mmol/L or higher. Smoking habits were catego-
rized as ever or never cigarette smoking. Plasma creatinine levels were assessed using 
an automated enzymatic procedure (Roche, Mannheim, Germany).
Lacunar brain infarcts and white matter lesions
We obtained axial T1-, T2-, and proton density-weighted scans on 1.5T MRI scanners 
(MR Gyroscan; Philips, Best, the Netherlands and MR VISION; Siemens, Erlangen, 
Germany). The slice thickness was 5 or 6 mm (scanner dependent) with a 20% interslice 
distance.
We deﬁ ned infarcts as focal hyperintensities of at least 3 mm in size on T2-weighted 
images. Lesions in the white matter also had to have corresponding prominent hypoin-
tensities on T1-weighted images. We deﬁ ned lacunar infarcts as focal hyperintensities 
3 to 20 mm in size and located in the subcortical white matter or basal ganglia on T2-
weighted images.
White matter lesions were considered present if visible as hyperintense on proton 
density and T2-weighted images, without prominent hypointensity on T1-weighted 
scans. We summed three region-speciﬁ c semiquantitative grades (lesions adjacent to 
the frontal horns, the lateral walls, and the occipital horns of the lateral ventricle) to get 
a total periventricular white matter lesions grade (range 0-9). We counted subcortical 
white matter lesions in three size categories based on their maximal diameter (<3 mm, 
3-10 mm, >10 mm). A total volume was approximated by assuming that these subcorti-
cal lesions were spherical with a ﬁ xed diameter (volume range 0-29.5 ml). Both intra-
rater and interrater studies (n=100) showed a good to excellent agreement (κ=0.79-0.90; 
r=0.88-0.95).8
Data analysis
Analyses were based on 1,026 participants with Aß levels within the limits of reliable as-
sessment. We analyzed the association between possible confounders and Aß levels with 
linear regression analysis and the correlation between Aß
1-40
 and Aß
1-42
 with Pearson’s 
correlation coefﬁ cient.
We quantiﬁ ed the associations between Aß levels, lacunar infarcts, and white mat-
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ter lesions with multiple logistic and linear regression analyses. We analyzed Aß levels 
in quintiles of their distribution and as continuous variables to test for trend and to 
quantify the strength of the associations. The ranges of the quintiles of Aß
1-40
 were 68-
158, 159-186, 187-212, 213-245, and 246-537pg/ml and of Aß
1-42
 were 5.6-14.1, 14.2-17.0, 
17.1-20.0, 20.1-24.0, and 24.1-97.6pg/ml. All analyses were adjusted for age and sex and 
additionally for creatinine levels, hypertension, and APOE genotype. For missing data 
on APOE genotype, we used a missing indicator.
It has been suggested that the ratio of Aß
1-42
 to Aß
1-40
 may be more important than 
separate levels, at least for Alzheimer’s disease.22 Therefore we additionally analyzed 
the association between the ratio of plasma Aß
1-42
/Aß
1-40
 and lacunar infarcts and white 
matter lesions.
We evaluated the association of Aß levels with lacunar infarct visible on MRI by 
excluding all persons with nonlacunar infarcts. Given that 88% of the brain infarcts on 
MRI were lacunar infarcts, we focused on lacunar infarcts. 
To assess a possible interaction between Aß levels and the APOE genotype, we did 
analyses stratiﬁ ed on the presence of an APOE ε4 allele. The signiﬁ cance of this interac-
tion was tested through regression models with Aß levels, the presence of an APOE ε4 
allele, and the interaction term as independent variables. We were not able to analyze 
the association in ε4 homozygotes separately because of low numbers (n=22). 
RESULTS
Characteristics of the study participants are given in Table 1. Plasma Aß
1-40
 and Aß
1-42
 
levels increased with age and creatinine levels. Aß
1-40
 levels were higher in hyperten-
sives and Aß
1-42
 levels were lower in APOE ε4 carriers. Sex, smoking and diabetes were 
not associated with plasma Aß levels. Aß
1-40
 and Aß
1-42
 levels were positively correlated 
(Pearson’s r=0.59, p<0.001).
Plasma Aß levels were positively associated with lacunar infarcts (Table 2). Strati-
ﬁ ed analysis on APOE genotype showed that this was entirely caused by an association 
in ε4 carriers. The interaction between Aß levels and the APOE ε4 genotype was sta-
tistically signiﬁ cant (p-values interaction terms Aß
1-40
 × APOE ε4 and Aß
1-42
 × APOE ε4 
0.03 and 0.01). Additional adjustments for creatinine and hypertension hardly changed 
these associations. The associations for any brain infarcts were almost identical (data 
not shown).
A similar pattern was seen for white matter lesions. Plasma Aß levels were positively 
associated with both periventricular and subcortical white matter lesions in APOE ε4 
carriers, but not in noncarriers (Table 3). The interaction between Aß levels and the 
APOE ε4 genotype was statistically signiﬁ cant (p-values interaction terms Aß
1-40
 × 
APOE ε4 and Aß
1-42
 × APOE ε4 in relation to periventricular white matter lesions <0.001 
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Table 1. Characteristics of study population
Characteristic
All participants
(n=1026)
Age, yr (SD)
Women, %
Hypertension, %
Ever smoked cigarettes, % 
Diabetes, %
Creatinine mmol/L, mean (SD)
Aß
1-40
 pg/ml, mean (SD)
Aß
1-42
 pg/ml, mean (SD)
Aß
1-42
 / Aß
1-40
, mean (SD)
APOE ε4 carrier, %a
White matter lesions
   Periventricular, grade 0-9, mean (SD)
   Subcortical, (ml), mean (SD)
Brain infarcts, %
Lacunar brain infarcts, %b
72.2 (7.4)
52
72
66
7
88.9 (18.6)
204.8 (57.8)
19.8 (8.1)
0.10 (0.03)
29
2.4 (2.2)
1.4 (2.9)
24
22
a Data available for 929 participants
b Percentage within people without other infarcts (n=995)
SD=standard deviation
Table 2. Odds ratio of lacunar infarcts per standard deviation increase in amyloid ß levels 
with 95% conﬁ dence intervals in all participants and stratiﬁ ed on APOE ε4 genotype.
Odds ratio for lacunar infarcts (95%CI)a
Amyloid ß All
APOE ε4
non-carriers
APOE ε4
carriers
1-40 (per SD)
Model 1 1.22 (1.04-1.42) 1.14 (0.93-1.40) 1.75 (1.27-2.41)
Model 2 1.14 (0.96-1.35) 1.01 (0.81-1.16) 1.72 (1.22-2.43)
1-42 (per SD)
Model 1 1.17 (1.02-1.36) 1.09 (0.91-1.30) 1.93 (1.31-2.85)
Model 2 1.15 (0.98-1.35) 1.02 (0.83-1.25) 1.93 (1.28-2.92)
Model 1: adjusted for age and sex
Model 2: adjusted for age, sex, creatinine, hypertension and APOE genotype (for the analyses in all 
participants).
a Subjects with nonlacunar infarcts were excluded from the analysis.
APOE=apolipoprotein E; CI=conﬁ dence interval; SD=standard deviation.
and 0.03; in relation to subcortical white matter lesions <0.001 and 0.05). Additional 
adjustments hardly changed these associations. The ratio of Aß
1-42
 to Aß
1-40
 was not as-
sociated with either lacunar infarcts or white matter lesions (data not shown).
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Figures 1 and 2 illustrate the linear increase in prevalence of lacunar infarcts and 
severity of white matter lesions with increasing plasma Aß levels in APOE ε4 carriers, 
but not in noncarriers.
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Figure 1. Association between quintiles of 
plasma amyloid ß 1-40 levels and lacunar in-
farcts (odds ratios (OR)), periventricular white 
matter lesions (WMLs) (grade) and subcortical 
white matter lesions volume (ml) stratiﬁ ed on 
the presence of an apolipoprotein E (APOE) 
ε4 allele, adjusted for age and sex (p-trend for 
continuous linear trend per stratum).
Figure 2. Association between quintiles of 
plasma amyloid ß 1-42 levels and lacunar in-
farcts (odds ratios (OR)), periventricular white 
matter lesions (WMLs) (grade) and subcortical 
white matter lesions volume (ml) stratiﬁ ed on 
the presence of an apolipoprotein E (APOE) 
ε4 allele, adjusted for age and sex (p-trend for 
continuous linear trend per stratum).
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DISCUSSION
This study demonstrates that plasma Aß
1-40
 and Aß
1-42
 levels are strongly associated with 
the presence of lacunar infarcts and severity of white matter lesions in nondemented 
elderly subjects who carry an APOE ε4 allele.
The strengths of this study are the population-based design and the large number 
of elderly nondemented participants in whom both brain imaging and plasma Aß as-
sessments were performed. The plasma Aß levels were measured without knowledge of 
other risk factors or presence of brain lesions. MRI rating was also performed blinded to 
all other data. Therefore, misclassiﬁ cation, if any, will have been random and will have 
resulted in an underestimation of the strength of any risk associations. We adjusted in 
the analyses for all known confounders. However, because we do not exactly know what 
determines plasma amyloid ß levels, lacunar infarcts, and white matter lesions, we can-
not exclude the possibility of confounding by yet unknown factors.
Several mechanisms may lead to increased plasma Aß levels. Plasma Aß levels are 
elevated in all genetic forms of early-onset Alzheimer’s disease due to increased produc-
tion.23 In nondemented subjects, cerebrospinal ﬂ uid and plasma Aß levels are in a dy-
namic equilibrium.24 An increased efﬂ ux from the cerebrospinal ﬂ uid to plasma may re-
sult in higher plasma levels.25 Furthermore, chronic hypoperfusion may upregulate APP 
expression and thereby increase Aß production.26 Finally, altered peripheral clearance 
may increase plasma Aß levels. Aß levels are positively correlated with plasma creati-
nine levels, indicating that with altered renal function peripheral Aß levels increase.27
It is not clear to what extent the above mechanisms contribute to increased plasma 
Aß levels in the general population. Our study consisted of only nondemented elderly 
subjects, and we adjusted in our analyses for creatinine levels as a measure of renal 
function. We consider that overproduction is probably the most important source of 
higher plasma Aß levels in our study.
Effects of Aß on the vessel wall are particularly described for Aß
1-40
, whereas Aß
1-42
 
is mainly involved in senile plaque formation.14,28 Because of the strong correlation be-
tween Aß
1-40
 and Aß
1-42
 plasma levels, we could not assess the individual effects of Aß
1-40
 
conditional on Aß
1-42
 and vice versa.
We found an association between higher plasma Aß levels and lacunar infarcts and 
white matter lesions in APOE ε4 carriers, but not in noncarriers. This may be explained 
by different mechanisms. Firstly, ﬁ brillary deposits of Aß in the vessel wall lead to oblit-
eration of vessel luminae and loss of vascular smooth muscle cells necessary to cerebral 
autoregulation. This subsequently may result in lacunar infarcts and white matter le-
sions.9,13,29,30 Overproduction of Aß may lead to deposition in the media and adventitia 
of meningiocortical arteries and arterioles.31 The apolipoprotein ε4 isoform supports ß-
sheet transformation of Aß, which has a stronger tendency to aggregate and deposit.14-17 
Furthermore, APOE ε4 may facilitate the transport of Aß from the cerebrospinal ﬂ uid 
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into smooth muscle cells of the vessel wall.32 
Secondly, soluble Aß may directly effect cerebral vasoreactivity by enhancing en-
dothelium dependent vasoconstriction.29,30 This effect might be stronger in APOE ε4 
carriers.33 Altered autoregulation will result in hypoperfusion of the brain, speciﬁ cally 
in regions with limited collateral blood ﬂ ow, and consequently may lead to white matter 
lesions and lacunar infarcts.9 APOE ε4 carriers may have a more generally increased 
susceptibility to ischemic cerebral damage.34
A third possible explanation is that higher Aß levels and lacunar infarcts and white 
matter lesions both result from cerebral hypoperfusion.26 Hypoperfusion might induce 
higher Aß levels which, in turn, via vascular depositions could reinforce hypoperfusion. 
Because adjusting for vascular risk factors did not effect the association, we consider 
hypoperfusion due to vascular risk factors a less likely explanation.
Our observations in nondemented elderly subjects are in line with ﬁ ndings from 
pathological and imaging studies in patients with Alzheimer’s disease and CAA-related 
intracerebral hemorrhage and otherwise selected patient groups that found an associa-
tion between CAA and brain infarcts and white matter lesions.9-12,35 The observation 
that plasma Aß level in combination with the APOE ε4 allele is strongly associated with 
cerebral small vessel disease-related lesions in asymptomatic elderly is novel. Therefore, 
conﬁ rmation of our results in other data sets and prospectively is needed.
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3.4.2
Plasma amyloid ß, APOE and impaired 
cerebral vasomotor reactivity 
Abstract
Background and purpose — Amyloid ß (Aß) may disturb cerebral autoregulation in elderly 
people through deposition in the walls of small cerebral blood vessels, or through its vasoactive 
properties. We assessed whether previous or concurrent plasma Aß
1-40
 and Aß
1-42
 levels were associ-
ated with impaired cerebral vasomotor reactivity. Furthermore, we assessed whether the APOE 
gene modiﬁ ed this association.
Methods — Plasma Aß
1-40
 and Aß
1-42
 levels were assessed in a random sample of the longitudinal 
population based Rotterdam Study at time of its baseline and second follow-up survey. At the sec-
ond follow-up survey, cerebral vasomotor reactivity to hypercapnia was measured with transcranial 
Doppler ultrasonography (TCD) in 442 people, aged 60 to 90 years. The association between Aß 
levels and impaired vasomotor reactivity was analyzed by age and sex adjusted logistic regression 
analysis.
Results — Plasma Aß
1-40
 and Aß
1-42
 levels assessed on average 6.5-year before TCD were linearly as-
sociated with impaired vasomotor reactivity (odds ratio 1.48 (95%CI 1.19; 1.84) per standard devia-
tion increase in Aß
1-40 
, and 1.36 (95%CI 1.09; 1.70) per standard deviation increase in Aß
1-42 
). Such 
an association was not present for Aß assessed concurrently with the TCD measurement. Decrease 
in plasma Aß
1-40
 in the 6.5-year period preceding TCD measurements was associated with a higher 
prevalence of impaired vasomotor reactivity. These associations were not signiﬁ cantly different for 
APOE ε4 carriers and non-carriers.
Conclusions — High plasma Aß
1-40
 and Aß
1-42
 levels measured on average 6.5 years earlier, and 
decline in Aß
1-40
 levels over time, are associated with impaired vasomotor reactivity. 
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INTRODUCTION
Small cerebral blood vessels have the intrinsic property to constantly adjust the cerebral 
blood ﬂ ow to changes in systemic blood pressure.1 Impairment in this cerebral autoregu-
lation can result in cerebral hypoperfusion and may consequently lead to ischemic white 
matter lesions and lacunar brain infarcts.2-5 Insufﬁ cient vasomotor response to vasodila-
tory stimuli is observed in major carotid artery stenosis and in cerebral small vessel 
disease.4,6 Hypertension and increased age are associated with cerebral autoregulation 
disturbances. The exact mechanism by which cerebral autoregulation is impaired is 
however unclear.
Animal studies have shown that amyloid beta peptide (Aß) may play a role in the 
disturbance of the cerebral autoregulation.7 Aß is a peptide consisting of 40 (Aß
1-40
) or 42 
(Aß
1-42
) amino acids.8 Aggregates of Aß in medium and small sized cerebral arteries, as 
seen in cerebral amyloid angiopathy (CAA), are cytotoxic to the smooth muscle cells of 
the vessel walls, which play an important role in the cerebral autoregulation.9 Next to 
this cytotoxic effect, Aß also has endothelium dependent vasoactive properties, enhanc-
ing endothelin-1 induced vasoconstriction.10,11
Until now no study has assessed the relationship between plasma Aß levels and 
cerebral vasomotor reactivity in humans. The autoregulatory capacity of arterioles can 
be assessed by measurement of the vasomotor response to a dilatory stimulus, such as 
carbon dioxide, with transcranial Doppler ultrasonography (TCD).6 
The aim of our study was to investigate the relationship between plasma Aß levels 
and impaired vasomotor reactivity assessed by TCD in a general elderly population. 
Since aggregation and clearance of Aß could be inﬂ uenced by the apolipoprotein E 
(APOE) polymorphism, we also investigated whether this relationship depended on the 
presence of an APOE ε4 allele.12-14
PARTICIPANTS AND METHODS
Participants
The study was conducted as part of the Rotterdam Study, a prospective population-
based cohort study aimed at investigating determinants of chronic and disabling dis-
eases in the elderly.15 The study started in 1990 when all inhabitants aged 55 years or 
over of Ommoord, a district of Rotterdam, were invited to participate. Of 10,275 eligible 
subjects 7,983 (78%) agreed to participate. A ﬁ rst follow-up survey was done in 1993-
1994, and a second follow-up survey in 1997-1999. 
From the baseline cohort, we drew a random sample of 1,756 people in which we 
assessed plasma Aß levels in baseline blood as well as in blood of the second follow up 
survey if available. Of the 1,756 people, 293 had died and 374 refused the second follow-
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up examination, which resulted in 1,089 people for whom we had repeated plasma Aß 
assessment available.
As part of the second follow-up survey, we performed transcranial Doppler examina-
tions in a random set of 2,735 participants. In 1,755 participants we succeeded to meas-
ure the cerebral vasomotor reactivity. Failure to complete the measurement was mainly 
due to bilateral window failure (n=687). The frequency of bilateral window failure is 
higher in women and increases with age.3
A total of 466 people were part of both the random sample in which plasma Aß levels 
were assessed and the random sample in which cerebral vasomotor reactivity measure-
ments were obtained. In 23 participants an Aß
1-40
 or Aß
1-42
 assessment was missing at 
the ﬁ rst or third survey, and in 2 participants the levels were outside the reliable meas-
urement range, leaving 441 participants available for the present analyses.
Each person gave written informed consent to participate in our study, which had 
been approved by the medical ethics committee of the Erasmus Medical Center Rot-
terdam.
Plasma amyloid ß levels
We collected non-fasting blood samples from participants into vacutainers containing 
sodium citrate in 1990-1993 and in 1997-1999. These whole blood samples were put 
on ice immediately, and centrifuged within 60 minutes, and aliquots of plasma were 
stored at –80 0C. In 2001-2002, plasma levels of amyloid ß were determined by a double-
antibody sandwich ELISA method (Pﬁ zer, USA).16 The mean coefﬁ cients of within and 
between assays variation were 4.4% and 4.9 % for Aß
1-40
, and 10.1% and 14.8 % for Aß
1-42
. 
The detection limits were 10-1,000 pg/ml for Aß
1-40
 and 5-100 pg/ml for Aß
1-42
. We calcu-
lated the change in Aß level per year, by dividing the difference in Aß levels between 
1990-1993 and 1997-1999 by the time between both assessments.
APOE genotyping
Apolipoprotein E (APOE) genotyping was done on coded genomic DNA samples. The 
APOE gene was ampliﬁ ed by means of the primers and ampliﬁ cation conditions de-
scribed by Wenham et al.17 The distribution of the APOE genotype and the allele fre-
quencies in this population were in Hardy-Weinberg equilibrium.
Measurements of other covariates
Hypertension was deﬁ ned as a systolic blood pressure of 140 mm Hg or over, a diastolic 
blood pressure of 90 mm Hg or over, and/or the use of blood pressure lowering medica-
tion. We considered diabetes mellitus to be present if a person used oral anti-diabetics 
or insulin and/or had a non-fasting glucose level over 11.1 mmol/l. Smoking habits were 
assessed by a structured questionnaire and categorized as ever or never cigarette smok-
ing.
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Participants underwent ultrasonography of both carotid arteries with a 7.5 MHz lin-
ear array transducer and a Duplex scanner (ATL Ultra-Mark IV, Advanced Technology 
Laboratories, USA). The intima-media thickness was calculated as the mean thickness 
of four locations: the near and far wall of both right and left common carotid artery.18
Vasomotor reactivity 
Transcranial Doppler ultrasonography monitoring was performed (Multi-Dop X-4, DWL, 
Germany) as earlier described.3 Cerebrovascular CO
2
 reactivity measurements were 
performed as follows: the cerebral blood ﬂ ow velocity (cm/s) was continuously measured 
in the middle cerebral artery on both sides, if possible. First, participants  breathed 
room air through an anesthetic mask until a steady expiratory end-tidal CO
2
 was ob-
tained. Subsequently, participants inhaled a mixture of 5% carbon dioxide and 95% oxy-
gen for 2 minutes. Cerebrovascular reactivity was deﬁ ned as the percentage increase in 
mean cerebral blood ﬂ ow velocity during inspiration of 5% CO
2
 divided by the absolute 
increase in end-tidal CO
2
 in the same period (%/kPa). End-tidal CO
2
 pressure (kPa) was 
recorded continuously with a CO
2
 analyser (Multines, Datascope, The Netherlands). 
End-expiratory CO
2
 was assumed to reﬂ ect arterial CO
2
. TCD-8 DWL special software 
VMR-CO
2
 was used. Changes in blood pressure due to hypercapnia may introduce mis-
classiﬁ cation in the vasomotor reactivity assessment.19,20 We monitored the blood pres-
sure dynamically during the vasomotor reactivity assessment in a random sub-sample 
of 134 participants, to assess whether blood pressure changes during hypercapnia in-
ﬂ uenced the associations under study. Right and left hemodynamic indices were highly 
correlated. We used their mean for all the analyses. In case of one-sided window-failure, 
the contralateral cerebral hemodynamic parameter was used in the analysis. We de-
ﬁ ned impaired vasomotor reactivity as the lowest tertile of its distribution, which cor-
responded with measures lower than 30%/kPa. The upper two tertiles were considered 
normal. This cut-off is consistent with that used by others.6
Data analysis
We assessed the association between age, sex, APOE genotype and Aß levels with linear 
regression analysis. We calculated Pearson’s correlation coefﬁ cient to quantify the cor-
relation between Aß
1-40
 and Aß
1-42
. We performed multiple logistic regression analysis to 
assess the relation between Aß levels and impaired vasomotor reactivity. We analyzed 
Aß levels in quintiles of its distribution and as a continuous variable (per standard de-
viation). The cut-off values for the quintiles of Aß
1-40
 at time of TCD were 155, 185, 207, 
and 243 pg/ml and for the measurements on average 6.5-years earlier 152, 173, 191, and 
217 pg/ml. For Aß
1-42
 the cut-off values at time of TCD were 12.0, 15.0, 18.4, and 23.2 
pg/ml and for the measurement on average 6.5-year earlier 13.7, 16.0, 18.2, and 21.0 
pg/ml.
We assessed the relation between change in Aß levels per year (in quintiles) and im-
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paired vasomotor reactivity with multiple logistic regression analysis. The cut-off values 
of the quintiles of change in Aß
1-40
 were –4.3, 0.0, 3.7, and 8.7 pg/ml/year and for the 
change in Aß
1-42
 –1.1, –0.4, 0.2, and 0.9 pg/ml/year. We used the middle quintile, which 
contained the people who did not change over time, as the reference group.
It has been suggested that the ratio of Aß
1-42
 to Aß
1-40
 may be more important than 
separate levels, at least for AD.22 Therefore we additionally analyzed the association 
between the ratio of plasma Aß
1-42
/Aß
1-40
 and lacunar infarcts and white matter lesions.
To assess a possible interaction between Aß levels and the APOE genotype, we ana-
lyzed the association between Aß levels and impaired vasomotor reactivity stratiﬁ ed 
on the presence of an APOE ε4 allele. To test whether this interaction was statistically 
signiﬁ cant, we did regression analysis with Aß levels, the presence of an APOE ε4 allele 
and the product of both variables (interaction term) as independent variables in one 
model.
All analyses were adjusted for age and sex. In additional analyses we adjusted for 
hypertension, diabetes mellitus, smoking, and carotid intima-media thickness. We sub-
sequently excluded people with prevalent stroke (n=11) or dementia (n=4) at time of 
TCD. In the group of 134 people with complete monitoring of blood pressure dynamics 
during the vasomotor reactivity assessment, we made additional adjustment for systolic 
and diastolic blood pressure changes during the assessment.
Table 1. Characteristics of participants on average 6.5-years before and at time of TCD
All participants (n=441)
6.5-years before TCD At time of TCD
Age, y
Women, %
Hypertension, %
Diabetes, %
Ever Smoked, %
Dementia, %
Stroke, %
Aß
1-40
, pg/ml
Aß
1-42
, pg/ml
APOE ε4 carrier, %
IMT CCA*, mm
63.7 (5.8)
48
46
3
71
0
1
188.4 (51.6)
18.1 (6.6)
30
-
70.2 (5.8)
48
65
4
72
1
3
207.9 (70.1)
18.3 (8.3)
30
0.87 (0.15)
Values are percentages or unadjusted means (standard deviation)
* Mean intima media thickness of the common carotid arteries
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RESULTS
Selected characteristics of the 441 study participants at time of TCD, and on average 6.5-
years (SD 0.4) earlier are given in table 1. In the 6.5-years between the two assessments, 
plasma Aß levels on average increased (Aß
1-40
 3.0 pg/ml/year (SD 11.4) and Aß
1-42
 0.04 
pg/ml/year (SD 1.39)). No differences were observed in mean plasma Aß levels between 
men and women and between APOE ε4 carriers and non-carriers. Plasma Aß
1-40
 and 
Table 2. Relation between plasma Aß levels (per standard deviation) assessed 6.5-years be-
fore and at time of TCD and impaired vasomotor reactivity (odds ratio’s with 95% conﬁ dence 
intervals, adjusted for age and sex)
Odds ratios of impaired vasomotor reactivity (95% CI)
Aß 6.5-years before TCD Aß at time of TCD
Aß
1-40
 (per standard deviation)
Aß
1-42
 (per standard deviation)
1.48 (1.19; 1.84)
1.36 (1.09; 1.70)
1.01 (0.87; 1.17)
1.00 (0.85; 1.18)
Figure 1. The relation between 
plasma Aß
1-40
 and Aß
1-42
 levels in 
quintiles, assessed at time of TCD, 
and impaired vasomotor reactivity 
(expressed as odds ratios with 95% 
conﬁ dence intervals, adjusted for 
age and sex ). Odds ratios are plot-
ted at the median Aß
1-40
 and Aß
1-42
 
levels of the different quintiles (p-
value for continuous linear trend).
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Aß
1-42
 levels were positively correlated (at time of TCD Pearson’s r=0.61 p<0.001, and 
6.5-years earlier r=0.68, p<0.001).
Plasma Aß
1-40
 and Aß
1-42
 levels at time of TCD were not related with impaired vaso-
motor reactivity (ﬁ gure 1, table 2). Higher Aß
1-40
 and Aß
1-42
 levels 6.5-years before TCD 
were linearly associated with a higher prevalence of impaired vasomotor reactivity (ﬁ g-
ure 2, table 2). Figure 3 shows the association between categories of change in Aß levels 
and impaired vasomotor reactivity. People who had clearly dropped in their Aß
1-40
 levels 
(ﬁ rst quintile, range -45.1; -4.3 pg/ml/year) had twice as frequently impaired vasomotor 
reactivity (odds ratio 1.9 (95% CI 1.0; 3.6)) compared to people with an average change 
in Aß
1-40
 levels (middle quintile, range 0 - 3.7 pg/ml/year). People who increased in Aß
1-40
 
levels (upper two quintiles) did not differ in impaired vasomotor reactivity prevalence 
from people with an average change (middle quintile). Changes in Aß
1-42
 levels were not 
associated with impaired vasomotor reactivity.
The associations between Aß levels assessed 6.5-years before TCD and impaired va-
somotor reactivity were similar for APOE ε4 carriers and non-carriers: odds ratios for 
Aß
1-40
 and Aß
1-42
 (per SD increase) were 1.49 (95% CI 0.99; 12.25) and 1.40 (95% CI 0.90; 
2.18) in ε4 carriers and 1.47 (95% CI 1.13; 1.91) and 1.34 (95% CI 1.04;1.73) in non-car-
riers. In APOE ε4 carriers, people who dropped in their Aß levels over time tended to 
Figure 2. The relation between plasma 
Aß
1-40
 and Aß
1-42
 levels in quintiles, as-
sessed 6.5-years before, and impaired 
vasomotor reactivity (expressed as 
odds ratios with 95% conﬁ dence 
intervals, adjusted for age and sex ). 
Odds ratios are plotted at the median 
Aß
1-40
 and Aß
1-42
 levels of the different 
quintiles(p-value for continuous linear 
trend).
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have a higher prevalence of impaired vasomotor reactivity than non-carriers (odds ratio 
third versus ﬁ rst quintile of Aß
1-40
 in carriers 3.16 (95% CI 0.89; 11.19) and in non-carri-
ers 1.46 (95% CI 0.68; 3.13), and odds ratio third versus ﬁ rst quintile of Aß
1-42
 in carriers 
1.82 (95% CI 0.63; 2.78), and in non-carriers 1.32 (95% CI 0.63; 2.78)). These interactions 
were however not statistically signiﬁ cant (p-values 0.16 and 0.87).
Neither additional adjustment for hypertension, smoking, diabetes, and carotid in-
tima-media thickness nor exclusion of people with prevalent stroke or dementia at time 
of TCD changed the associations (data not shown). The ratio of Aß
1-42
/Aß
1-40
 was not as-
sociated with either lacunar infarcts or white matter lesions (data not shown).
The average increases in systolic and diastolic blood pressure during the vasomotor 
reactivity assessment were 10.6 mmHg (SD 11.5) and 5.3 mmHg (SD 6.5). Additional 
adjustment for changes in systolic and diastolic blood pressure during the TCD proce-
dure did not change the odds ratios for Aß
1-40
 and Aß
1-42
 in relation to impaired vasomotor 
reactivity.
DISCUSSION
We found that in elderly people impaired cerebral vasomotor reactivity is related to 
Figure 3. The relation between 
quintiles of change in plasma Aß
1-40
 
and Aß
1-42
 per year and impaired 
vasomotor reactivity (expressed as 
odds ratios with 95% conﬁ dence 
intervals, adjusted for age and 
sex). Odds ratios are plotted at the 
median of Aß
1-40
 and Aß
1-42
 change 
in level per year of the different 
quintiles, with the third quintile as 
the reference category.
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higher plasma Aß
1-40
 and Aß
1-42
 levels on average 6.5-years earlier but not to concurrent 
Aß-levels. Furthermore, a decrease in plasma Aß
1-40
 levels over time is associated with a 
higher prevalence of impaired vasomotor reactivity.
The strengths of this study are the population-based design and the large number 
of elderly participants in whom TCD and plasma Aß assessments at two points in time 
were performed. The plasma Aß levels were measured without knowledge of other risk 
factors or presence of impaired vasomotor reactivity. Therefore, misclassiﬁ cation, if any, 
will have been random and may have resulted in an underestimation of the strength of 
any risk associations.
TCD measurements were not obtained in all participants at the second follow-up 
survey of the Rotterdam Study. The selection of people for TCD measurements was ran-
dom so this will not have biased the results. However, TCD measurements could not be 
successfully completed in 38% of those invited. People with unsuccessful completion of 
the TCD protocol were on average older and more often women. In older age and in post-
menopausal women the thickness of the temporal bone increases, resulting in a higher 
frequency of window failure.21 Furthermore, hyperostosis, which is predominantly found 
in women, is also thought to preclude TCD measurements. We do not think that this 
selection has signiﬁ cantly biased our results, because Aß levels of participants were not 
different from those of non-participants. Moreover, the association between Aß levels 
and impaired vasomotor reactivity was not modiﬁ ed by age or sex (data not shown).
Several factors may be responsible for the variance and change in plasma Aß levels 
in elderly people. Genetic factors may be responsible for a higher Aß production, given 
the elevated plasma Aß levels in all genetic forms of early-onset AD.22,23 Higher plasma 
Aß levels may also reﬂ ect a change in the dynamic equilibrium of CSF and plasma 
Aß.24,25 Clearance of Aß from the CSF to plasma can be disturbed by either obstruction 
of drainage pathways with amyloid deposits, or by a diminished soluble fraction of CSF 
Aß due to progressive aggregation and deposition of Aß.16,25-27 The two latter mechanisms 
will result in lower peripheral Aß levels with progression of intracerebral Aß deposition. 
This could possibly explain the difference in associations of Aß levels assessed 6.5-years 
before and at time of the TCD with impaired vasomotor reactivity. 
Impaired vasomotor reactivity can result from either cerebral small vessel disease 
or hemodynamic changes with maximally dilated arterioles. The latter is the case in 
high grade carotid stenosis or occlusion, in which cerebral perfusion can become directly 
dependent of the systemic arterial blood pressure.2,3,20 It is unlikely that large vessel 
disease has substantially contributed to our ﬁ ndings, given that high grade stenosis or 
occlusion were not present in our study sample. Furthermore Aß levels were not associ-
ated with carotid intima media thickness, which is a measure of large vessel pathology, 
and consequently adjustment for carotid intima media thickness did not change the 
associations. On the other hand, we recently found that plasma Aß levels are associated 
with white matter lesions and lacunar infarcts, which support the selective relationship 
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between plasma Aß and cerebral small vessel disease.28
Higher plasma Aß levels could be related to impaired vasomotor reactivity through 
two different mechanisms. Firstly, higher levels of Aß could lead to depositions in the 
media and adventitia of meningocortical arteries and arterioles. These deposits lead 
to obliteration of vessel lumina and loss of vascular smooth muscle cells necessary to 
autoregulation.7,9,10,29 Secondly, Aß may, apart from its cytotoxicity to smooth muscle 
cells, enhance the extent and duration of endothelial dependent vasoconstriction.7,10,11 
This could alter the ability of arterioles to dilate in response to blood pressure changes 
or hypercapnia.We observed an association between  impaired vasomotor reactivity and 
Aß measured 6.5-years earlier, but not with concurrently measured Aß levels. This dif-
ference in associations could be explained by differences in direct and long term effects 
of Aß.
High Aß levels assessed several years before the TCD assessment might reﬂ ect 
a tendency for vascular Aß deposition in the future, and may explain an association 
between impaired vasomotor reactivity 6.5-years later (long term effect). Aß levels as-
sessed at time of the TCD assessment may be related to the observed vasomotor reac-
tivity through a direct vasoactive effect (short term effect). Our observations are more 
compatible with Aß levels representing vascular deposits years later. However, they do 
not exclude a direct vasoactive effect.
In conclusion impaired cerebral vasomotor reactivity is associated with higher plas-
ma Aß
1-40
 and Aß
1-42
 levels assessed 6.5-years earlier and with decline in Aß
1-40
 levels over 
a 6.5-year time period, but not with concurrently assessed Aß levels. Plasma Aß might 
be involved in the impairment of cerebral autoregulation in the elderly via deposition in 
the small cerebral arteries.
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Abstract
Background and purpose — Cerebral white matter lesions in elderly people are mostly caused by 
cerebral small vessel disease and have been associated with an increased risk of stroke, dementia 
and depression. We studied the rate of white matter lesion progression over time, and its relation 
with cardiovascular risk factors.
Methods — Six hundred sixty-eight people, aged 60 to 90 years, underwent repeated MRI scanning 
within a 3-year follow-up, as part of the prospective population-based Rotterdam Scan Study. We 
rated change in periventricular and subcortical white matter lesion severity with a semiquantita-
tive scale, and graded progression as no, minor or marked. We assessed risk factors for white matter 
lesion progression by means of logistic and multinomial logistic regression analysis.
Results — Twenty-seven percent of participants showed any and 9% showed marked progression of 
white matter lesions in the periventricular region. Thirty-two percent showed any and 10% showed 
marked progression in the subcortical region. White matter lesion severity and presence of brain in-
farcts at baseline, higher age, high blood pressure, and current smoking were positively associated 
with progression of white matter lesions. Women had more marked progression of subcortical white 
matter lesions compared to men.
Conclusion — Approximately one-third of elderly people have progression of white matter lesions 
in 3-years. Presence and severity of white matter lesion and brain infarcts at baseline, higher age, 
female sex, elevated blood pressure and current cigarette smoking are associated with white matter 
lesion progression.
Progression of cerebral white matter
lesions
4.1
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INTRODUCTION
Cerebral white matter lesions are frequently seen on magnetic resonance imaging (MRI) 
scans in elderly people.1,2 These lesions mostly reﬂ ect demyelination and axon loss due 
to chronic ischemia associated with cerebral small vessel disease.3,4 People with more se-
vere white matter lesions have an increased risk of stroke, dementia, and depression.5-7
Cross-sectional studies have reported a higher prevalence and increased severity of 
white matter lesions with older age. Hypertension is considered the main risk factor, but 
other cardiovascular risk factors may be related to these lesions as well.4,8-13 In contrast, 
data on change of white mater lesions in community dwelling people are scarce.14 The 
Austrian Stroke Prevention Study reported progression of white matter lesions within 
three years in 18% of the 273 participants. Diastolic blood pressure and severe white 
matter lesions at baseline were the only predictors of lesion progression.14,15
We investigated in a large population-based sample of elderly people, the rate, lo-
cation and conﬁ guration of change of cerebral white matter lesions. Furthermore, we 
studied the association of age, sex, severity and presence of white matter lesions and 
brain infarcts at baseline, and cardiovascular risk factors with progression of cerebral 
white matter lesions.
METHODS
Subjects
The Rotterdam Scan Study is a prospective population-based cohort study designed 
to study the causes and consequences of age related brain changes in elderly people.9 
We randomly selected people 60 to 90 years of age, stratiﬁ ed on age and sex, from two 
ongoing population based studies, the Rotterdam Study and the Zoetermeer study.16,17 
A total of 1,077 elderly people without dementia participated (response rate 63%). The 
medical ethics committee of the Erasmus Medical Center approved the study, and each 
participant gave written informed consent. The baseline examination in 1995 to 1996 
comprised a structured interview, physical examination, blood sampling, and neuro-
psychological tests, as well as a cerebral MRI scan.
In 1999 to 2000, we re-invited 951 people who were eligible for a second MRI ex-
amination from the cohort of 1,077 people who had a MRI examination at baseline. In 
total 668 participated (response rate 70%). One-hundred-twenty-six participants were 
ineligible to undergo a second MRI for the following reasons: 82 died, 19 were institu-
tionalized, 19 had MRI contraindications, 3 moved abroad, and 3 could not be reached. 
The reasons for refusal to participate in the second examination were as follows: claus-
trophobia developed at the baseline MRI (n=98), too much hassle (n=90), no interest 
(n=77), and other reasons (n=18).
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MRI scanning 
At baseline, we made axial T1-, T2-, and proton-density- (PD) weighted cerebral MR 
scans on a 1.5-Tesla scanner (for participants from Zoetermeer, MR Gyroscan, Philips; 
for participants from Rotterdam MR VISION, Siemens, with comparable pulse sequenc-
es).18 In 1999 to 2000 all second MRI scans were made with the MR VISION scanner and 
the same sequences. 
Lesion rating
We considered white matter lesions to be periventricular if they were directly adjacent 
to the ventricle; otherwise we considered them subcortical. We scored periventricular 
white matter lesions semiquantitatively in order to obtain a total periventricular score 
(range 0-9).18 For subcortical white matter lesion, we approximated a total volume 
(range 0-29.5ml).18 We deﬁ ned infarcts as focal hyperintensities on T2-weighted im-
ages, 3mm in size or larger. Lesions in the white matter also had to have corresponding 
prominent hypointensities on T1-weighted images, in order to distinguish them from 
cerebral white matter lesions. We deﬁ ned lacunar infarcts as infarcts sized 3 to 20mm 
and located in the subcortical white matter or basal ganglia.
To assess change of white matter lesions, we transferred digital images to a Linux 
PC, and used viewing software developed in Matlab (MathWorks). Two raters independ-
ently analyzed progression of white matter lesions severity on PD- and T2-weighted 
images by direct scan comparison. We used a new white matter lesions change scale, 
since commonly used rating scales designed for cross-sectional assessments of white 
matter lesions are not well suited for measuring change.19 Baseline and follow-up series 
were downloaded side by side, with the baseline and follow-up scan randomly appearing 
on the right or left side of the screen. We assessed the difference in white matter lesion 
severity between the right and left images. In the periventricular region, we assessed 
difference in size of lesions in the frontal caps, lateral bands, and occipital caps, in the 
left and right hemisphere (negative difference -1 point, no difference 0 points, positive 
difference +1 point, resulting in a score of -6 to +6). In the subcortical region, we as-
sessed difference in number, size, or conﬂ uence of lesions in the frontal, parietal, tem-
poral, and occipital lobes of the left and right hemisphere (negative difference -1 point, 
no difference 0 points, positive difference +1 point, resulting in a score of -8 to +8). If 
periventricular lesion change extended beyond 10mm outside the border of the ventricle, 
we considered the change to have occurred in both the periventricular and subcortical 
region. Raters were blinded to all clinical information, including scan date, for partici-
pants derived from the Rotterdam Study. This was not possible for participants derived 
from the Zoetermeer Study due to the change in MRI between baseline and follow-up. If 
raters disagreed one point or less on the scale, we used the mean of the ratings, other-
wise we held a consensus meeting. The change rating showed good interobserver agree-
ment (intraclass correlation coefﬁ cient periventricular region 0.79; subcortical region 
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0.75), and good to very good intraobserver agreement (intraclass correlation coefﬁ cient 
periventricular region 0.70-0.89; subcortical region 0.78-0.93). We deﬁ ned progression 
as an increase of 1 point or more between baseline and follow-up. Progression was cat-
egorized into minor progression (score 1-2.5) and marked progression (score 3 or higher). 
Digital images were not available in 52 participants due to technical problems. In these 
participants, we assessed white matter lesion change on hardcopy.
We evaluated the effect of non-blinding of the scan date.19 The difference between 
non-blinded and blinded scores was 0.075 (95%CI -0.71;+0.86) points for periventricular 
white matter lesions, and 0.025 (95%CI -0.84;+0.89) points for subcortical white mat-
ter lesions. Therefore, non-blinding in the Zoetermeer Study part of our study did not 
introduce bias.
Cardiovascular risk factors
Blood pressure was measured twice on the right arm with a random-zero sphygmoma-
nometer. The two measurements were averaged. Hypertension was deﬁ ned according to 
WHO-ISH guidelines at time of blood pressure measurement, as systolic blood pressure 
of ≥160mmHg, diastolic blood pressure of ≥95mmHg, or the use of blood pressure low-
ering medication. Smoking habits were classiﬁ ed as never, former and current cigarette 
smoking. We considered diabetes mellitus to be present if the random glucose level 
was ≥11.1mmol/l or if a person was taking oral antidiabetics or insulin. To determine 
plasma total homocysteine levels, we used a ﬂ uorescence polarisation immunoassy on 
an IMx analyser (Abbott Laboratories).8 Partial arterial oxygen saturation was meas-
ured twice, with a pulse oximeter (Andos, Oxycount). The two measurements were 
averaged (range 86-99%).12 Participants underwent ultrasonography of both carotid 
arteries with a 7.5-MHz linear-array transducer and a Duplex scanner (ATL Ultra-
Mark IV, Advanced Technology Laboratories). We calculated the mean common carotid 
intima-media thickness as the mean of the near and far walls of both the right and left 
common carotid arteries.13 Apolipoprotein E (APOE) genotyping was done on coded ge-
nomic DNA samples.20 The distribution of the APOE genotype in this population was in 
Hardy-Weinberg equilibrium.
Data analysis
We used age and sex adjusted analysis of covariance to assess whether baseline risk fac-
tors differed between people with and without a second MRI assessment. We calculated 
Spearman’s rho for correlation between periventricular and subcortical white matter le-
sion progression. We used logistic and multinomial logistic regression analyses to study 
the association of risk factors with any, minor and marked white matter lesion progres-
sion. People with a negative difference in white matter lesion severity over time were 
added to the group of people with no progression. All analyses were adjusted for age and 
sex, and additionally for cardiovascular risk factors. We consider baseline white matter 
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lesion severity as an intermediate factor in the relation between risk factors and white 
matter lesion progression. Therefore, we did not adjust for baseline lesions. To assess 
whether the effect of blood pressure on lesion progression was different in people with 
already severe white matter lesions at baseline, we did separate analyses in people with 
and without severe white matter lesions at baseline. We deﬁ ned severe periventricular 
and subcortical white matter lesions as the upper quintile of their baseline distribu-
tion.9
RESULTS
People who underwent a second MRI were younger and less often used blood pressure 
lowering medication than people who refused a second examination (table 1). They were 
also younger, healthier and more often female than people who were ineligible for a 
second MRI (table 1). The mean follow-up between the two MRI assessments was 3.3 
(SD 0.2) years.
Table 1. Baseline characteristics of people who had a 2nd MRI assessment and for those who 
refused or were ineligible.
People with 
2nd MRI
assessment
n=668
People who 
refused
2nd MRI
assessment
n=283
People ineli-
gible for 2nd 
MRI assess-
ment
n=126
Age, year
Women
Systolic blood pressure, mmHg
Diastolic blood pressure, mmHg
Use of antihypertensive medication
Hypertension
Current smoking
Former smoking
Diabetes
Total homocysteine, µmol/l
Oxygen saturation, %SpO
2
Intima media thickness, mm
Periventricular white matter lesions (range 0-9)
Subcortical white matter lesions, ml
Brain infarcts
Lacunar infarcts
APOE ε4 allele
71 (7)
52
147 (21)
79 (12)
30
49
16
51
5
11.0 (3.6)
96.4 (1.3)
0.86 (0.15)
2.2 (2.1)
1.2 (2.5)
22
20
30
74 (7)*
57
149 (22)
79 (12)
42*
58
13
50
8
11.7 (4.2)
96.3 (1.2)
0.87 (0.13)
2.5 (2.1)
1.5 (3.1)
25
23
30
77 (8)*
41*
146 (23)
75 (12)*
43
58
21*
52
13*
13.9 (5.4)*
96.3 (1.5)
0.93 (0.17)
3.5 (2.5)*
2.1 (4.1)
34
28
22
Values are unadjusted means (SD) or percentages
*Age and sex adjusted mean or percentage is signiﬁ cantly different (p<0.05) from people with 
2nd MRI assessment
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Twenty-seven percent of the people had any progression of periventricular white 
matter lesions and 32% had any progression of subcortical white matter lesions, where-
as 39% had any progression of white matter lesions in at least one of these regions (table 
2). Spearman’s rho for the correlation between progression in the periventricular and 
subcortical region was 0.60 (p<0.001)). Two people had minor regression of white matter 
lesions in the periventricular and 13 in the subcortical region. Within the group with pe-
riventricular white matter progression, 17% had progression of the frontal caps, 56% of 
the bands, and 73% of the occipital caps. Within the group with subcortical white matter 
lesion progression, 71% had progression in the frontal, 63% in the parietal, 12% in the 
occipital, and 7% in the temporal lobe. The hemispheres were equally affected. Marked 
subcortical white matter progression predominantly consisted of growth and conﬂ uence 
of lesions, whereas minor progression mostly consisted of new small lesions (ﬁ gure 1).
White matter lesion severity and the presence of brain infarcts, of which 90% were la-
cunar, on baseline MRI were strongly related to progression of white matter lesions (ta-
ble 3). None of the people without lesions at baseline, and three people with only small 
punctate lesions (<3 mm) at baseline, had marked subcortical white matter lesion pro-
Table 2. Relationship between periventricular and subcortical white matter lesion (WML) 
progression
Periventricular WML progression
no minor marked totals
S
u
b
c
o
rt
ic
a
l 
W
M
L
p
ro
g
re
s
s
io
n
no
minor
marked
407 (61)
72 (11)
9 (1)
38 (6)
59 (9)
23 (3)
6 (1)
19 (3)
35 (5)
451 (68)
150 (23)
67 (10)
totals 488 (73) 120 (18) 60 (9) 668 (100)
Numbers are absolute numbers of people and percentages of overall total
Figure 1. Conﬁ guration 
of minor and marked 
subcortical white matter 
lesion progression.
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gression. The extent of progression of both periventricular and subcortical white matter 
lesions was strongly related to age (ﬁ gure 2). Women had a higher risk of subcortical 
white matter lesions progression than men, and this difference reached signiﬁ cance 
for marked subcortical white matter lesions (table 4). Systolic and diastolic blood pres-
sure were positively associated with white matter lesion progression (table 4), which 
remained after adjustment for use of blood pressure lowering medication. Current ciga-
rette smoking was positively associated with marked white matter lesion progression 
(table 4). We did not observe a relation between carotid intima-media thickness, homo-
cysteine levels, oxygen saturation and white matter lesion progression. The association 
of blood pressure and smoking with progression of white matter lesions hardly changed 
after additional adjustment for other cardiovascular risk factors (data not shown).
In subgroup analyses, the associations between blood pressure and white matter 
lesion progression was present in the people without severe white matter lesions at 
baseline (per standard deviation increase in respectively diastolic and systolic blood 
pressure, the age and sex adjusted odd ratios were 1.36 (95%CI 1.08;1.71) and 1.25 
(95%CI 0.99;1.59) for any periventricular white matter lesion progression and 1.15 
(95%CI 0.94;1.42) and 1.12 (95%CI 0.90;1.39) for any subcortical white matter lesion 
Figure 2. Proportions of periven-
tricular and subcortical white matter 
lesion progression in 10 years age 
strata.
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progression). In people with severe white matter lesions at baseline the effect of blood 
pressure was not present (per standard deviation increase in respectively diastolic and 
systolic blood pressure, the age and sex adjusted odd ratios were 0.89 (95%CI 0.60;1.32) 
and 0.98 (95%CI 0.67;1.44) for any periventricular white matter lesion progression and 
0.91 (95%CI 0.62;1.35) and 1.01 (95%CI 0.70;1.45) for any subcortical white matter le-
sion progression).
DISCUSSION
We found that approximately 30% of people between 60 and 90 years of age had any pro-
gression and 10% had marked progression of periventricular or subcortical white matter 
lesions within 3-years. Older age, female sex, higher blood pressure, current cigarette 
smoking and high white matter lesion severity and the presence of brain infarcts at 
baseline were associated with progression of white matter lesions. The associations 
were independent of other cardiovascular risk factors. 
The strengths of the present study are its large number of participating elderly peo-
ple from the general population, its prospective design, the good interobserver agree-
ment between raters, and the assessment of a large number of risk factors. Still, some 
methodological issues should be considered. First, there is a possibility of selection bias. 
People who participated were younger and healthier compared to those who were ineli-
gible or refused a second MRI scan. Therefore, the progression of white matter lesions in 
our study may be an underestimation of the progression in the population at large. The 
same selection may also have attenuated the estimates for the associations between risk 
factors and progression of white matter lesions. Second, we changed MRI scanner in half 
of our cohort, which made it not possible to blind for study date in that part. However, 
we evaluated the effect of non-blinding and found that it did not cause overestimation of 
progression in our study.19 Furthermore, the rate of progression and the strength of the 
associations were not different for the blinded and non-blinded group. Third, we used 
a semiquantitative measurement tool, which gives less precise estimates of total lesion 
progression than a volumetric measurement. The used scale showed however a good 
correlation with volumetric measurements.19 Furthermore, misclassiﬁ cation in lesion 
assessment, if any, would have resulted in an underestimation of the relation with risk 
factors due to regression towards the mean.
It is difﬁ cult to compare the distribution of white matter lesions between studies, due 
to differences in study population, imaging techniques, lesion rating, lesion categoriza-
tion and risk factor distributions, and the same holds for comparing progression of white 
matter lesions.2 In the Austrian Stroke Prevention Study, 18% of the participants had 
any, and 8% had marked progression within 3 years of follow-up.14,15 The lower propor-
tion of progression of white matter lesions in that study compared to our ﬁ ndings could 
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be explained by the exclusion of people with cerebrovascular disease, the 10 years lower 
mean age of the participants and the lower response rate.
In cross-sectional studies, older age and higher blood pressure, in particular diastolic 
blood pressure, were strongly associated with white matter lesion severity.1,18 Further-
more, women tended to have more severe white matter lesions.1 We observed that these 
risk factors are also associated with progression of white matter lesions. The Austrian 
Stroke Prevention study reported the same associations with age and diastolic blood 
pressure.14,15 In addition, we found that current cigarette smoking was associated with 
marked white matter lesion progression.
Our data conﬁ rm that white matter lesion severity and presence of brain infarcts at 
baseline are strongly associated with lesion progression.14,15,21 The association between 
brain infarcts and progression of white matter lesions can be explained by a shared 
exposure to risk factors and susceptibility for these factors, resulting in a common 
pathological substrate.21,22 Baseline white matter lesions and lacunar infarcts reﬂ ect 
small vessel disease and chronic hypoperfusion. Persistent hypoperfusion could, with-
out additional vessel damage, result in white matter lesion progression. The progression 
of white matter lesions from punctate to large conﬂ uent lesions is probably a continuous 
process, which has an exponential rather than a linear relation with time.
We found that in people with severe white matter lesions at baseline, higher blood 
pressure was not a risk factor for white matter lesion progression any more. This is 
in agreement with earlier ﬁ nding that blood pressure is not related to incident silent 
brain infarcts in people with prevalent silent brain infarcts.22 The vast majority of these 
infarcts were lacunar infarcts.22 In people with present small vessel disease, high blood 
pressure may lead to progression of small vessel damage on one hand and be necessary 
to maintain perfusion in a state of impairment autoregulation on the other. Apart from 
these potential opposite roles of blood pressure, another explanation of the negative 
results in people with vascular lesions at baseline, could  be that cardiovascular risk fac-
tors do not further discriminate within a group of people already at high risk.
We previously reported on the cross-sectional association between carotid atheroscle-
rosis11, homocysteine levels8, oxygen saturation12, and white matter lesions. We did not 
observe an association between these factors and progression of white matter lesions. 
This could be explained by selective follow-up as noted earlier. Alternative explanations 
for these distinct ﬁ ndings, are the smaller samples size, and the possibility that baseline 
white matter lesion distribution is a more robust measure of small vessel disease since 
it reﬂ ects accumulation of lesions over a longer period of time.
In this study we considered progression of white matter lesions as an increase in 
number, size or conﬂ uence of lesions. This “lesion volume”-based paradigm may not 
cover the complete pathophysiology, since progression could, apart from increase in 
volume, also be increase in tissue damage within existing lesions. A prospective study 
in patients with CADASIL showed progression in tissue damage with diffusion tensor 
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imaging.23 Future studies on the progression of white matter lesions should therefore 
also take change in integrity of the white matter into account.
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Abstract
Inﬂ ammatory processes are involved in the development and consequences of atherosclerosis. 
Whether these processes are also involved in cerebral small vessel disease is unknown. Cerebral 
white matter lesions and lacunar infarcts are caused by small vessel disease and commonly ob-
served on MRI scans in elderly people. These lesions are associated with an increased risk of stroke 
and dementia. We assessed whether higher C-reactive protein (CRP) levels were related to the sever-
ity and progression of white matter lesion, and the prevalence and incidence of lacunar infarcts.
We based our study on 1,033 participants of the population-based Rotterdam Scan Study who 
had complete data on CRP levels and underwent brain MRI scanning. Subjects were 60-90 years 
of age and free of dementia at baseline. Six hundred thirty-six subjects had a second MRI scan on 
average 3.3 years later. We used multivariate regression models to assess the associations between 
CRP levels and markers of small vessel disease. Higher CRP levels were associated with presence 
and progression of white matter lesions, particularly with marked lesion progression (Odds ratios 
for highest versus lowest quartile of CRP 3.1 (95%CI 1.3;7.2) and 2.5 (95%CI 1.1;5.6) for marked pe-
riventricular and subcortical white matter lesion progression). These associations were independent 
of cardiovascular risk factors and carotid atherosclerosis. Persons with higher CRP levels tended to 
have more prevalent and incident lacunar infarcts.
Our study suggests that inﬂ ammation is involved in the pathogenesis of cerebral small vessel 
disease, and in particular in the development of white matter lesions.
C-reactive protein and cerebral small
vessel disease
4.2
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INTRODUCTION
Inﬂ ammatory processes are part of the pathogenesis of atherosclerosis and a risk fac-
tor for myocardial infarction, stroke and peripheral arterial disease.1-4 Furthermore, 
these processes probably also play a role in the response to ischemic events resulting 
from atherosclerosis.5 Whether inﬂ ammatory processes, apart from their involvement 
in large vessel disease, are also part of the development and consequences of cerebral 
small vessel disease is yet unknown.
Lacunar brain infarcts and cerebral white matter lesions are caused by small vessel 
disease.6-9 These lesions are commonly observed on magnetic resonance imaging (MRI) 
scans of elderly people and are associated with an increased risk of stroke, dementia 
and depression.10-15 Although the pathophysiology of cerebral small vessel disease is not 
exactly clear increased age and hypertension are considered the main risk factors. Nar-
rowing of the vascular lumen and failure of cerebral autoregulation result in ischemic 
damage of the cerebral white and subcortical gray matter.8,16
The acute phase reactant C-reactive protein (CRP) has proven to be a sensitive 
systemic marker of inﬂ ammation.17,18 The objective of the present study was to assess 
whether higher levels of this inﬂ ammation marker are related to the presence and pro-
gression of cerebral small vessel disease in elderly people.
METHODS
Subjects
The Rotterdam Scan Study is a prospective, population based cohort study. We ran-
domly selected participants aged 60-90 years in strata of age (5 years) and sex from two 
large ongoing population-based studies.19,20 The characteristics of the 1,077 non-dement-
ed participants have been described previously.16 Baseline examination in 1995-1996 
comprised a structured interview, neuropsychological tests, physical examination, blood 
sampling, and a MRI scan of the brain. In 1999-2000, 668 (70%) of the 951 participants 
who were alive and eligible underwent a second MRI and were re-examined at the re-
search center similar to the baseline examination.21 Each subject gave written informed 
consent to participate in our study, which had been approved by the local medical ethics 
committee.
MRI scanning 
In 1995-1996, we made axial T1-, T2-, and proton density (PD)-weighted cerebral MR 
scans on a 1.5-Tesla scanner (MR VISION, Siemens, MR Gyroscan, Philips).22 In 1999-
2000, participants underwent a second MRI with the use of the MR VISION scanner and 
the same sequences.
EvD04-2.indd   102 23-03-2004, 13:51:07
C-reactive protein and cerebral small vessel disease
103
White matter lesions
We considered white matter lesions to be in the periventricular region if they were 
directly adjacent to the ventricle; otherwise we considered them subcortical. Baseline 
white matter lesions severity was scored on hardcopy with a visual rating scale.22 We 
scored periventricular white matter lesions semiquantitatively in three regions (lesions 
adjacent to the frontal horns, the lateral walls, and the occipital horns of the lateral ven-
tricle) resulting in a total score ranging from 0-9. For subcortical WML we approximated 
a total volume based on number and size of lesions (range 0-29.5ml).
Two raters independently assessed progression of white matter lesions severity on 
digital T2-weighted and PD-weighted images by direct scan comparison.21,23 Raters were 
blinded to all clinical information. We scored differences in white mater lesion severity 
in the 3 periventricular regions of both hemispheres (periventricular score range -6 to +6) 
and in the subcortical white matter of the 4 lobes of both hemispheres (subcortical score 
range -8 to +8).23 The change rating showed good interobserver agreement (intraclass 
correlation coefﬁ cient 0.75-0.79), and good to very good intraobserver agreement (intra-
class correlation coefﬁ cient 0.70-0.93). If raters disagreed one point or less on the scale, 
we used the mean of the ratings, otherwise we held a consensus meeting. Progression 
was deﬁ ned as an increase of one point or more between baseline and follow-up. We cat-
egorized progression into no progression (score <1), minor progression (score 1-2.5), and 
marked progression (score 3 or higher). Hyperintensities on PD- and T2-weighted images 
around an incident infarct were not considered as progression of white matter lesions.
Cerebral infarcts
The presence of brain infarcts was rated similarly at the baseline and second MRI.15 
We deﬁ ned brain infarcts as areas of focal hyperintensity on T2-weighted images sized 
≥3mm. Areas of hyperintensity in the white matter also had to have corresponding 
prominent hypointensity on T1-weighted images, in order to distinguish them from 
white matter lesions. We deﬁ ned lacunar infarcts as infarcts sized 3-20mm and located 
in the subcortical white matter or basal ganglia. Non-lacunar infarcts were excluded in 
the analyses of lacunar infarcts.
High-sensitivity C-reactive protein (CRP)
We collected non-fasting blood samples into vacutainers in 1995-1996. Samples were put 
on ice immediately, centrifuged within 60 minutes, and aliquots of serum were stored 
at -80˚C. In 2003, serum levels of C-reactive protein were determined by Rate Near 
Infrared Particle Immunoassay method (Immage®high sensitive CRP, Beckman Coul-
ter, USA). This method has an intra-laboratory imprecision of less than 5%. CRP level 
distribution was highly skewed. In the study population 5.2% (n=54 of whom 31 had 
repeated MRI assessments) had levels of CRP >10mg/L. Outliers (values three standard 
deviations above the population mean of log-transformed CRP, n=14 of whom 10 had 
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repeated MRI assessments) were excluded, since they may indicate the presence of an 
active inﬂ ammatory disease.24 We assessed CRP levels in 1,047 people of the baseline 
cohort of whom 636 people had a second MRI scan. In the other 30 people we failed to 
obtain blood samples.
Cardiovascular risk factors21
Hypertension was deﬁ ned according to WHO-ISH guidelines at time of blood pressure 
measurement, as systolic blood pressure of ≥160mmHg, diastolic blood pressure of 
≥95mmHg, or the use of blood pressure lowering medication. Smoking habits were clas-
siﬁ ed as never, former and current cigarette smoking. We considered diabetes mellitus 
to be present if the random glucose level was ≥11.1mmol/l or if a person was taking 
oral anti-diabetics or insulin. Non-fasting serum total cholesterol and high-density lipo-
protein were determined. Body mass index was calculated as weight divided by height 
squared. Participants underwent ultrasonography of both carotid arteries to obtain 
an atherosclerotic plaque score (range 0-6) and an intima-media thickness measure-
ment.25
Data analysis
We categorized CRP levels in quartiles of the baseline distribution and used linear 
regression analyses to assess its relation with periventricular and subcortical white 
matter lesions at baseline and multinomial logistic regression analyses to assess its 
relation with white matter lesion progression. We used logistic regression analyses to 
study the relation between quartiles of CRP levels and prevalent and incident lacunar 
infarcts. All analyses were adjusted for age and sex and cardiovascular risk factors, and 
subsequently for measurements of carotid atherosclerosis. We did additional analyses 
in which we excluded people who used non-steroidal anti-inﬂ ammatory drugs (NSAIDs) 
or statins and people with a prevalent myocardial infarction or stroke, to check whether 
these factors inﬂ uenced the associations under study.
RESULTS
Selected baseline characteristics of all participants and of those with repeated MRI as-
sessments are shown in table 1. The mean follow-up period between the ﬁ rst and second 
MRI was 3.3 years (standard deviation 0.2 years). During this period, 172 participants 
(27%) showed white matter lesion progression in the periventricular region, 59 (9%) of 
whom showed marked progression. Two-hundred-ﬁ ve participants (32%) showed pro-
gression in the subcortical region, 62 (10%) of whom showed marked progression. Ninety 
participants (14%) had a new cerebral infarct on the follow-up MRI, of which 76 (12%) 
were lacunar.
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People with high CRP levels (upper quartile) had more severe periventricular and 
subcortical white matter lesions at baseline than people with low CRP levels (lowest 
quartile), adjusted for age, sex and cardiovascular risk factors (table 2). This association 
in all 1,033 subjects was similar for the 636 subjects with repeated MRI assessments. 
Additional adjustment for carotid plaques and intima-media thickness hardly changed 
these associations (table 2). Persons with higher CRP levels tended to have more lacu-
nar infarcts at baseline, but this was non-signiﬁ cant.
People with high CRP levels (upper quartile) also had more progression of periven-
tricular and subcortical white matter lesions than people with low CRP levels (lowest 
quartile), adjusted for age, sex and cardiovascular risk factors (table 3). Additional 
adjustment for carotid plaques and intima-media thickness hardly changed these asso-
ciations (table 3). The association between CRP levels and white matter lesion progres-
sion was stronger for marked than for any white matter lesion progression. People with 
higher CRP levels tended to have more new lacunar infarcts than people with lower CRP 
levels, however the association was non-signiﬁ cant (table 3). Exclusion of people with 
Table 1. Baseline characteristics of all participants and of the participants with repeated MRI 
assessments
All participants
(n=1,033)
Participants with 
repeated MRI 
assessment (n=636)
Age, years 
Women, %
Hypertension, %
Diabetes Mellitus, %
Body mass index, kg/m2
Current smoking, %
Former smoking, %
Cholesterol/HDL ratio
CRP, mg/l
Use of NSAIDs, %
Use of statins, %
Periventricular WML (grade)
Subcortical WML (ml)
Infarcts, %
Lacunar infarcts, %*
Carotid plaques, (range 0-6)
Intima-media thickness, mm
Prevalent myocardial infarction, %
Prevalent stroke, %
72 (7)
51
53
7
26.7 (3.6)
16
51
4.9 (1.5)
2.0 (1.0;3.6)
6
7
2.4 (2.2)
1.4 (2.8)
24
22
1.7 (1.6)
0.87 (0.15)
8
6
71 (7)
51
47
6
26.8 (3.7)
16
51
4.9 (1.4)
1.8 (1.0;3.5)
6
7
2.1 (1.5)
1.1 (2.4)
22
20
1.5 (1.5)
0.86 (0.15)
6
4
Values are percentages, unadjusted means (standard deviation), and for CRP levels medians (inter-
quartile range) *non-lacunar infarcts excluded
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prevalent myocardial infarction or stroke or of people who used statins or NSAIDs did 
not change these associations.
DISCUSSION
We found in a general population of non-demented elderly that higher CRP levels were 
associated with presence and progression of periventricular and subcortical white mat-
ter lesions, and in particular with marked lesion progression. These associations were 
independent of cardiovascular risk factors or carotid atherosclerosis. People with higher 
CRP levels tended to have more prevalent and incident lacunar infarcts than people 
with lower CRP levels, however these associations were non-signiﬁ cant.
Some methodological issues need to be discussed. First, non-participation both at 
baseline and at follow-up was associated with older age.16,21 People with higher CRP 
levels and more severe white matter lesions and lacunar infarcts may have selectively 
not participated. The cross-sectional association between CRP levels and white matter 
lesions was however not different for all participants compared to the group of partici-
pants who had repeated MRI assessments. Hence, although the potential selection of 
Table 2. Association between levels of C-reactive protein in quartiles and white matter le-
sion (WML) severity and prevalent infarcts (95% conﬁ dence intervals) in 1,033 subjects at 
baseline.
Mean baseline 
white matter lesions severity 
(95%CI)
Odds ratio 
prevalent infarcts (95%CI)
Quartiles Periventricular 
(grade)
Subcortical 
(ml)
All infarcts
Lacunar 
infarcts
Model 1
1 (0.20-1.01mg/l)
2 (1.02-1.82mg/l)
3 (1.83-3.49mg/l)
4 (3.50-22.50mg/l)
p-trend
2.3 (2.1;2.5)
2.2 (2.0;2.5)
2.3 (2.1;2.6)
2.7 (2.4;2.9)†
<0.05
1.2 (0.8;1.5)
1.2 (0.8;1.5)
1.4 (1.0;1.7)
1.7 (1.4;2.0)†
<0.05
1 (ref)
1.2 (0.8;1.9)
1.3 (0.9;2.1)
1.3 (0.9;2.1)
0.18
1 (ref)
1.3 (0.8;2.0)
1.4 (0.9;2.2)
1.3 (0.8;2.1)
0.25
Model 2
1 (0.20-1.01mg/l)
2 (1.02-1.82mg/l)
3 (1.83-3.49mg/l)
4 (3.50-22.50mg/l)
p-trend
2.3 (2.1;2.6)
2.2 (2.0;2.5)
2.4 (2.1;2.6)
2.6 (2.4;2.9)‡
0.06
1.2 (0.9;1.5)
1.2 (0.8;1.5)
1.4 (1.0;1.7)
1.7 (1.4;2.0)†
<0.05
1 (ref)
1.1 (0.7;1.8)
1.3 (0.9;2.0)
1.3 (0.9;2.1)
0.14
1 (ref)
1.2 (0.7;1.9)
1.4 (0.9;2.2)
1.3 (0.8;2.1)
0.19
Model 1 adjusted for age, sex, diabetes, smoking, BMI, hypertension and cholesterol/HDL ratio
Model 2 adjusted for age, sex, and carotid plaques and IMT
*p<0.01 †p<0.05 ‡p<0.10 for comparison with ﬁ rst quartile, p-trend over quartiles
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participants may have somewhat limited the range of baseline and outcome measure-
ments we do not think that it has effected the validity of the associations. Second, al-
though two experienced raters independently assessed all MRI scans with a good agree-
ment, there still is a possibility of misclassiﬁ cation of brain lesions. Also, CRP levels 
may have been measured with some  error, since we only assessed them once.26 However, 
a study in which CRP was measured regularly over a 6-month period concluded that 
CRP levels are tightly regulated with few short-term ﬂ uctuations.17 Since CRP levels, 
covariates and brain lesions were assessed independently and blindly from each other, 
misclassiﬁ cation, if any, will have been random and resulted in an underestimation of 
the associations.
Elevated CRP levels are not disease speciﬁ c but are sensitive markers produced in 
response to tissue injury, infectious agents, immunological stimuli and inﬂ ammation. 
Cytokines such as interleukin-1, interleukin-6 and tumor necrosis factor-α are highly 
correlated with CRP levels and their function.18,27 Elevated CRP levels may be related to 
cerebral white matter lesions and lacunar infarcts via different mechanisms.
First, CRP levels may be a marker for arteriolosclerosis or small vessel disease, as 
it is for atherosclerosis. Arteriolosclerosis may result in white matter lesions and lacu-
nar infarcts through vessel occlusion, disturbed cerebral autoregulation or increases 
vascular permeability.8,28 Although no inﬂ ammatory cells are observed in the vessel 
wall in case of arteriolosclerosis, inﬂ ammatory endothelial activation may play a role in 
both small and large vessel disease.6,7,29,30 Increased levels of inﬂ ammatory endothelial 
inﬂ ammation markers (e.g. ICAM and VCAM) have been reported in people with white 
matter lesions and lacunar infarcts.30
Second, inﬂ ammation may be a response to ischemic tissue damage.31-33 Microglial 
activation is shown in chronic cerebral hypoperfusion and may contribute to even fur-
ther tissue damage.34,35 In a state of chronic low-grade inﬂ ammation, oligodendrocytes 
and neurons may be more susceptible to hypoperfusion and hence accelerate lesion 
progression.36,37 Third, elevated CRP levels could reﬂ ect large vessel atherosclerosis.1-5,18 
Carotid atherosclerosis is related to cerebral white matter lesions, probably by reducing 
the cerebral blood ﬂ ow and by production of inﬂ ammatory mediators and free-radicals 
that effect the micro-vascular endothelium.4,25,38 Furthermore, carotid atherosclerosis 
also reﬂ ects longstanding exposure to cardiovascular risk factors, which it shares with 
small vessel disease. Adjusting for carotid atherosclerosis and for cardiovascular risk 
factors hardly changed the association, indicating that other mechanism are more 
likely. Fourth, inﬂ ammatory processes are strongly related to and probably part of the 
pathogenesis of Alzheimer’s disease,27,39,40 in which white matter lesions and lacunar 
infarcts are frequently observed.41-44 Cerebral amyloid angiopathy is a part of Alzheim-
er’s disease pathology and may result in white matter lesions and infarcts.27,40,45 In our 
study, although none of the participants were demented at baseline, pre-clinical stages 
of Alzheimer’s disease could nonetheless have been responsible for the association. At 
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present and based on our observations we can not conclude which mechanism underlies 
the relations we found between CRP levels and small vessel disease. More than one 
mechanism and probably a combination of mechanisms could underlie the association 
between inﬂ ammation and white matter lesions.5
The observation that inﬂ ammation may be involved in the pathophysiology of cer-
ebral small vessel disease, is in line with observations in stroke and dementia, although 
conﬁ rmation by other studies is needed. Furthermore, more insight in the exact mecha-
nisms underlying the association and their relative contribution are necessary. Since 
statins, NSAIDs, and aspirin could possibly reduce inﬂ ammatory activity, they are 
potential candidates to attenuate progression of lesions related to small vessel disease 
and their consequences.46
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Abstract
Background and Purpose – Silent brain infarcts and white matter lesions are associated with 
an increased risk of subsequent stroke in minor stroke patients. In healthy elderly people, silent 
brain infarcts and white matter lesions are common, but little is known about their relevance. We 
examined the risk of stroke associated with these lesions in the general population.
Methods – The Rotterdam Scan Study is a population-based prospective cohort study among 1077 
elderly people. The presence of silent brain infarcts and white matter lesions was scored on cerebral 
MRI scans obtained from 1995 to 1996. Participants were followed for stroke for on average 4.2 
years. We estimated the risk of stroke in relation to presence of brain lesions with Cox proportional 
hazards regression analysis.
Results – Fifty-seven participants (6%) experienced a stroke during follow-up. Participants with 
silent brain infarcts had a 5 times higher stroke incidence than those without. The presence of 
silent brain infarcts increased the risk of stroke >3-fold, independently of other stroke risk factors 
(adjusted hazard ratio 3.9, 95% CI 2.3 to 6.8). People in the upper tertile of the white matter lesion 
distribution had an increased stroke risk compared with those in the lowest tertile (adjusted hazard 
ratio for periventricular lesions 4.7, 95% CI 2.0 to 11.2 and for subcortical lesions 3.6, 95% CI 1.4 
to 9.2). Silent brain infarcts and severe white matter lesions increased the stroke risk independently 
of each other.
Conclusion – Elderly people with silent brain infarcts and white matter lesions are at a strongly 
increased risk of stroke, which could not be explained by the major stroke risk factors.
Silent brain infarcts, white matter lesions 
and the risk of stroke
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INTRODUCTION
Prior brain infarctions and cerebral white matter lesions are frequently seen on MRI 
scans in patients admitted with a ﬁ rst stroke. In patients with a minor stroke, both 
silent brain infarcts and white matter lesions increased the risk of recurrent stroke.1,2 
With the increased use of imaging techniques, these lesions are more often seen in non-
stroke patients as well. Silent brain infarcts and white matter lesions are thought to 
have a vascular origin and are frequently seen in neurologically asymptomatic elderly 
people.3-9 Little is known about the relevance of these lesions in the general population. 
Recently, a population-based study reported a 2-fold-increased risk of stroke in elderly 
people with silent brain infarcts.10 We examined whether the presence of silent brain 
infarcts and white matter lesions increased the rate and risk of stroke in the general 
population. Furthermore, we quantiﬁ ed this relation and investigated if this was inde-
pendent of the established stroke risk factors and of each other.
METHODS
Participants
The Rotterdam Scan Study was designed to study causes and consequences of brain 
changes in the elderly. In 1995 to 1996, we randomly selected participants aged 60 to 90 
years in strata of age (5 years) and sex from two large ongoing population-based stud-
ies.11,12 A total of 1,077 nondemented elderly people participated in our study (overall 
response 63%). The study design has been described in detail.8 The medical ethics com-
mittee of the Erasmus Medical Centre approved the study and each participant gave 
informed consent.
Cerebral infarcts and white matter lesions
All participants underwent MRI of the brain in 1995 to 1996. We made axial T1-, T2-
weighted, and proton-density scans on 1.5 Tesla MRI scanners (MR Gyroscan, Philips, 
and MR VISION, Siemens). The slice thickness was 5 or 6 mm with an interslice gap of 
20%.
Infarcts were rated by a single rater and were deﬁ ned as focal hyperintensities on 
T2-weighted images, 3 mm in size or larger. Proton-density scans were used to distin-
guish infarcts from dilated perivascular spaces. Lesions in the white matter also had to 
have corresponding prominent hypointensities on T1-weighted images, in order to dis-
tinguish them from cerebral white matter lesions. Intrarater study (n=110) for detecting 
infarcts showed good agreement (κ=0.80).9 We obtained a history of stroke and transient 
ischemic attack (TIA) by self-report, and by checking medical records in all 1,077 partici-
pants. An experienced neurologist subsequently reviewed the medical history and scans 
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and categorized the infarcts as silent or symptomatic. We deﬁ ned silent brain infarcts 
as evidence of 1 or more infarcts on MRI, without a history of a (corresponding) stroke 
or TIA. Participants with both symptomatic and silent infarcts were categorized in the 
symptomatic infarct group. Twenty participants with a conﬁ rmed history of stroke had 
no infarcts on MRI. Three of them experienced a hemorrhagic stroke; the 17 others with 
ischemic (n=12) or unspeciﬁ ed (n=5) stroke had minor symptoms. Participants with 
symptomatic infarcts on MRI (n=42, 16 of whose symptoms of a TIA corresponded to the 
infarct)9 and participants with a previous stroke without infarcts on MRI (n=20) were 
excluded from all analyses.
White matter lesions were considered present if visible as hyperintense on proton-
density and T2-weighted images, without prominent hypointensity on T1-weighted 
scans. Two raters scored periventricular and subcortical white matter lesions separately. 
Periventricular white matter lesions were rated semiquantitatively (grade range 0 to 9). 
A total volume of subcortical white matter lesions was approximated based on number 
and size of lesions (volume range 0 to 29.5 mL). Both intrareader and interreader stud-
ies (n=100) showed a good to excellent agreement (κ=0.79 to 0.90, r=0.88 to 0.95).8 
Cardiovascular risk factors
We obtained the cardiovascular risk factors by interview and physical examination from 
1995 to 1996. Blood pressure was measured twice on the right arm with a random-zero 
sphygmomanometer. We used the average of these 2 measurements. Participants were 
asked to bring all prescribed drugs to the research center, where a physician checked 
the use. Hypertension was deﬁ ned as a systolic blood pressure of 140 mmHg or over, a 
diastolic blood pressure of 90 mmHg or over, and/or the use of blood pressure-lowering 
medication. We considered diabetes mellitus to be present if the random glucose level 
was 11.1 mmol/L or higher, or if a person used antidiabetic medication. Serum total 
cholesterol was determined using an automated enzymatic procedure (Hitachi analyzer, 
Roche Diagnostics). Plasma total homocysteine levels were determined by ﬂ uorescence 
polarization immunoassay on an IMx analyzer (Abbott Laboratories).13 The presence 
of atrial ﬁ brillation was assessed by MEANS interpretation of a 12-lead ECG (ACTA 
ECG, ESAOTE).14 In 4 participants, ECG was missing. The intima-media thickness was 
measured by longitudinal 2-dimensional ultrasound of the carotid artery. We calculated 
the mean common carotid artery intima-media thickness as the mean of 4 locations: 
the near and far wall of both the right and left common carotid artery.15 Nineteen par-
ticipants lacked the measurement of the common carotid intima-media thickness. A 
physician assessed participants’ smoking habits using a structured questionnaire and 
classiﬁ ed smoking status as current or not.
Follow-up for incident stroke
In 1999 to 2000, we reinterviewed 787 of the participants that were alive about symp-
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toms of stroke and TIA using a structured questionnaire (response rate 81%). In ad-
dition, we continuously monitored the medical records of all 1,077 participants at the 
general practitioner’s ofﬁ ce to obtain information on the occurrence of stroke since the 
last visit until January 1st, 2001. For all reported strokes, we recorded information 
about signs and symptoms, date of onset, duration, and hospital stay. If participants 
had been hospitalized for a stroke, we retrieved discharge letters and radiology reports 
from the hospital where they had been treated. By reviewing all available information, 
an experienced neurologist assessed the exact day of onset and classiﬁ ed the stroke. 
Stroke was deﬁ ned as an episode of relevant focal deﬁ cits with acute onset, documented 
by neurological examination, and lasting for >24 hours. On the basis of radiological 
ﬁ ndings strokes were further subdivided into hemorrhagic or ischemic stroke subtypes. 
Follow-up was complete.
Data analysis
We used the Kaplan−Meier method to estimate the rates of stroke. The follow-up time 
was calculated from the date the MRI scan was made until the date of stroke, death, 
or end of follow-up, whichever came ﬁ rst. We did Cox proportional hazards regression 
analysis to determine whether the presence of brain lesions on MRI was predictive of 
subsequent stroke, by estimation of its hazard ratio (HR) and 95% CI. Adjustments were 
made for age and sex, and for the established stroke risk factors hypertension, diabetes 
mellitus, atrial ﬁ brillation, common carotid intima-media thickness, smoking, and his-
tory of TIA.16 Separate models were used for presence of silent brain infarcts, periven-
tricular, and subcortical white matter lesions. For silent brain infarcts, no distinction 
was made between participants with 1 or more infarcts on MRI. We did a subanalysis 
to examine whether the risk of stroke was different between participants with >1 silent 
infarct and those with only 1 infarct on MRI, by comparing them both to participants 
without infarcts. The association with periventricular and subcortical white matter le-
sions was analyzed in tertiles of their distribution, and continuously if the relation was 
linear. Furthermore, we investigated whether silent brain infarcts and white matter 
lesions predicted future stroke independently of each other, by including them in one 
model. In addition, we repeated the above analyses after exclusion of participants with 
previous TIA without infarcts on MRI (n=33).
RESULTS
The baseline characteristics of the study population are shown in Table 1. Fifty-seven 
participants (6%) experienced at least 1 stroke during 4,260 person-years (mean follow-
up 4.2 years). Six of these strokes were hemorrhagic, 42 ischemic, and in 9 the stroke 
subtype was unspeciﬁ ed. Thirty-one of these 57 participants (54%) had 1 or more silent 
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brain infarcts present on MRI. They had more severe periventricular and subcortical 
white matter lesions.
The 4-year mortality was 7% (95% CI 6% to 9%). The overall stroke rate was 11 per 
1,000 person years (95% CI 8 to 15). Thirty-one of the 217 participants (14.3%) with 
silent brain infarcts developed a stroke during an average follow-up of 4.2 years. The 
absolute risk of developing stroke within 4 years was 11.7% for participants with silent 
brain infarcts and 2.3% for those without. This absolute risk was 5.0 times higher (95% 
CI 2.7 to 9.2) for participants with 1 or more silent brain infarcts on MRI compared 
with the ones without, both for participants younger and older than 75 years of age 
(Figure). There were no statistically signiﬁ cant differences in stroke risk between men 
and women (absolute risk of developing stroke within 4 years: 4.9% for men and 3.7% 
for women). 
The presence of silent brain infarcts more than tripled the risk of stroke after ad-
justment for the established stroke risk factors (Table 2). Participants with >1 silent 
infarct (n=76) had a higher stroke risk than those with only 1 infarct on MRI (n=141), 
although these risk estimates were not signiﬁ cantly different (age- and sex-adjusted 
HR 4.9, 95% CI 2.5 to 9.4, and 2.8, 95% CI 1.5 to 5.3, respectively). Both participants in 
the upper tertile of the distribution of periventricular white matter lesions (n=291) and 
subcortical white matter lesions (n=336) had an increased stroke risk, independent of 
other stroke risk factors (Table 2). Additional adjustment for blood pressure levels did 
not change the results (HR for silent brain infarcts 3.5, 95% CI 2.0 to 6.0; for the upper 
Table 1. Baseline characteristics of all participants who were free of stroke and symptomatic 
infarcts on MRI at baseline.
All participants
n = 1015
Age, yr 72 ± 7
Women 526 (52%)
Hypertension 727 (72%)
Diabetes mellitus 66 (7%)
Atrial ﬁ brillation 28 (3%)
Mean intima-media thickness, mm 0.87 ± 0.15
Current smoking 163 (16%)
History of TIA 33 (3%)
Presence of silent brain infarcts 217 (21%)
Periventricular white matter lesions, grade 2.3 ± 2.2
Subcortical white matter lesions, mL 1.3 ± 2.8
Values are unadjusted mean ± SD or no. of participants (percentages).
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Table 2. Relationship between the presence of silent brain infarcts, tertiles of periventricular, 
and subcortical white matter lesions (WML) on MRI and the risk of stroke.
Risk of stroke
(Hazard ratio [95% CI])
Adjusted for
age and sex
Adjusted for
stroke risk factors*
Adjusted for
MRI lesions†
Silent brain infarcts
Absent
Present
1 (reference)
3.6 (2.1-6.1)
1 (reference)
3.9 (2.3-6.8)
1 (reference)
3.3 (1.8-5.9)
Periventricular WML
1st tertile (grade 0-1.0)
2nd tertile (grade 1.5-3.0)
3rd tertile (grade 3.5-9.0)
1 (reference)
2.5 (1.0-6.3)
4.7 (2.0-11.2)
1 (reference)
2.5 (1.0-6.2)
4.7 (2.0-11.2)
1 (reference)
2.0 (0.8-5.3)
2.8 (1.0-7.6)
Subcortical WML
1st tertile (0-0.05 ml)
2nd tertile (0.05-0.6 ml)
3rd tertile (0.6-29.5 ml)
1 (reference)
2.2 (0.8-5.7)
3.7 (1.5-9.1)
1 (reference)
2.3 (0.9-6.1)
3.6 (1.4-9.2)
1 (reference)
1.4 (0.5-4.0)
1.4 (0.5-4.0)
* Age, sex, hypertension, diabetes mellitus, atrial ﬁ brillation, mean intima-media thickness, smok-
ing, and history of TIA.
† Adjusted for stroke risk factors and additionally for the presence of silent brain infarcts and ter-
tiles of periventricular and subcortical white matter lesions.
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Figure. Kaplan−Meier curves of the 
stroke-free survival, stratiﬁ ed for the 
presence of silent brain infarcts (SBI) 
on MRI and age.
tertile of periventricular white matter lesions 4.5, 95% CI 1.9 to 10.7, and for the upper 
tertile of subcortical white matter lesions 3.5, 95% CI 1.4 to 8.6), nor did adjustment for 
the duration of hypertension or diabetes mellitus (data shown). There was no interac-
tion between hypertension and silent brain infarcts for the risk of stroke. When silent 
brain infarcts, tertiles of periventricular, and subcortical white matter lesions were all 
included in the same model, the associations with stroke risk remained for silent brain 
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infarcts, but diminished for periventricular and especially subcortical white matter le-
sions. For subcortical white matter lesions, the risk of stroke did not increase linearly. 
The largest risk difference was between no and very small volumes of subcortical white 
matter lesions (0.05 mL). With larger volumes the stroke risk only marginally increased 
further. The relationship between periventricular white matter lesions and the risk of 
stroke was linear, and remained after adjustment for stroke risk factors (adjusted HR 
per grade increase of periventricular lesions 1.36, 95% CI 1.20 to 1.54), and after addi-
tional adjustment for silent brain infarcts and subcortical white matter lesions (adjust-
ed HR 1.27, 95% CI 1.10 to 1.47). Results of above analyses were similar after exclusion 
of participants with previous TIA (data not shown). Additional adjustment for the less 
established stroke risk factors homocysteine and cholesterol levels did not change any 
of the associations (data not shown).
DISCUSSION
We found that elderly people with silent brain infarcts have a >3-fold-increased risk of 
stroke, compared with those without infarcts on MRI in the general population. The 
presence of more severe white matter lesions also increased stroke risk. This was inde-
pendent of other established stroke risk factors and of each other.
The strengths of this study are the large number of participating elderly people and 
its population-based design. Furthermore, we had no losses to follow-up, and therefore 
no selection bias. A potential methodological limitation of our study is misclassiﬁ cation. 
Despite good agreement, we may have systematically over- or underrated infarcts or 
white matter lesions on MRI. We do not have pathological veriﬁ cation of the lesions seen 
on MRI. Furthermore, infarcts may have been erroneously classiﬁ ed as silent or symp-
tomatic. Both the readers who identiﬁ ed white matter lesions and infarcts and the neu-
rologist who classiﬁ ed infarcts into silent or symptomatic were blinded to all other data. 
Misclassiﬁ cation may also have occurred in the identiﬁ cation of strokes during follow-
up. People probably underreport symptoms of TIA and minor stroke, which will have 
resulted in an underestimation of the true number of events. But because we obtained 
information about these events both by self-report and from medical records, without 
knowledge of baseline MRI ﬁ ndings, it is unlikely that this has introduced a major bias 
in our study. If anything, this nondifferential misclassiﬁ cation will have resulted in an 
attenuation of the relation.
We report a >3-fold-increased risk of stroke in elderly people with silent brain infarcts 
on MRI in the general population. This is in line with the ﬁ nding of the Cardiovascular 
Health Study, the only other population-based study that examined this relationship.10 
This study also observed that people deﬁ ned as having white matter lesions by cluster 
analysis had a higher risk of stroke.17 We extended this ﬁ nding and found that more 
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severe white matter lesions, both periventricular and subcortical located, also increased 
the risk of stroke. A Japanese study of healthy volunteers found an increased stroke risk 
when silent brain infarcts and white matter lesions were present on MRI, but this study 
was based on adults who wished to receive health screening at their own expense and 
it obtained information about 19 incident strokes by self-report only.18 Unfortunately, 
numbers were too small in our study to do separate analyses for stroke subtypes.
Both silent brain infarcts, of which the majority are lacunar infarcts,6,9 and white mat-
ter lesions reﬂ ect mainly small-vessel disease. We showed however that the increased 
stroke risk with the presence of silent infarcts and white matter lesions remained after 
adjustment for cardiovascular risk factors. These risk factors did not explain the effect 
of silent brain infarcts and white matter lesions on stroke risk. There may be residual 
confounding by the way we adjusted for these stroke risk factors, because we could not 
account totally for duration and severity of exposure. However, we do not think it will 
dispel the strong risk increase of stroke by the presence of silent brain infarcts and 
white matter lesions. This suggests that silent brain infarcts and white matter lesions 
are not just intermediates in the relation of vascular risk factors and the risk of stroke, 
but that these lesions might be markers for other, yet unknown, factors that lead to 
symptomatic stroke.
In conclusion, we found that elderly people with silent brain infarcts and white mat-
ter lesions from the general population are at a high risk of stroke. The major stroke risk 
factors seemed to account for only part of this increased stroke risk. Because the clinical 
relevance of these lesions was long unknown, no special treatment regimen has been 
developed for these people. The stroke risk for people with silent brain infarcts is com-
parable with the risk of TIA patients, of whom approximately 20% develop stroke within 
4 years. Further research will have to show if treatment of these people, comparable to 
the treatment regimen for people with TIA, effectively prevents stroke.
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T
he objective of this thesis was to gain more insight in the etiology of cerebral small 
vessel disease in elderly people. I have described the frequency, severity and pro-
gression of cerebral small vessel disease, its potential causes, and its association 
with stroke. In this chapter, I will summarize the main ﬁ ndings and discuss some of the 
general methodological issues. I will review the results in the broader perspective of the 
presumed pathophysiology of cerebral small vessel disease and discuss their clinical 
relevance. Finally, I will provide suggestions for further research.
MAIN FINDINGS
Frequency, distribution and progression of cerebral small vessel disease
White matter lesions and lacunar infarcts are frequently observed on CT and MRI scans 
of healthy elderly people, as well as in patients with dementia and stroke (chapter 2). 
The frequency of these lesions varies widely among studies due to differences in meth-
odology and risk factor proﬁ les. In the Rotterdam Scan Study, almost all participants 
had periventricular or subcortical white matter lesions and about one-ﬁ fth had lacunar 
infarcts on MRI. These numbers are in accordance with those from the Cardiovascu-
lar Health Study, a methodologically comparable study in the USA.1,2 Given the high 
prevalence of white matter lesions, it may be more informative to describe its severity 
distribution, i.e. the frequencies of more severe white matter lesions (ﬁ gure 1, chapter 
2). We found that the presence and severity of white matter lesions and lacunar infarcts 
strongly increased with age. Silent lacunar infarcts were more common in women.3 
Women also tended to have more severe white matter lesions than men,4 in line with 
other studies.1,2,5
Periventricular and subcortical white matter lesions showed progression in one-third 
of the participants within 3-years. Ten percent of all participants had marked white 
matter lesion progression (chapter 4.1). The Austrian Stroke Prevention Study reports 
any white matter lesion progression in 18% and marked progression in 8% of their par-
ticipants within 3 years.6 These participants were healthier and younger compared to 
ours. Marked subcortical white matter progression predominantly consisted of growth 
and conﬂ uence of lesions, whereas minor progression mostly consisted of new small le-
sions. The extent of progression of both periventricular and subcortical white matter le-
sions was, similar to the presence of lesions at baseline, strongly related to age. Women 
had a higher risk of marked subcortical white matter lesion progression than men. In 
our study, 14% of the people had one or more new infarcts on the second MRI, of which 
the vast majority were lacunar infarcts.7 Incidence of lacunar infarcts strongly increased 
with age, but was not different between men and women. In the Cardiovascular Health 
Study, 18% of the people without a prevalent infarct had new infarcts on MRI after 5 
years follow-up.8 Over 90% of these infarcts were lacunar infarcts.
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Risk factors
Blood pressure and hypertension 
Higher systolic and diastolic blood pressure levels were associated with more severe 
periventricular and subcortical white matter lesions (chapter 3.1). The same relation-
ship was found for concurrently and previously (on average 6 years earlier) assessed 
blood pressure levels. Increase in blood pressure over time was strongly related with 
periventricular white matter lesions in particular. We did not observe large differences 
in these associations among nine European cohorts. Higher blood pressure was also re-
lated to the progression of white matter lesions (chapter 4.1). People who were success-
fully treated for hypertension had a lower risk of severe white matter lesion compared to 
those with uncontrolled hypertension (chapter 3.1). These data conﬁ rm the eminent role 
of high blood pressure and are in line with the observation that longstanding hyperten-
sion is the main risk factor in the development of white matter lesions.9
A clear decrease in diastolic blood pressure over time approximately doubled the 
risk of severe periventricular white matter lesions (chapter 3.1). The observation among 
nine pooled European cohorts that both an increase and a decrease in diastolic blood 
pressure is related to severe white matter lesions, conﬁ rms earlier ﬁ ndings in the Rot-
terdam Scan Study.10 We found that in people with severe white matter lesions at base-
line, higher blood pressure was no longer a risk factor for white matter lesion progres-
sion (chapter 4.1). This is in agreement with an earlier ﬁ nding that blood pressure is not 
related to incident silent brain infarcts in people with prevalent silent brain infarcts.7
Homocysteine
Plasma homocysteine levels are associated with silent brain infarcts and white matter 
lesions (chapter 3.2). The relationship between these MRI lesions and homocysteine 
levels was continuous. People within the top quintile of homocysteine had 3 times the 
risk of either silent brain infarcts or severe white matter lesions compared to those in 
the lowest quintile. Other studies have conﬁ rmed these observations.11-13
Arterial oxygen saturation and chronic obstructive pulmonary disease
We found that people with COPD or lower arterial oxygen saturation had more severe 
periventricular white matter lesions, but not subcortical white matter lesions or lacunar 
infarcts (chapter 3.3). However, we did not ﬁ nd an association with the progression of 
periventricular white matter lesions.
Plasma amyloid ß
Plasma Aß
1-40
 and Aß
1-42
 levels are strongly associated with white matter lesions and la-
cunar brain infarcts in people who carry an APOE ε4 allele, while in non-carriers there 
were no or only weak associations (chapter 3.4.1).
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Additionally, we found that in the elderly participants of the Rotterdam Study 
impaired cerebral vasomotor reactivity, as measured with transcranial Doppler ultra-
sonography, is related to higher plasma Aß
1-40
 and Aß
1-42
 levels measured on average 6.5 
years earlier, but not to concurrent Aß levels (chapter 3.4.2). Furthermore, a decrease 
in plasma Aß
1-40
 levels over time is associated with a higher prevalence of impaired va-
somotor reactivity. 
Cigarette smoking
Current cigarette smoking was associated with an almost 3 times increased risk of 
marked white matter lesion progression compared to never smoking (chapter 4.1). Peo-
ple who formally smoked cigarettes did not have a higher risk of white matter lesion 
progression compared to people who never smoked. As in other studies, smoking was not 
associated with lacunar infarcts in our population.2,14
Inﬂ ammation
Higher CRP levels were associated with baseline severity and progression of white 
matter lesions, and in particular with marked lesion progression (chapter 4.2). These 
associations were independent of cardiovascular risk factors and carotid atherosclerosis. 
Higher CRP levels showed a non-signiﬁ cant trend toward more lacunar infarcts at base-
line and new lacunar infarcts during follow-up.
Diabetes
We did not observe an association between diabetes and white matter lesions (chapter 
4.1). People with diabetes, who did not have an infarct at baseline had a 3 times increased 
risk of an incident silent brain infarct. Other population-based studies did not observe 
an association between diabetes and cerebral small vessel disease either.2,6,8,15-17
Small vessel disease and the risk of lesion progression and stroke
Elderly people with silent brain infarcts or severe white matter lesions had a more than 
3-fold increased risk of stroke, which could not be explained by established stroke risk 
factors (chapter 5). This is in line with observations from the Cardiovascular Health 
Study and the Atherosclerosis Risk In Community study.18,19
People with lacunar infarcts had about 6 times the risk of having marked progres-
sion of periventricular or subcortical white matter lesions within 3 years, compared 
to those without infarcts (chapter 4.1). The strongest predictor of progression of white 
matter lesions was the severity of white matter lesions at baseline. Progression of white 
matter lesions was strongly related to new infarcts on MRI and incident stroke.20 The 
Cardiovascular Health Study reported that in people without infarcts on MRI, white 
matter lesions severity was the strongest predictor of incident lacunar infarcts.8
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METHODOLOGICAL CONSIDERATIONS
We aimed to study the etiology of cerebral small vessel disease. The success of identify-
ing causes depends on the precision of measurements, the validity of the results and the 
possibility of inference from these results. In the previous chapters, I have discussed the 
methodological issues of our studies separately. Here I would like to discuss the main 
issues in a more general perspective. I will do so  on the basis of principles described in 
detail by Rothman and Greenland.21
Precision of measurements
Precision of measurements involves minimizing random error. Random error may result 
either in imprecise effect estimates (broad conﬁ dence intervals) or in underestimated 
effects (regression dilution bias). The latter occurs in particular when one investigates 
associations with determinants that have a large within-person variability such as 
blood pressure levels. We reduced random error ﬁ rst by having a large overall sample 
size. Next, we sampled participants in strata of age and sex to obtain equal precision 
over the entire age and sex distribution. Third, we optimized the accuracy of individual 
measurements by repeating the majority of the measurements of both the determinants 
and the outcome and subsequently using the average values. Finally, we used tools with 
a high reproducibility and also designed a new rating method to more precisely measure 
change in white matter lesions seen on MRI.22
Despite these efforts to optimize the measurements, precision could have been fur-
ther improved. Double assessment of blood sample level could prevent underestimation 
of the risk association, for instance for homocysteine up to 10 to 15%.23 Automated white 
matter lesions detection with volumetric measurement could reduce measurement er-
ror in the outcome assessment. Extensive periventricular and subcortical white matter 
lesions on MRI are sometimes hard to distinguish just as lacunar infarcts, microbleeds 
and widened Virchow-Robin spaces.24,25 Pathological conﬁ rmation of brain lesions on 
MRI could in theory further improve precision.
Validity of results
Validity of results involves restricting systematic error or bias. Three general types of 
bias can be identiﬁ ed: selection bias, information bias and confounding. 
Selection bias
Selection bias results from the selective (non-)participation of people who have a dif-
ferent association between a determinant and an outcome compared to those who 
participate in the study. A population-based sample greatly reduces the potential for 
selection bias. Unlike most clinical-based samples, inclusion of persons in our study 
was random and therefore not distorted by determinants related to disease. However, 
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the response at baseline and at follow-up was not complete. People that did not par-
ticipate at baseline were older and had a higher frequency of hypertension in the past 
than participants. Since age, hypertension, white matter lesions and lacunar infarcts 
predict stroke, depression, and dementia independently of each other, older people with 
hypertension and severe brain lesions may have  refused to participate more often than 
people with a higher age and hypertension without severe brain lesions.18-20,26,27 This 
would have resulted in an underestimation of the effects of age and hypertension on cer-
ebral small vessel disease. Selection at follow-up may have also occurred and therefore 
risk estimates in relation to progression of lesions could have been underestimated even 
further. As it is not possible to correct for selection bias in the analyses, the only rem-
edy is a maximal response rate. Our response rate at baseline was equal to that of the 
Cardiovascular Health Study, and higher than in most other studies (chapter 2). The 
relatively demanding MRI procedure and the high mortality in elderly people, inherent 
to this kind of research, make some selection almost unavoidable.
Information bias
Information bias results from measurement error of the determinant that depends on 
the outcome or of the outcome that depends on the determinant. In our studies, the as-
sessments of the risk factors, white matter lesions, lacunar infarcts and incident strokes 
were performed independently and blindly from each other. Therefore, it is very unlikely 
that misclassiﬁ cation would have been differential and hence would have resulted only 
in random error. The relation between baseline periventricular and subcortical white 
matter lesions and its progression could, however, have been biased. Therefore, we 
blinded for scanning date in half of the study and assessed the effect of non-blinding. 
We concluded that non-blinding had not introduced bias.22
Confounding
Confounding results from confusion of the effect under study with that of an extraneous 
factor. A confounder is associated with both the determinant and the outcome and is 
not an intermediate factor in the causal pathway leading to the outcome variable under 
study. In our studies, we dealt with confounding by adjusting for potential confounders 
in multivariate regression models. Adjusting for an intermediate factor would result in 
an underestimation of effects.
In some instances a factor could be both a confounder and an intermediate factor. 
White matter lesion severity at baseline is related both to blood pressure at baseline 
and progression of white matter lesions and could therefore potentially confound the 
relationship between blood pressure and white matter lesion progression. Higher blood 
pressure most likely leads to white matter lesion progression through the continuation 
of a process that has resulted in the brain lesions at baseline, with possibly an accelera-
tion or deceleration of the ongoing pathological process. Therefore, adjusting for base-
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line white matter lesions would be equal to adjusting for a factor in the causal pathway, 
resulting in over adjusted estimates.28
Since white matter lesion and lacunar infarcts largely result from the same under-
lying pathological substrate, they should not be treated as confounders. Taking them 
together in one variable, as in the analyses with homocysteine, gives stronger and most 
likely better results. Whether lacunar brain infarcts and white matter lesions are re-
lated to incident stroke, is not purely an etiological question. The brain lesions per se 
will not cause stroke, but rather are indicators of a combination of exposure to stroke 
risk factors, the duration of this exposure, susceptibility to risk factors and possible 
interactions between these risk factors. The purpose of adjusting here is to estimate the 
independent association with incident stroke, which has a prognostic value and reﬂ ects, 
at least partly, the shared pathophysiology.
Causal inference
A precisely measured association between a factor and an outcome that is free of bias, 
does not imply that the observed association is a causal one. There has been much 
philosophical debate on causal inference which has not lead to one set of “hard-and-fast 
rules of evidence” to judge causation. Despite criticism, inductively oriented criteria are 
useful in evaluating causality.29 Probably the most important criterion for causality is 
establishing a temporal relationship. Several of the studies (Chapter 3.2, 3.3 and 3.4.1) 
had a cross-sectional design, leaving the possibility that the proposed determinant is in 
fact the cause of the disease. A more biologically plausible explanation in these studies 
is that the determinants reﬂ ect their past levels, which are responsible for the associa-
tion with the outcome. Other studies had a longitudinal design with repeated measure-
ment of the determinant (Chapter 3.1 and 3.4.2). This reduced the possibility of inverse 
relations. However, since we do not know whether white matter lesions, lacunar infarcts 
and impaired vasomotor reactivity were already present in the past, inverse causality 
is still possible. Finally, we performed studies with a longitudinal design with repeated 
measurement of the outcome or with incident disease as the outcome (Chapter 4.1, 4.2 
and 5), in which confusion of cause and effect is unlikely.
Among other criteria, in my opinion, causality should be further judged mainly on 
the basis of consistency of ﬁ ndings, their biological plausibility within the framework of 
current knowledge and on experimental data (i.e. randomized trials).
ETIOLOGY OF CEREBRAL SMALL VESSEL DISEASE
We studied the etiology of white matter lesions and lacunar infarcts on MRI scans. 
These MRI abnormalities correspond to a variety of pathological lesions. Lacunar in-
farcts are subcortical located ischemic infarcts of less than 20 mm in diameter.30 Severe 
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irregular white matter lesions correspond to incomplete infarction with demyelination, 
loss of oligodendrocytes and nerve ﬁ bers, and reactive astrocytic gliosis. Small subcorti-
cal white matter lesions and smooth periventricular white matter lesions correspond to 
moderate changes with rarefaction and palor of myelin sheets, mild edema and widened 
Virchow-Robin spaces.31-35
In elderly people, these lesions result mostly from damage of the long penetrating 
medullary arteries and the short perforating arterial branches of the choroidal and 
striatal arteries that nourish the cerebral white matter and deep cerebral nuclei.30-34,36-38 
Damage of these vessels could lead to brain lesions by ischemia or by disturbances in the 
blood-brain barrier with leakage of ﬂ uid and macromolecules.35,39,40 Since risk factors for 
lacunar infarcts and white matter lesions may be involved in either vessel damage or in 
the process from vessel damage to brain lesions, I will discuss them separately. Finally, 
I will brieﬂ y point at genetic factors in relation to cerebral small vessel disease.
Damage to small vessels
Different pathologies may affect the cerebral small vessels. The most frequently ob-
served are micro-atheroma at the origin of perforating arterioles resembling large ves-
sel atherosclerosis, concentric hyaline wall thickening of smaller distal arterioles with 
loss of smooth muscle cells, ﬁ brinoid necrosis, amyloid angiopathy and elongation and 
tortuosity of long penetrating arterioles.35,39
These pathological features are all more common in older age. In our study, as in 
most other studies, age was strongly related to white matter lesions and lacunar in-
farcts. Since almost all people of 60 years and over have any white matter lesions on 
MRI (ﬁ gure 2, Chapter 2), these lesions may to some extent be regarded to as “normal 
aging”. Higher age is related to longer exposure to risk factors and their possible interac-
tions. Furthermore, adaptive and compensating mechanism may fail with older age and 
hence increase susceptibility to disease.41
Higher blood pressure levels, higher homocysteine levels, and smoking were risk 
factors for cerebral small vessel disease in our study. These risk factors are involved in 
damage to vascular endothelial cells, which is the initial step in the process of athero-
sclerosis. Atherosclerosis principally occurs in large and medium-sized arteries but 
micro-atheroma may also be present in the most proximal parts of the small cerebral 
vessels. Inﬂ ammatory processes are an integral part of atherosclerosis. Increased CRP 
levels are found in different stages of atherosclerosis.42,43 We observed that higher CRP 
levels are related to the presence and progression of small vessel disease independent of 
carotid atherosclerosis.
In people with chronic hypertension, vascular smooth muscle cells and elastic lamina 
of distal arterioles are replaced by ﬁ brohyaline material and depositions of components 
of extracellular matrix, chieﬂ y collagens.44 Furthermore, cerebral arterioles may un-
dergo structural remodeling, resulting in elongation and tortuosity of the arteries. This 
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remodeling may lead to widening of the perivascular or Virchow-Robin spaces, visible 
on MRI as “l’etat crible”.24,25,45
We observed that plasma amyloid ß combined with the APOE ε4 allele is related to 
cerebral small vessel disease. Soluble amyloid ß can be internalized by smooth muscle 
cells and form insoluble ﬁ brils, in particular in people who carry an APOE ε4 allele.46-48 
This ﬁ brillized amyloid ß replaces smooth muscle cells, just like hyaline in reaction to 
hypertension, a process called cerebral amyloid angiopathy. These changes make the 
vessels stiff and fragile.49 Cerebral white matter lesions and infarcts are common in 
patients with cerebral amyloid angiopathy.50-52
Endothelial cells of the cerebral vessels have, apart from providing a non-thrombo-
genic surface between blood and vessel wall, two other important functions, namely the 
blood-brain barrier and autoregulation of cerebral blood ﬂ ow. Homocysteine and soluble 
amyloid ß may, next to cytotoxic effects, also directly impair cerebral autoregulatory 
function, by initiating an endothelial inﬂ ammatory response that interferes with the 
main vaso-active substances derived by the endothelium, nitric oxide and endothe-
lin.11,53-57 We found a relationship between impaired cerebral vasomotor reactivity and 
soluble amyloid ß levels assessed 6.5 years earlier, but not with levels concurrently as-
sessed. These observations are more compatible with a cytotoxic effect of amyloid ß on 
smooth muscle cells than a direct vaso-active effect.
Women tended to have more small vessel disease than men. For atherosclerosis and 
myocardial infarction the reverse was found. Women selectively survive the period in 
which myocardial infarction is the main killer in men. Single risk factor exposure in 
women at midlife versus multiple risk factor exposure in men may underlie this differ-
ence. Postmenopausal hormonal and metabolic status may be a factor as well.58,59 No 
interaction between risk factors and sex and cerebral small vessel disease was observed 
in our studies.
Consequences of damaged small vessels
Occlusion of arteries by localized micro-atheroma at the origin of perforating arterioles 
may be responsible for isolated, larger lacunar infarcts.30,60 Inﬂ ammation may play a 
part in (micro-) atherosclerotic plaque rupture responsible for acute vessel occlusion, as 
in coronary syndromes.42,43
Critical stenosis and tortuous elongation of vessels result in increased vascular 
resistance. Loss of smooth muscle cells, stiffening of the vessels, and endothelial dys-
function lead to a disturbed autoregulation. Both could result in chronic or intermittent 
hypoperfusion and consequently in white matter lesions and probably multiple small 
lacunar infarcts. Periods of systemic hypotension due to aggressive blood pressure 
lowering treatment, orthostasis, cardiac failure, atrial ﬁ brillation or dehydration may 
worsen cerebral hypoperfusion in people with a disturbed autoregulation. This in line 
with our observation that a decrease in blood pressure over time was associated with 
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more severe white matter lesions. Furthermore, a high blood pressure was not related to 
progression of white matter lesions and incident lacunar infarcts in people with severe 
white matter lesions or prevalent infarcts. Furthermore, a high blood viscosity due to 
inﬂ ammation or pro-trombotic agents increases vascular resistance and hence further 
decreases cerebral perfusion.61-65 
Penetrating and medullary arterioles lack anastomoses. They are end-arteries that 
form an arterial border zone. Only the direct subcortical U-ﬁ bers that are spared from 
white matter lesions have a collateral circulation. Usually the border zone is located 
3-10mm from the ventricular wall.36,66 We observed stronger relationships between risk 
factors and periventricularly located white matter lesions than with subcortically locat-
ed white matter lesions. The periventricular white matter may be particularly sensitive 
to autoregulation disturbances and low blood pressure.67-69
Oligodendrocytes are highly vulnerable to hypoperfusion.66 A longer duration of 
hypoperfusion would be just enough for white matter lesions to progress. The oxygen 
extraction rate is increased in areas with severe white matter lesions as measured with 
positron emission tomography, reﬂ ecting compensation of altered cerebral blood ﬂ ow.70,71 
We found that a lower arterial oxygen saturation was associated with periventricular 
white matter lesions. Low oxygen content in the blood may aggravate the consequences 
of hypoperfusion by failure to compensate decreased blood ﬂ ow by increased oxygen 
extraction.72
Endothelial damage may result in loss of the blood-brain barrier and thus, in plasma 
protein extravasation and reactive astrogliosis, microgliosis and inﬂ ammation with 
secondary release of neuro-toxic molecules that might injure adjacent brain parenchy-
ma.40,73 Edema and inﬂ ammation are visible as white matter lesions on MRI.
The progression of white matter lesions from punctate to large conﬂ uent lesions is 
probably a continuous process, which has an exponential rather than a linear relation 
with time. People with no or only a few small lesions show no or minor progression 
within 3 years, whereas a large proportion of the people with large lesions at baseline 
show marked progression. The ﬁ rst small lesions probably indicate the start of small 
vessel damage. Growth and conﬂ uence of lesions is the combination of new vessel dam-
age, continuation of existing hypoperfusion and failure of compensatory mechanisms. 
This is possibly further enhanced by inﬂ ammation and up-regulation of amyloid ß pro-
duction as a consequence of ischemia.74-77 Therefore, the development of white matter 
lesions will accelerate over time. The Austrian Stroke Prevention Study with follow-up 
MRI scans at 3 and 6 years after baseline showed such an exponential development of 
white matter lesions.78
Genetic factors
Monogenic disorders, such as cerebral autosomal dominant arteriopathy with subcorti-
cal infarcts and leucoencephalopathy (CADASIL) and various forms of familial cerebral 
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amyloidosis, that are both phenotypically characterized by cerebral small vessel disease, 
do not play a role in population-based studies in elderly people. These diseases are rare, 
their onset is for the most part well before the age of 60 years and their prognosis is 
poor.
Genetic polymorphisms may contribute to cerebral small vessel disease. Associations 
with polymorphisms in a variety of candidate genes have been investigated in relation 
to stroke.79 In this thesis, we described an interaction between the APOE polymorphism 
and higher amyloid beta levels in relation to cerebral small vessel disease. We did not 
observe an association with the ACE I/D polymorphism and white matter lesions and 
infarcts,80 although previous studies did.81
CLINICAL IMPLICATIONS AND TREATMENT
We found that people with silent (lacunar) brain infarcts and severe cerebral white mat-
ter lesions on MRI have more than a 3-fold increased risk of stroke. These people also 
have an increased risk of dementia, depression and death.8,18,19,27,82-84 Furthermore, peo-
ple with cerebral small vessel disease perform worse on cognitive tests and more often 
have depressive symptoms, gait disturbances and urine incontinence.85-88 Accordingly, 
these lesions are not “silent” and lead to a poor prognosis. Several questions emerge. 
How can we prevent the development of these lesions and how should we treat people 
with lacunar infarcts and severe white matter lesions to prevent lesion progression and 
the occurrence of stroke, dementia, depression and death?
To prevent the development of cerebral small vessel disease, modiﬁ able risk factors 
should be treated. We observed that people with hypertension have a higher risk of 
severe white matter lesions than people without. Moreover, people with successfully 
treated hypertension had a lower risk of severe white matter lesions than people with 
uncontrolled hypertension. People should be treated for hypertension as early as pos-
sible, since mid-life blood pressure and duration of hypertension are strong predictors of 
late life disease.9,10,89,90 The optimal blood pressure level in elderly people may be differ-
ent from that used in blood pressure lowering trials. These trials mostly include younger 
people. We found that in elderly people a strong decrease in diastolic blood pressure was 
related to more severe white matter lesions. Data from the Rotterdam Study show that 
a low diastolic blood pressure, among people that use blood pressure lowering drugs, is a 
risk factor for stroke.91 The Syst-Eur trial indicated that blood pressure lowering by cal-
cium-antagonists may prevent dementia in people over the age of 60 years with systolic 
hypertension.92 However, the number of cases in the trial was very small, due to prelimi-
nary ending. Whether or not the protective effect was through blood pressure lowering 
is debated since another trial using diuretics and beta-blockers was negative.93
We found that an elevated homocysteine level is a risk factor for small vessel disease. 
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Homocysteine is also a risk factor for cognitive decline, stroke and dementia.94-96 Trials 
have shown that vitamines B6 and B12 as well as folate supplements, reduce homo-
cysteine levels.97 New trials are underway to study the preventive effect of homocysteine 
lowering by vitamin suppletion on stroke.98,99 An important advantage of this treatment 
is that it is unlikely to have side effects.
We observed that individuals who smoke have an increased risk of white matter le-
sions and those with diabetes have an increased risk of silent brain infarcts. No effects 
of hypercholesterolemia on white matter lesions or lacunar infarcts was found. Apart 
from speciﬁ c goals in cerebral small vessel disease, prevention should be aimed at car-
diovascular disease in general. For primary prevention of stroke, myocardial infarction 
and peripheral arterial disease, I refer to published guidelines.100
Whether people with present non-overt cerebral small vessel disease need extra medi-
cal attention is unknown. The clinical relevance of these lesions has not been recognized. 
General screening of the elderly population with MRI seems to be a very expensive and 
laborious way of identifying these people. However, in the future, it might be part of a 
“late-life check-up”. In elderly people with cognitive dysfunction, depressive symptoms, 
gait disturbances or urine incontinence, screening for cerebral small vessel disease may 
be useful. What additional treatment could be effective to prevent stroke, depression, 
dementia and progression of cerebral small vessel disease in these people?
Aspirin is part of the standard therapy in TIA patients, who have a similar risk of 
stroke as people with silent brain infarcts or severe white matter lesions. TIAs, however, 
may apart from small vessel disease also be caused by large vessel atherosclerosis or 
atrial ﬁ brillation.101,102 It is uncertain whether people with cerebral small vessel disease 
beneﬁ t less from aspirin. Two trials showed a beneﬁ cial effect of anti-platelet therapy 
in people with lacunar infarction.103,104 On the other hand, bleeding complication may 
be more common in people with small vessel disease, as observed in trials with oral 
anticoagulants.105
The PROGRESS trial shows that the combination therapy of an ACE-inhibitor and 
a diuretic gives a clear decrease in blood pressure and prevents stroke and myocardial 
infarction among both hypertensive and non-hypertensive patients with a history of 
stroke or TIA.106 So blood pressure lowering treatment may be effective in prevention of 
stroke and myocardial infarction also in normotensives. It is however unknown whether 
the positive results of the combination therapy are generalizable to elderly people with 
cerebral small vessel disease.
Severe white matter lesions, reﬂ ecting areas of incomplete infarction, are in a way 
comparable with the penumbra of large territorial infarcts. In these people, cerebral 
perfusion is critical and depends solely on the systemic blood pressure. Aggressive blood 
pressure lowering strategies increase the risk of ischemia and may outweigh the ben-
eﬁ cial effects of a lower blood pressure. Neuro-protection and vasodilatation in chronic 
hypoperfusion may be beneﬁ cial. Nimodipine, a calcium channel-blocker, has these 
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properties and prevents small vessel disease in experimental animals.107 In humans, it 
has been proven protective in vasospasm after subarachnoid hemorrhage.108 Further, in 
post-hoc subgroup analysis, nimodipine seems to have a beneﬁ cial effect on cognitive 
performance in people with dementia due to small vessel disease.109 Memantine, an N-
methyl-D-aspertate receptor antagonist, also has neuro-protective properties and seems 
to be effective and safe in those with mild-to-moderate vascular dementia.110
Statins (HMG-CoA reductase inhibitors) have, apart from their cholesterol lower-
ing properties, characteristics that might be useful in people with cerebral small vessel 
disease. Statins reduce the levels of amyloid ß, stabilize atherosclerotic plaques, and 
may be anti-inﬂ ammatory and neuro-protective.100,111 They also seem to increase cer-
ebral blood ﬂ ow and vasomotor reactivity by up-regulation of endothelium derived nitric 
oxide.112,113
Inﬂ ammatory processes seem to play a role in progression of white matter lesions 
as well as in atherosclerosis and Alzheimer’s disease. Non-steroidal anti-inﬂ ammatory 
drugs are currently being studied for Alzheimer’s disease and the initial results are 
positive.114,115 They might be effective in the prevention of small vessel disease progres-
sion as well.
Until now, no randomized trial has speciﬁ cally addressed the treatment of peo-
ple with small vessel disease to prevent stroke, depression and dementia in late life. 
Because cerebral small vessel disease, stroke, depression and dementia are common 
disorders in elderly people, it should be involved in future research. Trials in patients 
with dementia probably due to small vessel disease (Subcortical Ischemic Vascular De-
mentia), are underway and the results may be generalizable to people with small vessel 
disease who are not yet demented.109 However, in dementia, the damage may already be 
done and prevention may be too late.
FUTURE RESEARCH
The etiology of cerebral small vessel disease is complex. Risk factors for small vessel 
disease on MRI could be involved in either small vessel damage (e.g. hypertension) or 
in the process from damaged small vessel to brain tissue damage (e.g. hypotension). 
Hence different risk factors may have effects at different disease stages. Furthermore, 
different pathophysiological mechanisms may lead to small vessel damage (hyperten-
sion related versus amyloid angiopathy) and to brain tissue damage (ischemia versus 
disturbed blood brain barrier). The same white matter lesions on MRI could reﬂ ect dif-
ferent stages of tissue damage (mild edema versus demyelination and axonal loss). The 
relationship of these brain lesions with dementia, depression and stroke is even more 
complex. Future research should be aimed at unraveling this complexity.
More advanced imaging techniques are now available to study the progression 
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of white matter lesions. Repeated imaging with thinner slices in combination with a 
valid automated lesion detection tool could quantify the total change in lesion volume 
more precisely. Further, recent advances in MRI techniques could contribute greater 
insight into the underlying pathology in vivo than the conventional fast-spin echo MRI 
sequences. Diffusion-weighted MRI can differentiate between new and old lesions, mag-
netization-transfer MRI can assess the integrity of neuronal tracts and gradient echo 
sequences can detect microbleeds and distinguish them from ischemic lacunar infarcts. 
The correlation between these new MRI techniques and pathology should be studied.
Combinations of anatomical images and functional images with data on perfusion, 
oxygen extraction, glucose metabolism, integrity of the blood-brain barrier and localiza-
tion of vasomotor reactivity impairment could give new insight into the occurrence of 
lesions at speciﬁ c locations.116 Furthermore, these combinations could help to elucidate 
the interaction and temporal relationship between blood pressure, autoregulation dis-
turbances and hypoperfusion in the occurrence of severe white matter lesions.
In our studies, we were unable to assess the pathological status of the small vessels 
themselves. Photographs of retinal arteriolar and venular changes could be a good proxy 
for the cerebral small vessels.19,117 Stratiﬁ cation on hypertensive retinal vasculopathy 
could provide new insight into the relation of blood pressure and white matter lesions.
Apart from structural changes of the cerebral small vessels, endothelial dysfunction 
or an endothelial inﬂ ammatory state may result in autoregulation disturbances and 
hence, in hypoperfusion. Both amyloid ß and homocysteine seem to have a negative 
inﬂ uence on endothelial function by disturbing the balance between nitric oxide and en-
dothelin.11,53-55 The exact mechanism is unknown and warrants new research in relation 
to small vessel disease.
We described a potential interacting role of amyloid ß, APOE and ischemia. First, 
this relation needs conﬁ rmation in an independent sample. Second, it should be fur-
ther studied in relation to the development of dementia. The combination of ischemic 
brain damage and amyloid ß and tau related neurodegeneration may result in earlier 
passage of the cognitive threshold of dementia than the two separately.118 Additionally, 
ischemia may directly up-regulate amyloid precursor protein expression and increase 
amyloid ß production. On the other hand, vascular amyloid ß depositions may induce 
ischemia.74,76,119 Imaging of parenchymal and vascular amyloid ß could help in studying 
this potential self strengthening mechanism.120,121
To understand the role of homocysteine in dementia, more insight is needed into how 
high homocysteine levels result in vascular and structural brain changes.94,95,122 Vita-
mins and polymorphisms that play a role in methionine metabolism, probably underlie 
hyperhomocysteinemia. Their relative contribution to brain lesions, stroke and demen-
tia is of potential interest for treatment strategies.
The predominance of severe small vessel disease in women needs further attention. 
Is it explained by selective survival? Or do postmenopausal metabolic and hormonal 
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status and genetic predisposition inﬂ uence the risk of small vessel disease?5,15,59
Finally, the relation between different vascular and structural brain lesions on MRI 
with respect to a common pathophysiology and their temporal relation needs to be 
studied. Particularly, research is needed to clarify the complex interactions of ischemic 
brain infarcts, white matter lesions, general brain atrophy and temporal lobe atrophy 
in relation to dementia.123-125 Not all people with lacunar infarcts or severe white matter 
lesions will become demented or develop a clinical manifest stroke. More knowledge is 
needed in order to identify those people who are at the highest risk. A larger MRI study, 
with more dementia and stroke cases, without selection due to an overextended follow-
up, may provide new answers.
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Summary
C
erebral white matter lesions and lacunar brain infarcts are frequently seen on 
magnetic resonance imaging (MRI) scans of elderly people. Damage of small 
cerebral blood vessels, also known as cerebral small vessel disease, is involved 
in the etiology of these lesions. There is accumulating evidence that these lesions are 
associated with an increased risk of gait disturbances, cognitive decline and depression 
at late-life. Eventually, they may either by themselves or in combination with neuro-de-
generative changes, lead to dementia. In addition to clinically manifest infarcts and he-
morrhages, white matter lesions and lacunar infarcts are frequently observed on brain 
images, suggesting a common etiology. A better understanding of the etiology of cerebral 
small vessel disease could contribute to the prevention of stroke, dementia and also of 
more subtle limitations in daily living within a rapidly increasing elderly population.
To gain more insight in the etiology of cerebral small vessel disease in elderly people, 
we used data from the Rotterdam Scan Study, a large ongoing population-based cohort 
study among 1,077 people aged 60 to 90 years. All participants underwent brain MRI in 
1995 to1996, of whom 668 underwent a second MRI more than three years later. All MRI 
scans were rated for the presence, severity and progression of cerebral white matter le-
sions and lacunar brain infarcts. We distinguished periventricularly and subcortically 
located white matter lesions.
In chapter 2 we review studies on the frequency of cerebral small vessel disease on 
CT and MRI scans in healthy elderly people, as well as in patients with dementia and 
stroke. The frequency varies largely among studies due to differences in methodology 
and risk factor proﬁ les.
In chapter 3 we describe the relationship between several risk factors and cerebral 
small vessel disease. In chapter 3.1 we studied, within a large European collaborative 
study, the relationship with blood pressure, change in blood pressure, hypertension and 
treatment of hypertension. Higher systolic and diastolic blood pressure levels were asso-
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ciated with more severe periventricular and subcortical white matter lesions. The same 
relationship was found for blood pressure levels assessed concurrently with the MRI 
and blood pressure levels assessed 6 years earlier. Both a clear increase and decrease in 
diastolic blood pressure over time was strongly related with periventricular white mat-
ter lesions. People who were successfully treated for hypertension had a lower risk of 
severe white matter lesion compared to those who had uncontrolled hypertension.
In chapter 3.2 we show the relationship between homocysteine and cerebral small 
vessel disease. Homocysteine is a potential modiﬁ able risk factor for stroke and demen-
tia. People within the group with the 20 percent highest homocysteine levels had a 3 
times increased risk of either silent brain infarcts or severe white matter lesions com-
pared to people within the group with the 20 percent lowest levels.
Chapter 3.3 showed that people with COPD or lower arterial oxygen saturation had 
more severe periventricular white matter lesions, but not more subcortical white matter 
lesions or lacunar infarcts.
Chapter 3.4 reports on the role of plasma amyloid β (Aβ) and APOE ε4 in relation to 
lacunar infarcts and white matter lesions and impaired cerebral autoregulation. Plasma 
Aβ1-40 and Aβ1-42 levels were strongly associated with white matter lesions and lacunar 
brain infarcts in people who carry an APOE ε4 allele, while in non-carriers there were 
no or only weak associations (chapter 3.4.1). Impaired cerebral vasomotor reactivity, 
as measured with transcranial Doppler, was related to higher plasma Aβ1-40 and Aβ1-42 
levels measured on average 6.5 years earlier, but not to concurrent Aβ levels. Further-
more, a decrease in plasma Aβ1-40 levels over time was associated with a higher preva-
lence of impaired vasomotor reactivity (chapter 3.4.2).
In chapter 4 we describe the progression of white matter lesions and the risk factors 
associated with this progression. In chapter 4.1 we report that one third of the people 
in our study had progression of white matter lesion within 3 years. In total 10 percent 
had marked progression. Higher age, higher blood pressure, smoking and the presence 
of severe white matter lesion and lacunar brain infarcts at baseline were related to pro-
gression of white matter lesions. Women had a higher risk of marked subcortical white 
matter lesion progression than men. Higher CRP levels were associated with baseline 
severity and progression of white matter lesions, and in particular with marked lesion 
progression. Higher CRP levels showed a non-signiﬁ cant trend toward more lacunar 
infarcts at baseline and new lacunar infarcts during follow-up (chapter 4.2).
Finally, we compare the risk of stroke between people with and without cerebral 
small vessel disease on MRI in chapter 5. Elderly people with silent brain infarcts or 
severe white matter lesions had a more than 3-fold-increased risk of stroke, which could 
not be explained by established stroke risk factors.
In chapter 6 I reﬂ ect on the main ﬁ ndings in the context of current knowledge and 
give suggestions for future research.
On the basis of our studies and current literature we presume that white matter 
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lesions and lacunar brain infarct develop as follows: cardiovascular risk factors, in par-
ticular hypertension, cause atherosclerosis-like changes and narrowing of the lumen 
of small cerebral vessels. Aβ may be involved in cerebral small vessel damage as well. 
Narrowing of the vessel lumen and the inability of the damaged vessels to regulate the 
cerebral blood pressure results in chronic ischemia of the cerebral white matter. This 
ischemia is made worse by drops in systemic blood pressure and possibly by low arte-
rial oxygen saturation. The ischemic changes in the white matter are visible on MRI as 
white matter lesions. A total occlusion of the small cerebral vessels results in a lacunar 
brain infarct.
Successful treatment of hypertension and lowering of homocysteine levels probably 
helps to prevent cerebral small vessel disease. People with cerebral small vessel disease 
have an increased risk of stroke and dementia. It is yet unknown whether medication 
additional to that used for treatment of these risk factors is effective to prevent stroke 
and dementia. 
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Samenvatting
C
erebrale wittestofafwijkingen en lacunaire herseninfarcten worden vaak gezien 
op “magnetic resonance imaging (MRI) scans” van oudere mensen. Beschadiging 
van de kleine bloedvaten van de hersenen, ook wel cerebrale microangiopathie 
genoemd, speelt een rol bij het ontstaan van deze afwijkingen. In toenemende mate 
zijn er aanwijzingen dat deze afwijkingen gerelateerd zijn aan een verhoogd risico op 
cognitieve achteruitgang, loopstoornissen en depressie op latere leeftijd. Uiteindelijk 
kunnen ze, al dan niet in combinatie met neuro-degeneratieve veranderingen, leiden tot 
dementie. Wittestofafwijkingen en lacunaire herseninfarcten worden ook vaak gezien 
op afbeeldingen van de hersenen van mensen die kort geleden een beroerte hebben ge-
had. Dit zou op een gemeenschappelijke oorzaak kunnen wijzen. Een beter begrip van 
het ontstaan van cerebrale microangiopathie, kan bijdragen aan het voorkomen van 
beroerte, dementie en ook van meer subtiele achteruitgang in het dagelijks functioneren 
van een steeds groter wordende groep ouderen.
Om meer inzicht te krijgen in het ontstaan van cerebrale microangiopathie bij ou-
dere mensen hebben we onderzoek gedaan binnen de Rotterdam Scan Study. Dit is 
een groot prospectief onderzoek onder 1077 mensen van 60 tot 90 jaar uit de algemene 
bevolking. Alle deelnemers ondergingen een MRI-scan van de hersenen in 1995-1996 en 
bij 668 van hen volgde een tweede MRI-scan meer dan drie jaar later. Alle MRI-scans 
werden beoordeeld op aanwezigheid, ernst en progressie van wittestofafwijkingen en la-
cunaire herseninfarcten. Onderscheid werd gemaakt in periventriculair en subcorticaal 
gelokaliseerde wittestofafwijkingen.  
In hoofdstuk 2 geven we een overzicht van studies waarin is gekeken naar de fre-
quentie van voorkomen van cerebrale microangiopathie op CT- en MRI-scans bij zowel 
gezonde mensen als bij patiënten met een beroerte of dementie. De gerapporteerde fre-
quentie varieerde enorm tussen de verschillende studies ten gevolge van verschillen in 
gebruikte onderzoeksmethodologie en risicoproﬁ elen.
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In hoofdstuk 3 beschrijven we de relatie tussen verschillende risicofactoren en ce-
rebrale microangiopathie. In hoofdstuk 3.1 bestuderen we binnen een groot Europees 
samenwerkingsverband de relatie met bloeddruk, veranderingen in bloeddruk, hyper-
tensie en de behandeling van hypertensie. Hogere systolische en diastolische bloeddruk-
waarden waren geassocieerd met ernstigere periventriculaire en  subcorticale wittestof-
afwijkingen. Deze associatie was hetzelfde zowel voor de bloeddruk gemeten ten tijde 
van de MRI-scan, als voor de bloeddruk gemeten zes jaar eerder. Zowel een duidelijke 
toename als een duidelijke afname in diastolische bloeddruk correspondeerde met een 
toename van het risico op ernstige periventriculaire wittestofafwijkingen. Mensen met 
succesvol behandelde hypertensie hadden een lager risico op ernstige wittestofafwijkin-
gen dan mensen met niet-succesvol behandelde hypertensie.
In hoofdstuk 3.2 laten we de relatie tussen homocysteïne spiegels en cerebrale 
microangiopathie zien. Homocysteïne is een mogelijk behandelbare risicofactor voor 
beroerte en dementie. Mensen in de groep met de 20 procent hoogste homocysteïne 
waarden hadden een drie keer verhoogd risico op stille herseninfarcten of wittestofafwij-
kingen vergeleken met mensen uit de groep met de 20 procent laagste waarden.
In hoofdstuk 3.3 tonen we dat mensen met COPD of een lage arteriële zuurstof-
saturatie een verhoogd risico hebben op ernstige periventriculaire wittestofafwijkingen, 
maar niet op subcorticale wittestofafwijkingen of lacunaire infarcten.
Hoofdstuk 3.4 geeft de rol van plasma amyloïd β (Aβ) en APOE ε4 weer in relatie tot 
lacunaire herseninfarcten, wittestofafwijkingen en gestoorde cerebrale autoregulatie. 
Plasma Aβ1-40 en Aβ1-42 spiegels waren sterk gerelateerd aan wittestofafwijkingen en la-
cunaire infarcten bij mensen die drager zijn van het APOE ε4 allel. Bij mensen die geen 
drager zijn van dit allel werd geen of alleen een zwakke relatie gevonden (hoofdstuk 
3.4.1). Gestoorde cerebrale vasomotor-reactiviteit gemeten met transcraniële Doppler, 
was geassocieerd met hogere plasma Aβ1-40 en Aβ1-42 spiegels gemeten 6.5 jaar eerder, 
maar niet met spiegels die ten tijde van de transcraniële Doppler-meting waren geme-
ten. Verder vonden we dat een daling in de plasma Aβ1-40 spiegels geassocieerd was met 
het vaker voorkomen van een gestoorde vasomotor-reactiviteit (hoofdstuk 3.4.2).
In hoofdstuk 4 beschrijven we hoe de frequentie en ernst van wittestofafwijkingen 
veranderen in de tijd en welke risicofactoren gerelateerd zijn aan die veranderingen. 
Eén derde van de mensen vertoonde progressie van wittestofafwijkingen in een periode 
van ruim drie jaar. In totaal 10 procent had ernstige progressie. Een hogere leeftijd, 
hogere bloeddruk, roken en de aanwezigheid van ernstige wittestofafwijkingen en la-
cunaire infarcten aan het begin van de studie waren gerelateerd aan progressie van 
wittestofafwijkingen. Vrouwen hadden meer progressie van subcorticale wittestofafwij-
kingen dan mannen (hoofdstuk 4.1). Mensen met een hogere bloedspiegel van het ont-
stekingseiwit C-reactief-proteïne hadden ook meer progressie van wittestofafwijkingen. 
Ze hadden mogelijk ook meer lacunaire infarcten, deze resultaten waren echter niet 
signiﬁ cant (hoofdstuk 4.2).
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Hoofdstuk 5 beschrijft het verband tussen stille, meestal lacunaire, herseninfarc-
ten, wittestofafwijkingen en de kans op beroerte. Mensen met deze afwijkingen hebben 
een ruim drie keer verhoogd risico op een beroerte. Dit werd niet verklaard door de 
aanwezigheid van reeds bekende risicofactoren voor beroerte.
In hoofdstuk 6 worden de belangrijkste bevindingen in de context van de bestaande 
literatuur besproken en worden suggesties voor verder onderzoek gedaan. 
Op basis van onze studies en bestaande literatuur veronderstellen wij dat witte-
stofafwijkingen en lacunaire herseninfarcten als volgt ontstaan: cardiovasculaire risi-
cofactoren en met name hypertensie veroorzaken atherosclerose-achtige afwijkingen en 
lumen vernauwing van de kleine bloedvaten van de hersenen. Ook Aβ kan een rol spelen 
in het beschadigen van de kleine cerebrale bloedvaten. Als gevolg van de vaatvernau-
wing en het onvermogen van de beschadigde bloedvaten om de cerebrale bloeddruk te 
reguleren, ontstaat er chronische ischemie van de cerebrale witte stof. Deze ischemie 
wordt verergerd door systemische bloeddrukdalingen en mogelijk ook door een lage ar-
teriële zuurstof-saturatie. De ischemische veranderingen in de witte stof leiden tot het 
MRI-beeld van wittestofafwijkingen. Een totale afsluiting van de kleine bloedvaten kan 
resulteren in een lacunair herseninfarct.
Het succesvol behandelen van hoge bloeddruk en het verlagen van homocysteïne 
spiegels helpt waarschijnlijk bij het voorkomen van cerebrale microangiopathie. Men-
sen met cerebrale microangiopathie hebben een verhoogd risico op dementie en beroerte. 
Het is nog onbekend of bij deze mensen, naast het behandelen van risicofactoren, het 
geven van extra medicatie zinvol is ter voorkoming van deze ziekten.
Samenvatting
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Figure 1. Incident lacunar infarct. A,C: T1-weighted spin echo MR image at baseline. B,D: T1-
weighted spin echo MR image at follow-up with hypointense lesion in right putamen.
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Figure 2. Incident lacunar infarct and progression of white matter lesions. A: T1-weighted spin 
echo MR image at baseline. B: T1-weighted spin echo MR image at follow-up with new hypoin-
tense lesion in the left periventricular white matter C: PD-weighted spin echo image at baseline. 
D: PD-weighted spin echo image at follow-up with more hyperintense lesions in both the peri-
ventricular as the subcortical region.
A B
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Figure 3. Progression of white matter lesions in periventricular and subcortical region. A,C: 
PD-weighted spin echo image at baseline. B,D: PD-weighted spin echo image at follow-up with 
extensive hyperintense lesions ranging from the border of the lateral ventricle to the subcortical 
U-ﬁ bers.
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Figure 4. Progression of white matter lesions in the periventricular and subcortical regions. 
A,C,E,G,I,K: PD-weighted spin echo image at baseline. B,D,F,H,J,L: PD-weighted spin echo im-
age at follow-up.
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Epiloog
V
eel mensen hebben bijgedragen aan de totstandkoming van dit proefschrift. Voor-
dat ik een aantal van hen persoonlijk wil bedanken, wil ik de deelnemers aan de 
Rotterdam Scan Studie, de ERGO studie, de EPOZ studie en de CASCADE studie 
heel hartelijk dank zeggen. Zij hebben door hun geheel vrijwillige deelname de in dit 
proefschrift beschreven studies mogelijk gemaakt. In dit woord van dank wil ik ook hun 
huisartsen betrekken, die belangeloos hun medewerking verleenden.
Mijn bijzondere dank gaat uit naar mijn promotoren Prof.dr. M.M.B. Breteler en 
Prof.dr. P.J. Koudstaal. Beste Monique, jij hebt de Rotterdam Scan Studie tot een groot 
succes gemaakt. Dat straalt af op de promovendi binnen je groep en heeft mij vele mo-
gelijkheden gegeven. Ik heb veel van je geleerd over het combineren van wetenschap, 
taal en vormgeving. De recente benoeming tot hoogleraar en de toekenning van grote 
subsidies komen je toe.
Beste Peter, jij hebt mij vier jaar geleden geënthousiasmeerd voor dit promotie on-
derzoek en mij overtuigd dat de overgang van neurochirurgie naar epidemiologie en van 
subarachnoïdale bloedingen naar wittestofafwijkingen niet onoverkomelijk is. Ik heb je 
snelle en scherpe commentaar en je morele support erg gewaardeerd. Ik vind het een 
uitdaging om in de toekomst een bijdrage te leveren aan het onderzoek binnen jouw 
neurovasculaire team.
Naast mijn promotoren wil ik graag Prof.dr. Hofman bedanken. Beste Bert, je we-
tenschappelijke kennis en visie en de wijze waarop je deze uitdraagt maken de afdeling 
Epidemiologie & Biostatistiek tot een inspirerend instituut, dat jonge onderzoekers zal 
blijven aantrekken. Ik voel me vereerd dat je deel uit maakt van mijn promotie commis-
sie.
Prof.dr. Van Gijn, Prof.dr. Myriam Hunnink en Prof.dr. Reinhold Schmidt wil ik 
danken voor hun bereidheid om in de kleine commissie en Prof.dr. Frederik Barkhof, 
Prof.dr. Duncker en Prof.dr. Bert Hofman in de grote commissie van deze promotie 
plaats te nemen.
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Graag wil ik Prof.dr. Oudkerk dank zeggen voor de faciliterende rol bij het MRI on-
derzoek. I would like to thank Prof.dr. Clarke for our collaboration in the homocysteine 
studies.
Prof.dr. Philip Scheltens, Prof.dr. Frederik Barkhof en Ilse van Straaten hebben een 
belangrijke bijdrage geleverd aan het ontwerpen en valideren van een methode om pro-
gressie van wittestofafwijkingen op MRI te meten. Ik dank hen ook voor de gastvrijheid 
in Amsterdam.
The members of the CASCADE research group gave me the opportunity to partici-
pate in a large international study. It was a valuable experience.
Mijn collega’s van de afdeling Epidemiologie & Biostatistiek en in het bijzonder de 
Neurogroep (Annemieke, Mirjam, Sarah, Monika, Henning, Marianne, Niels, Tom, Mar-
jolein, Kamran, Lonneke, Frank-Jan, Bess, Marieke, Maarten, Michiel) wil ik bedanken 
voor het juiste wetenschappelijke klimaat en hun collegialiteit.
Frank-Erik de Leeuw, Jan Cees de Groot, Sarah Vermeer, Tom den Heijer en Niels 
Prins hebben allen bijgedragen aan de enorme data verzameling van de Rotterdam Scan 
Studie. Bij het interpreteren en op schrift stellen van de onderzoeksresultaten uit deze 
studie waren mijn kamergenoten Sarah, Tom en Niels nauw betrokken. Ik dank hen 
voor hun positieve bijdrage. Ingrid van Vuuren heeft erg geholpen door onder andere 
het Zoetermeerproject tot een succes te maken. I would like to thank Bess Leroy for cor-
recting my English and helping to archive our data. 
Prof.dr. Theo Stijnen en ook Maria, Bettina, Lidia en Maarten bedank ik voor de 
onvermoeibare statistische ondersteuning en adviezen. Henri Vrooman en Rik Stokking 
ontwierpen de viewing software en hielpen bij het archiveren van de digitale MRI’s. 
Frank van Rooij dank ik voor het datamanagement. Marti von Stein, Petra van Rikxoort, 
Marjolijn Kasi en Marga van den Bergh droegen zorg voor de ideale secretariële onder-
steuning. Computer ondersteuning werd verzorgd door Nano Suwarno, Eric Neeleman, 
René Molhoek, René Vermeeren en Marcel Rond.
Niels Prins en Justian Hofmans, bedankt dat jullie mijn paranimfen willen zijn. 
Niels: het is bijzonder om met iemand zowel wetenschappelijk, klinisch als vriendschap-
pelijk zoveel dezelfde interesses te delen. Ik realiseer me hoeveel geluk ik heb met jou 
als collega. Justian: We hebben vanaf het begin van de studie medicijnen elkaar op vele 
fronten leren kennen en ik ben blij dat jij ook bij de verdediging van mijn proefschrift 
naast me zal staan. Bedankt voor je steun en vriendschap. 
Mijn familie en vrienden: bedankt voor jullie interesse en alle gezellige aﬂ eiding af-
gelopen jaren, maar ook voor jullie geduld en begrip als ik mijn werk weer eens voorrang 
moest geven. Mijn ouders: bedankt voor jullie nooit afnemende belangstelling en inte-
resse in mijn werk en het inspireren tot nadenken over de meest belangrijke elementen 
van het leven.
 Lieve Boukje, je hulp en steun waren belangrijk voor het voltooien van dit 
boekje. Je liefde is de essentie van al het overige. Jij bent onze thuis dokter!
Epiloog
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